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Abstract 
Critically ill patients often exhibit abnormal glycaemia that can lead to severe 
complications and potentially death. In critically ill adults, hyperglycaemia is a 
common problem that has been associated with increased morbidity and 
mortality. In contrast, critically ill infants often suffer from hypoglycaemia, which 
may cause seizures and permanent brain injury. Further complicating the matter, 
both of these conditions are diagnosed by blood glucose (BG) measurements, 
often taken several hours apart, and, as a result, these conditions can remain 
poorly managed or go completely undetected. Emerging ‘continuous’ glucose 
monitoring (CGM) devices with 1-5 minute measurement intervals have the 
potential to resolve many issues associated with conventional intermittent BG 
monitoring. The objective of this research was to investigate and develop 
methods and models to optimise the clinical use of CGM devices in critically ill 
patients. 
 
For critically ill adults, an in-silico study was conducted to quantify the potential 
benefits of introducing CGM devices into the intensive care unit (ICU). 
Mathematical models of CGM error characteristics were implemented with 
existing, clinically validated, models of the insulin-glucose regulatory system, to 
simulate the behaviour of CGM devices in critically ill patients. An alarm 
algorithm was also incorporated to provide a warning at the onset of predicted 
hypoglycaemia, allowing a virtual dextrose intervention to be administered as a 
preventative measure. The results of the in-silico study showed a potential 
reduction in nurse workload of approximately 75% and a significant reduction in 
hypoglycaemia, while also providing insight into the optimal rescue dose size 
and resulting dynamics of glucose recovery. 
 
During 2012, ten patients were recruited into a pilot clinical trial of CGM devices 
in critical care with a primary goal of assessing the reliability of CGM devices in 
this environment, with a specific interest in the effects of CGM device type and 
sensor site on sensor glucose (SG) data. Results showed the mean absolute 
relative difference of SG data across the cohort was between 12-24% and CGM 
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devices were capable of monitoring some patients with a high degree of 
accuracy. However, certain illnesses, drugs and therapies can potentially affect 
sensor performance, and one particular set of results suggested severe oedema 
may have affected sensor performance. A novel and first of its kind metric, the 
Trend Compass was developed and used to assesses trend accuracy of SG in a 
mathematically precise fashion without approximation, and, importantly, does so 
independent of glucose level or sensor bias, unlike any other such metrics. In this 
analysis, the trend accuracy between CGM devices was typically good.  
 
A recent hypothesis suggesting that glucose complexity is associated with 
mortality was also investigated using the clinical CGM data. The results showed 
that complexity results from detrended fluctuation analysis (DFA) were 
influenced far more by CGM device type than patient outcome. In addition, the 
location of CGM sensors had no significant effect on complexity results in this 
data set. Thus, while this emerging analytical method has shown positive results 
in the literature, this analysis indicates that those results may be misleading 
given the impact of technology outweighing that of physiology. This particular 
result helps to further delineate the range of potential applications and insight 
that CGM devices might offer in this clinical scenario. 
 
In critically ill infants, CGM devices were used to investigate hypoglycaemia 
during the first 48 hours after birth. More than 50 CGM data sets were obtained 
from several studies of CGM in infants at risk of hypoglycaemia at the Waikato 
hospital neonatal ICU (NICU). In light of concerns regarding CGM accuracy, 
particularly during the first few hours of monitoring and/or at low BG levels, an 
alternative, novel calibration scheme was developed to increase the reliability of 
SG data. The recalibration algorithm maximised the value of very accurate 
calibration BG measurements from a blood gas analyser (BGA), by forcing SG 
data to pass through these calibration BG measurements.  
 
Recalibration increased all metrics of hypoglycaemia (number, duration, severity 
and hypoglycaemic index) as the factory CGM calibration was found to be 
reporting higher values at low BG levels due to its least squares calibration 
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approach based on the assumption of a less accurate calibration glucose meter. 
Thus, this research defined new calibration methods to directly optimise the use 
of CGM devices in this clinical environment, where accurate reference BG 
measurements are available. Furthermore, this work showed that metrics such 
as duration or area under curve were far more robust to error than the typically 
used counted-incidence metrics, indicating how clinical assessment may have to 
change when using these devices. 
 
The impact of errors in calibration measurements on metrics used to classify 
hypoglycaemia was also assessed. Across the cohort, measurement error, 
particularly measurement bias, had a larger effect on hypoglycaemia metrics 
than delays in entering calibration measurements. However, for patients with 
highly variable glycaemia, timing error can have a significantly larger impact on 
output SG data than measurement error. Unusual episodes of hypoglycaemia 
could be successfully identified using a stochastic model, based on kernel density 
estimation, providing another level of information to aid decision making when 
assessing hypoglycaemia.  
 
Using the developed algorithms/tools, with CGM data from 161 infants, the 
incidence of hypoglycaemia was assessed and compared to results determined 
using BG measurements alone. Results from BG measurements showed that 
~17% of BG measurements identified hypoglycaemia and over 80% of episodes 
occurred in the first day after birth. However, with concurrent BG and SG data 
available, the SG data consistently identified hypoglycaemia at a higher rate 
suggesting the BG measurements were not capturing some episodes. Duration of 
hypoglycaemia in SG data varied from 0-10+%, but was typically in the range 4-
6%. Hypoglycaemia occurred most frequently on the first day after birth and an 
optimal measurement protocol for at risk infants would likely involve CGM for 
the first week after birth with frequent intermittent BG measurements for the 
first day.  
 
Overall, CGM devices have the potential to increase the understanding of certain 
glycaemic abnormalities and aid in the diagnosis/treatment of other conditions 
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in critically ill patients. This research has used a range of prospective and 
retrospective clinical studies to develop methods to further optimise the use of 
CGM devices within the critically ill clinical environment, as well as delineating 
where they are less useful or less robust. These latter results clearly define areas 
where clinical practice needs to adapt when using these devices, as well as areas 
where device makers could target technological improvements for best effect. 
Although further investigations are required before these devices are regularly 
implemented in day-to-day clinical practice, as an observational tool they are 
capable of providing useful information that is not currently available with 
conventional intermittent BG monitoring. 
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Chapter 1. Introduction 
Critically ill patients often exhibit abnormal glycaemia due to the severity of their 
illness. In critically ill adults, stress induced hyperglycaemia, or high blood 
glucose (BG), has been associated with increased morbidity and mortality (Capes 
et al. 2000; Krinsley 2003; McCowen et al. 2001; Mizock 1995; Umpierrez et al. 
2012). Hyperglycaemia has also been linked to other negative clinical outcomes, 
including infection (Bistrian 2001), sepsis and septic shock (Branco et al. 2005; 
Das 2003; Marik & Raghavan 2004), myocardial infarction (Capes et al. 2000), 
and, polyneuropathy and multi-organ failure (Langouche et al. 2005; van den 
Berghe et al. 2001). In contrast, in critically ill infants, a common metabolic 
problem is neonatal hypoglycaemia, or low BG, which may cause seizures and 
permanent brain injury in affected babies (Stanley & Baker 1999).  
 
Both of these common conditions are diagnosed by BG measurements, typically 
done by a nurse at the bedside and only taken every few hours at the most 
frequent. In the critical care environment, frequent BG measurements are often 
not feasible due to the increase in nurse workload (Aragon 2006; Carayon & 
Gurses 2005; Holzinger et al. 2005). Furthermore, for very small infants in the 
neonatal intensive care unit (NICU), blood draw constraints can limit the number 
of BG measurements permitted each day. Thus, with conventional, intermittent 
BG monitoring using handheld glucose meters or a local blood gas analyser 
(BGA), these conditions can remain poorly managed or go completely 
undetected, ultimately increasing the risk of negative outcomes for patients.  
 
Interestingly, the technology that could potentially resolve the issue of 
infrequent BG measurements has been around for over 10 years, in the form of 
continuous glucose monitoring (CGM) devices. CGM devices were originally 
developed to help people with diabetes manage their condition. They typically 
offer a 1-5 minute measurement interval, giving information about BG level and 
BG trends. Several types of CGM devices have been proposed over the years, 
including subcutaneous glucose sensors (Girardin et al. 2009), micro-dialysis 
systems (Valgimigli et al. 2010) and a number of methods that offer non-invasive 
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BG measurements (Vashist 2012). Overall, the most common and widely used 
type is the subcutaneous sensing CGM devices, which measures glucose 
concentration just beneath the skin in order to estimate BG concentration. There 
are several manufacturers of the subcutaneous type CGM device who have 
approved devices in the market, in contrast to the other approaches.  
 
Although the technology has been developed and is well tested in people with 
diabetes, there are only a limited number of studies that have investigated CGM 
devices in critically ill patients, despite their obvious potential benefits (Weiss & 
Lazar 2007). In the adult intensive care unit (ICU), CGM devices have the 
potential to increase patient safety through better monitoring, while reducing 
nurse workload through fewer manual BG measurements required per day. In 
the NICU, these devices have the potential to help diagnose episodes of 
hypoglycaemia that would have otherwise gone undetected, while increasing the 
limited knowledge on the duration and severity of such episodes. However, there 
are still concerns regarding the accuracy of CGM devices (Rabiee et al. 2009; 
Vlkova et al. 2009), especially in critically ill patients where illnesses, 
drugs/therapies and other clinical factors may impede performance (Moser et al. 
2010). Hence, a thorough investigation of CGM devices in the intensive care 
environment, both ICU and NICU, could potentially improve the standard of care 
for these critically ill patient cohorts.  
 
The research presented in this thesis is primarily aimed at investigating and 
optimising the use of commonly available off-the-shelf CGM devices in critically 
ill adults and infants. More specifically, several of the limitations identified by 
previous studies of these devices are presented and solutions are developed, 
proposed and validated. The results and findings presented here are largely 
derived from data collected during previous or ongoing clinical trials of CGM 
devices. Finally, the findings from this research can be used to improve the 
standard of clinical care in the Christchurch ICU and the Waikato Hospital NICU, 
the centres where this research was primarily located, as well as other ICUs in 
New Zealand by its impact and potential to change clinical practice.  
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1.1 Preface 
This thesis is presented in two parts: Part I investigates the use of CGM in 
critically ill adults, in the ICU and, Part II investigates the use of CGM in critically 
ill infants in the NICU. The chapters in this document are arranged as follows: 
 
Part I - Adult ICU 
Chapter 2 provides a thorough background on hyperglycaemia in critically ill 
patients and an overview of tight glycaemic control, before the potential benefits 
of CGM in the ICU are discussed. 
 
Chapter 3 contains a review of the literature of CGM error models, robust 
filtering methods and hypoglycaemia alarm algorithms, all of which can be 
implemented in-silico.  
 
Chapter 4 presents an in-silico feasibility study to determine whether CGM 
devices can be couple with an existing glycaemic control protocol to improve 
patient safety and reduce nurse workload, while maintaining control of 
glycaemia. Material in Chapter 4 has been published in: Signal, M, Pretty, CG, Chase, 
JG, Le Compte, AJ and Shaw, GM (2010). “Continuous Glucose Monitors and the 
Burden of Tight Glycemic Control in Critical Care: Can they cure the time cost?” 
Journal of Diabetes Science and Technology (JoDST), Vol 4(3), pp. 625-635, ISSN: 
1932-2968. 
 
Chapter 5 discusses CGM data analysis and highlights the distinction between 
point-to-point accuracy and trend accuracy. A novel trend accuracy metric, the 
Trend Compass, is developed and validated. 
 
Chapter 6 presents the results of an observational 10 patient pilot clinical trial at 
Christchurch Hospital's ICU assessing the reliability of off-the-shelf CGM devices 
in critically ill patients. Material in Chapter 6 has been published in: Signal, M Fisk, 
L, Shaw, GM and CG, Chase (2013). “Concurrent continuous glucose monitoring in 
critically ill patients: Interim results and observations," Journal of Diabetes Science 
and Technology (JoDST), Vol 6(7), (invited). 
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Chapter 7 tests a new hypothesis on glucose complexity using CGM data 
collected during the pilot clinical trial at Christchurch Hospital's ICU. Material in 
Chapter 7 has been published in: Signal, M, Thomas, F, Shaw, GM and Chase, JG 
(2013). “Complexity of continuous glucose monitoring data in critically ill patients: 
CGM devices, sensor locations and DFA methods," Journal of Diabetes Science and 
Technology, in press (Oct. 2013). 
 
Chapter 8 summarises the research on CGM in critically ill adults, presented in 
Chapters 2-7. 
 
Part II - Neonatal ICU 
Chapter 9 provides an in-depth background on neonatal hypoglycaemia and its 
resulting complications, before the potential benefits of CGM in the NICU are 
discussed. 
 
Chapter 10 investigates one of the key technological aspects of CGM devices, the 
calibration algorithms that convert raw sensor signals into useful glucose data. 
An alternative calibration scheme is developed and the impacts it has on metrics 
used to classify hypoglycaemia are assessed. Material in Chapter 10 has been 
published in: Signal, MK, Le Compte, AJ, Harris, DL, Weston, PJ, Harding, JE and 
Chase, JG for the CHYLD Study Group (2012). “Impact of Calibration Algorithms on 
Hypoglycaemia Detection in Newborn Infants Using Continuous Glucose 
Monitoring,” Diabetes Technology & Therapeutics (DTT), 14:10, ISSN: 1520-9156. 
 
Chapter 11 assesses the impact of timing delays and measurement errors in 
calibration BG measurements on output SG data. Specifically, how these sources 
of error affect metrics used to classify hypoglycaemia.  
 
Chapter 12 develops a method of detecting and classifying unusual episodes of 
hypoglycaemia in SG data. The classifications are presented graphically by colour 
coding a time series plot of SG data. Material in Chapter 12 has been published in: 
Signal, MK, Le Compte, AJ, Harris, DL, Weston, PJ, Harding, JE and Chase, JG for the 
CHYLD Study Group (2012). “Using Stochastic Modelling to Identify Unusual 
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Continuous Glucose Monitor Measurements in Newborn Infants,” BioMedical 
Engineering OnLine, 11:45, (open access), ISSN: 1475-925X. 
 
Chapter 13 investigates hypoglycaemia in neonates that are at risk of 
developing the condition. Results determined using conventional intermittent BG 
monitoring methods are compared to results from analyses of CGM device data.  
 
Chapter 14 summarises the research on CGM in critically ill infants, presented in 
Chapters 9-13. 
 
Chapter 15 contains a discussion of future work, both in the adult ICU and the 
neonatal ICU. 
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Chapter 2. Background - Adult ICU 
This chapter provides background on hyperglycaemia in critically ill patients and 
its resulting complications. In particular, one proposed method of reducing 
hyperglycaemia is tight glycaemic control (TGC). An overview of the literature on 
this subject, with specific reference to several key studies, is presented and some 
of the risks associated with TGC are highlighted. Finally, the application of CGM 
devices to TGC is presented as a means of enhancing glycaemic control. 
 
2.1 Hyperglycaemia in critically ill patients 
Critically ill patients often experience stress induced hyperglycaemia, which has 
been associated with increased morbidity and mortality (Capes et al. 2000; 
Krinsley 2003; McCowen et al. 2001; Mizock 1995; Umpierrez et al. 2012). 
Hyperglycaemia has also been linked to other negative clinical outcomes, 
including infection (Bistrian 2001), sepsis and septic shock (Branco et al. 2005; 
Das 2003; Marik & Raghavan 2004), myocardial infarction (Capes et al. 2000), 
and, polyneuropathy and multi-organ failure (Langouche et al. 2005; van den 
Berghe et al. 2001). BG measurements are used to diagnose hyperglycaemia, but 
diagnostic criteria can vary between critical care centres. Typically, 1-2 BG 
measurements above a threshold of ~8-10mmol/L constitutes hyperglycaemia 
(Singer et al. 2009; Umpierrez et al. 2012).  
 
Stress induced hyperglycaemia is prevalent in both diabetic and non-diabetic 
critically ill patients. The primary cause of hyperglycaemia is increased levels of 
counter-regulatory hormones, released in response to critical illness (McCowen 
et al. 2001). During the acute phase of critical illness, several hormones including 
glucagon, growth hormone, catecholamines and glucocorticoids are significantly 
elevated in response to physiological stress (Turina et al. 2005). These hormones 
increase glucose production by stimulating the metabolic pathways for 
gluconeogenesis, glycogenolysis and lipolysis. Gluconeogenesis is the formation 
of glucose from lactic acid and certain amino acids, glycogenolysis is the 
breakdown of glycogen into glucose, and, lipolysis is the breakdown of lipids into 
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its constituents, including glycerol, which is subsequently converted into glucose 
by the liver. Hence, these avenues represent forms of unregulated endogenous 
glycaemic production, raising BG levels. In addition, these hormones increase 
insulin resistance, which reduces insulin mediated glucose uptake and further 
increases BG concentration (Chase et al. 2011; Gearhart & Parbhoo 2006).  
 
Exogenous factors, such as the administration of some medications and/or the 
use of some therapies, can interact with physiological processes, increasing the 
severity of hyperglycaemia. In particular, glucocorticoid steroids, the 
catecholamines epinephrine and norepinephrine, and β-blockers are reported to 
reduce insulin sensitivity and thus increase BG levels in critically ill patients 
(Pretty et al. 2011). Other sources of increased BG levels include excess calories 
from parenteral and enteral nutrition, as well as dextrose infusions used for fluid 
resuscitation and drug delivery (Mizock 1995; Nylen & Muller 2004). 
 
As critical illness evolves, hyperglycaemia can remain persistent for days or even 
weeks, increasing the risk of negative outcomes. Although the exact mechanisms 
are not completely understood, it is thought that long term exposure to high BG 
levels induces inflammatory changes and oxidative stress, which harm 
cardiovascular and endothelial function (Ellahham 2010). Furthermore, elevated 
BG levels have a detrimental effect on immune function and may significantly 
increase a patient’s susceptibility to infection (Van den Berghe et al. 2003). Thus, 
it was hypothesised that controlling BG levels to a euglycaemic range might 
reduce some of the negative outcomes associated with hyperglycaemia. 
 
2.2 Tight glycaemic control in critically ill patients 
In 2001, Van den Berghe et al. published the results of a prospective, 
randomised, controlled trial that used a TGC protocol to reduce hyperglycaemia 
in critically ill cardiac surgery patients (van den Berghe et al. 2001). Patients 
were randomly assigned to either the intensive insulin therapy (IIT) treatment 
group whose BG was maintained between 80-110mg/dL, or, the conventional 
treatment group whose BG was maintained between 180-200mg/dL. The 
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primary outcome was ICU mortality, and the secondary outcomes included 
hospital mortality as well as several measures of patient morbidity. 
 
The trial was a success and the results showed a reduction in ICU mortality of 18-
45%, depending on length of admission, for patients assigned to the IIT treatment 
group. Furthermore, significant reductions in hospital mortality and several 
measures of morbidity were also observed in the IIT group (van den Berghe et al. 
2001; Van den Berghe et al. 2003). These measures of morbidity included a 
reduction in the duration of ventilator support, a reduction in renal impairment, 
a reduction in bloodstream infection, a reduction in polyneuropathy, a reduced 
need for blood transfusions and fewer therapeutic interventions. Overall, the 
researchers concluded that TGC reduces morbidity and mortality among 
critically ill patients in the surgical ICU. 
 
During the following years, several studies attempted to reproduce the positive 
results of Van den Berghe. In particular, two studies achieved similar results with 
TGC reporting reductions in hospital mortality of 29-35% (Chase et al. 2008c; 
Krinsley 2004). However, several others failed to achieve this result (Brunkhorst 
et al. 2008; Finfer et al. 2009; Preiser et al. 2009). Another significant outcome of 
the study by Chase et al. was the reduction in severe hypoglycaemia with TGC, 
which has been independently associated with increased mortality in critically ill 
patients (Egi et al. 2010; Hermanides et al. 2010b). This latter result was in 
contrast to increased hypoglycaemia with TGC seen in almost all other studies 
(Griesdale et al. 2009). 
 
Interestingly, successful TGC studies also report significant economic benefit, 
with savings averaging approximately $1500-3200USD per patient treated, at 
the time of publication (Krinsley & Jones 2006; Van den Berghe et al. 2006). 
These savings were primarily attributed to reduced ICU length of stay, fewer 
ventilator days, less imaging and fewer laboratory requirements (Krinsley & 
Jones 2006). Hence, there are economic motivations, as well. 
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As noted, in addition to successful TGC trials, there have been several studies 
that have failed to match the positive results (Brunkhorst et al. 2008; De La Rosa 
Gdel et al. 2008; Finfer & Delaney 2008; Griesdale et al. 2009; Meijering et al. 
2006; Preiser et al. 2009; Treggiari et al. 2008). Most notably, one study was 
stopped early due to unintended protocol violations (Preiser et al. 2009), and 
another study was stopped for safety concerns due to the level of hypoglycaemia 
in the TGC treatment group (Brunkhorst et al. 2008). Following the publication 
of the NICE-SUGAR study, which reported higher mortality and hypoglycaemia 
with TGC (Finfer et al. 2009), a meta-analysis of several TGC studies showed that 
most TGC studies failed to achieve a result either way (Griesdale et al. 2009). 
However, due to large variations in the number of centres, cohorts and ICU types, 
comparisons between studies are very difficult. Thus, TGC remains a highly 
contentious subject with the benefits/risks still heavily debated. 
 
When drawing conclusions about the benefits and risks of TGC it is important to 
ensure results are interpreted correctly. There is potential for negative results to 
be falsely negative due to unintended patient crossover or cohort overlap, which 
can lead to misinterpretation of results. For example, it should not be assumed 
that all patients in the TGC treatment group achieved TGC, while patients in the 
conventional treatment group did not have BG levels in the TGC target glycaemic 
band.  
 
Thus, there are two separate questions that need to be answered. The first is a 
physiological question: Is normoglycaemia associated with better outcomes in 
critically ill patients, irrespective of how it comes about? The second is a clinical 
question: Is glucose control achievable, consistently and reliably, in a clinical 
setting? 
 
Evidence in response to the first question suggests that normoglycaemia is 
associated with lower mortality, irrespective of how it is achieved (Signal et al. 
2012b). The second question, regarding the difficulties involved with 
implementing a successful and consistent TGC protocol, potentially highlights 
one of the causes of inconsistent findings in TGC studies to date. Achieving TGC 
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on a per-patient basis is extremely difficult, largely due to the inter-patient 
variability in illness and response to insulin treatment (Chase et al. 2011; Lin et 
al. 2008; Suhaimi et al. 2010). Further complicating the matter, each patient's 
condition evolves over time and the TGC protocol must adjust in response to any 
intra-patient variability. It is likely that failing to manage variability will result in 
poor control and an inability to separate the cohorts of a randomised controlled 
trial, ultimately making it difficult to show the benefits of TGC (Chase et al. 2011). 
 
Overall, the aim of any TGC protocol is to reduce elevated BG levels with minimal 
or zero hypoglycaemia. However, protocols or clinical practices that utilize large 
insulin doses can suffer from high glycaemic variability and/or excessive 
hypoglycaemia (Chase et al. 2011; Meijering et al. 2006), both of which have 
been independently associated with mortality in critically ill patients (Bagshaw 
et al. 2009; Egi et al. 2006; Egi et al. 2010; Hermanides et al. 2010a; Hermanides 
et al. 2010b; Krinsley 2008). Furthermore, the frequency of BG measurements 
required for TGC needs careful consideration, as a trade-off often exists between 
TGC performance/safety and nurse burden. Due to this trade-off, BG is typically 
only measured every 1–4 h and more frequently only if the levels are already at 
or near hypoglycaemia. More frequent measurements, and even 1–2 hourly 
measurements, are uncommon due to the clinical effort required (Carayon & 
Gurses 2005; Chase et al. 2008a). 
 
2.3 Continuous glucose monitoring in critically ill patients 
CGM devices, with their 1-5 minute measurement interval (Girardin et al. 2009), 
have the potential to eliminate the trade-off in TGC between performance/safety 
and nurse workload. Originally designed to help people with diabetes manage 
their condition, the most widely used CGM devices consist of a subcutaneous 
sensor which measures glucose in the interstitial fluid for up to 7 days, and a 
monitor which stores/displays data (Girardin et al. 2009). Figure 2.1 shows the 
elements of a commonly available and widely used CGM system.  
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In general, there are two families of CGM devices. First, there are retrospective 
devices, which store data in a blinded manner until the end of monitoring. 
Second, there are real-time devices, which display glucose values throughout the 
monitoring period. Both types of device require multiple (3-6) independent BG 
measurements per day for calibration, but, all else equal, can deliver different 
results due to their different calibration and processing of the sensor signal. 
 
 
Figure 2.1 The Medtronic Guardian Real-Time CGM - a commonly available and 
widely used CGM device. 
 
Although well studied in people with diabetes (Gandhi et al. 2011; Hoeks et al. 
2011b), there have been relatively few investigations of CGM devices in critically 
ill patients, despite their obvious potential benefits with TGC. An early study of 
automated closed loop BG control using CGM in critically ill patients failed to 
show improvements over manual control, in part due to high glucose sensor 
glucose (SG) error (Chee et al. 2003). More recently, several studies reported 
CGM to be clinically useful in critical care units, particularly for early detection of 
hypoglycaemia (Holzinger et al. 2010; Westhoff et al. 2010). One larger study, 
analysing SG data from 174 patients, found CGM device accuracy to be "very 
good" and regarded the device to be safe to guide insulin therapy (Brunner et al. 
2011).  
 
However, despite a positive report, there are still concerns regarding the 
reliability of CGM devices in critical care units (Rabiee et al. 2009; Vlkova et al. 
2009), as certain conditions/illnesses including sepsis, septic shock, and 
peripheral oedema, could potentially affect CGM device performance (Lorencio 
Monitor 
Sensor 
Wireless 
transmitter 
13 
 
et al. 2012). In addition, certain medications/therapies commonly used in the 
ICU, such as paracetamol, can influence CGM device performance (Moser et al. 
2010). Interestingly, vasoactive medications, such as dopamine, norepinephrine, 
ketanserin, enoximone and nitro-glycerine, are reported to have little or no affect 
on the accuracy of one type of glucose sensor (Holzinger et al. 2009; Westhoff et 
al. 2010).  
 
Overall, regardless of specific results, a common factor among all of these studies 
is the recognition of the potential benefits of CGM in critically ill patients, which 
include: 
 
1. Improve BG control with a well designed TGC algorithm  
2. Improve hypoglycaemia detection, a benefit that is already being realised.  
3. Decrease nurse burden by reducing the number of manual BG measurements 
required to 3-4 per day for CGM device calibration. 
 
However, further investigations are required before CGM devices can be 
implemented in critical care units to guide clinical insulin delivery to manage 
hyperglycaemia. The following chapters investigate using CGM devices in an 
adult ICU, with the overall goal of improving BG control and increasing patient 
safety, while reducing nurse workload. 
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Chapter 3. CGM error models, filtering and alarms  
Prior to using CGM devices in the critical care unit, a search of the literature was 
undertaken to determine whether enough information could be gathered to 
allow an in-silico feasibility study to be completed. The elements required to 
complete the feasibility study, in addition to a clinically validated patient 
simulation package that was already available (Chase et al. 2010), were a CGM 
error model, an appropriate filtering algorithm and an alarming algorithm. This 
chapter describes those elements and the sources of the information. 
 
3.1 CGM error models 
Despite significant outpatient use and promise, the literature contains very few 
reports of error models derived from clinical SG data. Two studies in particular 
provide sufficient details of CGM device error characteristics to allow models to 
be created or reproduced for use in-silico (Breton & Kovatchev 2008; Goldberg 
et al. 2004). Although the models described in this section were developed by 
other researchers, the details are presented due to their extensive use 
throughout this thesis. 
 
3.1.1 Gaussian based error model 
The Gaussian based CGM error model was created using data from a study 
published by Goldberg et al. (Goldberg et al. 2004). This study investigated the 
accuracy of CGM devices in critically ill patients admitted to the 14-bed medical 
ICU in Yale New Haven Hospital. Patients admitted to the ICU that were 
considered at risk of hyperglycaemia were eligible to take part in the study, but 
those expected to stay for <24 hours were excluded. Risk factors for 
hyperglycaemia included a BG measurement ≥11.1mmol/L, a clinical history of 
Diabetes Mellitus (DM), or the use of clinical interventions associated with 
hyperglycaemia such as corticosteroids, vasopressors and/or enteral/parenteral 
nutrition.  
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This study used Medtronic Continuous Glucose Monitoring System (CGMS - 
Medtronic Minimed, Northridge, CA) monitors, receiving information from 
Medtronic SOF sensors (Medtronic Minimed, Northridge, CA). Sensors were 
inserted in the lateral abdomen, or upper, outer buttocks. At the time of this 
specific study, SOF sensors were validated for up to 72 hours use, after which 
time they were removed or replaced. Monitoring continued until discharge from 
the ICU. During monitoring, the CGM device was calibrated at least 4 times per 
day matching manufacturer guidelines (Mastrototaro 2000), with capillary BG 
measurements from a Surestep Flexx (Lifescan, Johnson & Johnson, Milpitas, CA) 
glucose meter. At the end of the monitoring period, data were downloaded using 
Minimed software Solutions V3.0 (Medtronic Minimed, Northridge, CA). 
 
The study enrolled 22 patients and each patient had between 1 and 5 sensors 
inserted sequentially, resulting in a total of 41 CGM data sets. The SG data from 
CGM were compared to capillary BG measurements to assess accuracy and a total 
of 546 paired BG-SG measurements were available for analysis. Accuracy of the 
CGMS device was reported based on absolute glucose level, which was defined as 
the mean of the BG-SG paired measurements. The relevant accuracy results 
reported are shown in Table 3.1. 
 
Table 3.1 Error characteristics of the CGMS in ICU patients, by absolute BG level 
(Goldberg et al. 2004) 
 
 
The mean absolute percent error (MAPE) accuracy data from Table 3.1 were 
used to create a mathematical model of SG error (Chase et al. 2006; 
Gschwendtner 2007). The model consists of five independent Gaussian 
distributions, one for each of the BG-SG bins reported in Table 3.1. The 
Mean SG/BG (mg/dL) Number of paired measurements MAPE (%)
<100 43 20.0
100-149 219 13.5
150-199 185 11.3
200-249 66 11.4
≥250 33 9.8
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probability density function of a zero mean Gaussian distribution with scale 
parameter sG, can be described:  
 
Using the Box-Muller transform, Equation 3.1 takes the form: 
 
 
With uniformly distributed variates   ,    ϵ (0,1].  
 
Equation 3.2 represents the basis of the model and for each of the 5 BG-SG bins, 
the scale parameter is adjusted so the MAPE of the Gaussian distribution is the 
same as the corresponding MAPE reported in Table 3.1. Furthermore, each scale 
parameter can be approximated: 
 
 
The scale factors used to obtain the appropriate MAPE values from Table 3.1 are 
shown in Table 3.2. 
 
Table 3.2: Scale factors (SG) used in Gaussian CGMS error model 
 
 
With the error distributions for each BG range defined, SG data is generated by 
adding error from the model to known, underlying BG values. Ideally, underlying 
BG data will be produced at 5-minute intervals to replicate the sampling rate of 
BG Range (mg/dL) Paired BG-SG measurements MAPE (%) SG
<100 43 20 0.25
100-149 219 13.5 0.17
150-199 185 11.3 0.14
200-249 66 11.4 0.14
≥250 33 9.8 0.12
      
 
     
 
 
  
   
 
 3.1 
                            3.2 
   
   
 
                      3.3 
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real CGMS data. Modelled sensor error is added to each individual BG value, as 
defined:  
 
 
Where: 
         True blood glucose concentration (mmol/L) 
          CGMS blood glucose approximation (mmol/L) 
        Gaussian distributed error factor (where n depends on        ) 
 
 
As there are no reported limits on maximum/minimum error for the CGMS 
sensor in the literature, bounds were placed on the output value          at 
2.2mmol/L and 22.2mmol/L. These values are consistent with the limits on 
output SG data specified by the manufacturer of the CGMS (Mastrototaro et al. 
2002). 
 
The model was validated using a virtually generated cohort that has similar BG 
characteristics to those described by Goldberg et al. A total of 546 BG 
measurements, with the same number of BG measurements in each glycaemic 
interval as Goldberg et al., were used in the validation. Randomly sampled CGM 
error was added to each BG measurement to give virtual SG measurements, 
which were analysed and compared to the results reported by Goldberg et al. 
The metrics used to validate the model were the rPearsons correlation coefficient, 
the overall MAPE and the Clarke Error Grid (Clarke et al. 1987). Table 3.3 shows 
the results of this model validation and in comparing the results with those 
reported by Goldberg et al., it is clear the model replicates the CGMS error 
characteristics well.  
 
Table 3.3: Validation of the error model against results reported by Goldberg et al.  
 
rPearsons MAPE ± SD Zone A (%) Zone B (%) Zone C-E (%)
Goldberg 0.88 12.8 ± 11.9 78.4 20.3 1.3
Guassian model 0.91 12.8 ± 10.0 81.3 18.2 0.5
Clarke Error Grid
                               3.4 
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It should be noted that although model was designed to match Goldberg et al.'s 
reported results on a similar data set, the overall rPearson, MAPE and Clarke Error 
Grid results can change depending on the underlying BG data used as         with 
the model. Also, the model described in this section assumes each SG value is 
independent of the previous values. However, without any quantification in the 
literature of the time dependent aspects of CGMS error, such as drift, they could 
not be included in this model.  
 
3.1.2 Autoregressive based error model 
The second CGM error model was created using data from a study published by 
Breton et al. in 2008 (Breton & Kovatchev 2008). In their paper, researchers 
proposed three important aspects of CGM that should be quantified in the model: 
 
1. Physiological lag between BG and IG concentrations 
2. Sensor lag between IG and SG at the sensor electrode 
3. Residual sensor error or noise.  
 
Two data sets containing BG and Freestyle Navigator (Abbott Diabetes Care, 
Alameda, CA) SG data were used to create the model. The first data set was from 
136 patients who used the CGM device at home, calibrating via self-monitoring at 
irregular intervals. A total of 4000 days of 10-minute sampled SG data and 
40,745 BG measurements were collected. After pre-analysis data processing, 
data set 1 contained 20,660 paired BG-SG paired measurements that could be 
used for modelling.  
 
The second data set was from 28 patients who were monitored in a clinical 
environment. The CGM device in these patients produced a value every minute, 
and BG concentration was measured every 15 minutes using a YSI device (YSI 
Life Sciences, Yellow Springs, OH). A total of 56 sensors were used, two per 
patient, and after pre-analysis data processing, data set 2 contained 
approximately 7,000 paired BG-SG paired measurements 
 
Data set 1 was used to address points 1 and 2 above, specifically, to approximate 
the overall lag between glucose in the blood reaching the sensor electrode. First, 
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SG data were recalibrated using a linear regression method, similar to the 
methods used by sensor manufacturers. Second, data were stratified into bins 
based on the linearly regressed rate of change of data in a 20 minute sliding 
window. Third, kernel density estimation was used to approximate the 
distributions of the sensor readings across a range of different reference glucose 
values.  
 
The premise behind their methodology was that if SG measurements are delayed 
due to interstitial lag and/or signal processing, then sensor error will be 
dependent on the rate of change of glucose. Thus, the location of the kernels for 
each bin could be assessed to quantify the delay. The main observations made 
from the kernel density data were:  
 
 At negative rate of change, the sensors tend to read high 
 At positive rate of change, the sensor tends to read low 
 The extent to which the sensor systematically reads high or low is correlated 
to the amplitude of the rate of change.  
 
The researchers found that a correlation exists between glucose rate of change 
and average BG-SG discrepancy, irrespective of reference glucose concentration. 
The average discrepancy was linearly related to the rate of change and the slope 
of this relationship gave an estimation of the overall delay as 17 minutes. 
 
The delay was modelled by a first-order diffusion process: 
 
 
Where    represents glucose at the sensor and   represents the blood to sensor 
time lag. Empirical estimations gave a time lag of 5mins, producing a delay of 
around 15 minutes, which is comparable with the 17 minute delay that was 
detected in data set 1.  
 
  
  
 
 
 
        3.5 
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Data set 2 was used to quantify the residual error in SG measurements and their 
interdependence over time. SG data was synchronised and recalibrated to BG 
data using a first-order diffusion model, which minimised delay and residual 
error. The time dependent aspect of SG errors was determined using classical 
time-series techniques. Specifically, the autocorrelation function and the partial 
autocorrelation function. The analysis suggested that sensor error was best 
predicted by a linear combination of the sensor error 15 minutes earlier and a 
random white noise term.  
 
The distribution of residual SG errors had a mean of 0.04mmol/L and a standard 
deviation of 0.61mmol/L, but its skewness and kurtosis showed it to be non-
Gaussian. However, an unbounded Johnson distribution, with parameters   = -
5.471,   = 15.96,   = -0.5444 and   = 1.6898, fit the empirical data well. This 
distribution was coupled with an autoregressive moving average process to 
model the non-white, non-Gaussian SG errors: 
 
 
where           is IID,   = -5.471,   = 15.96,   = -0.5444 and   = 1.6898. 
 
Throughout the remainder of this thesis, where applicable, the implementation 
of this autoregressive based model was achieved in three steps. First, clinically 
validated metabolic system models were used to generate a continuous time 
series of glucose values from clinical BG measurements, insulin treatments and 
parenteral/enteral feed data. Second, an overall lag was applied to the data using 
the diffusion model shown in Equation 3.5, to account for physiological and 
sensor lags. Finally, Equation 3.6 was used to add time-dependent sensor error 
to the delayed glucose data, creating virtual SG data. Virtual SG data produced 
using this model have been previously validated and shown to be consistent with 
empirical data (Breton & Kovatchev 2008). 
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3.2 Filtering CGM data  
Digital filtering techniques have been used to reduce the impact of seemingly 
random fluctuations in SG data on the overall trends in the time series (Bequette 
2010). This research investigates common digital filters, such as finite impulse 
response (FIR) filters and infinite impulse response (IIR) filters, as well as a 
novel median least mean square filter. All filters were tested in silico using 
virtual SG data, generated using the Gaussian CGM error model described in 
Section 3.1.1. 
 
3.2.1 Patients and methods 
A 20 patient benchmark cohort (Chase et al. 2008b) was used to test the filter 
designs and optimise filter performance. Each patient in the cohort was on the 
SPRINT TGC protocol during their ICU stay (Chase et al. 2008c). While on 
SPRINT, BG was measured every 1-2 hours to guide therapy. Demographics for 
the patients are shown in Table 3.4. The use of these patient records fell under 
existing ethics approval granted by the Upper South Regional Ethics Committee, 
New Zealand.  
 
Table 3.4: Demographics for the 20 patient benchmark cohort 
 
 
Clinically validated metabolic system models were used to produce a continuous 
glucose time series from the BG measurements, insulin treatments and 
parenteral/enteral feed data. This continuous glucose data was used as the 
foundation for generating virtual SG data. Randomly sampled error values from 
the Gaussian based error model described in Section 3.1.1 were added to the 
underlying BG trace, producing virtual SG data. The Gaussian model was used as 
it was derived from CGM in critically ill patients, which is the application of this 
research. 
Patients (N) 20
Age (years) 68 [60 - 73]
Gender (M/F) 12/8
Length of data (h) 276 [173 - 472]
BG measurements (N) 170 [130 - 260]
APACHE II 19 [16 - 24]
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3.2.2 Filter designs 
3.2.2.1 Finite Impulse Response (FIR) filters 
FIR filters are a type of signal processing filter whose response to an external 
input of finite duration will decay to zero in a finite period of time. The general 
form of an Nth order FIR filter can be described: 
 
 
where      is the filter output,      are the filter inputs,    are the filter 
coefficients, and N is the filter length/order. 
 
There are a several methods available for determining optimal filter coefficients 
for a FIR filter, such as the window design method, frequency sampling method 
and weighted least squares design. In this research, a window design method 
was used and the filter was implemented in MATLAB (The Mathworks, Natick, 
Massachusetts). Finally, several filter length and cut-off frequency parameters 
were tested to optimise performance. 
 
3.2.2.2 Infinite Impulse Response (IIR) filters 
Unlike FIR filters, an IIR filter's response to an external input will remain non-
zero for an infinite duration of time. This behaviour is due to the feedback terms 
in the general form of an Nth order IIR filter, which can be described: 
 
 
where      is the filter output,      are the filter inputs,    are the feedforwared 
coefficients and    are the feedback coefficients.   is the feed forward filter 
length and  is the feedback filter length. 
 
                                3.7 
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Four different types of IIR filters were tested in this research, specifically, 
Butterworth, Yulewalk, Chebyshev type 1 and Chebyshev type 2. Briefly, 
Butterworth filters are designed to minimise ripple in the passband and 
stopband. Chebyshev filters are designed to minimise the error between ideal 
and actual filter performance at the expense of some passband (type 1) or 
stopband (type 2) ripple. Yulewalk filters are recursively designed filters that 
utilise a least squares fit to a specified frequency band. Each filter was 
implemented in MATLAB. 
 
3.2.2.3 Median Least Mean Square filter 
A novel median least mean square (LMS) filter was also tested in this study 
(Pretty et al. 2010). The filter uses a composite trailing 3 point and 7 point 
median value together with a linear least squares approximation to filter data in 
real-time. The fundamental steps to implement the median filter at any given 
time, t=x are: 
 
1. Calculate the median value, M3, of the current and two prior SG readings 
(three samples, 10-minute window) 
2. Calculate the median value, M7, of the current and six prior SG readings 
(seven samples, 30-minute window) 
3. Determine average of M3 and M7 = MA 
4. Fit LMS first-order polynomial line to the current MA value and 12 prior 
MA values (1-hour window of median-filtered values) 
5. Output value at time t = x is the value of this fitted line at t = x 
 
Similar to the FIR and IIR filters, this algorithm was implemented in MATLAB to 
assess filter performance. 
 
3.2.3 Analysis  
Due the random nature of SG data generation, Monte Carlo (MC) simulations 
consisting of 50 runs per patient were used to assess filter performance. The 
overall MAPE and Median absolute percent error (APE) of the unfiltered virtual 
SG data were compared to results for the filtered data. For the FIR and IIR filter 
variants, five cut-off frequencies (ωc) and six filter lengths (NF) were tested, but 
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only the results from the optimal combination of parameters are presented. The 
median filter was implemented as described in Section 3.2.2.3.  
 
3.2.4 Filter results 
The filter performance results in Table 3.5 show that all filter types reduced the 
overall MAPE and Median APE, compared to the unfiltered virtual SG data. The 
Yulewalk IIR filter and Median LMS filter have the biggest impact, reducing the 
MAPE by approximately ~5.8% and the Median APE by 4.8%.  
 
Table 3.5: Filter results from 50-run simulations of 20 virtual SG data sets 
 
 
Based on these results, the Median LMS filter was selected for the remainder of 
the in-silico studies in this research. Furthermore, for retrospective filtering, 
median filters can be centred on the time point of interest to eliminate filter lag. 
More advanced filtering methods, such as Kalman filtering, could be investigated 
in future with a larger cohort of clinical SG data. These results simply provide an 
initial quantification of the effectiveness of basic digital filtering methods. 
 
3.3 Hypoglycaemic alarms 
Hypoglycaemic alarms can be used to predict the onset of hypoglycaemia, 
alerting the user before the BG level drops to a dangerous level. There are a wide 
range of algorithms that can be used, such as threshold alarms, integral alarms 
and Kalman or model-based alarms (Bequette 2010). This section investigates 
the performance of two types of hypoglycaemia alarms: 1) a simple threshold 
alarm, and, 2) an integral alarm (Pretty et al. 2010; Signal et al. 2010). 
 
3.3.1 Patients and methods 
This research was conducted as a retrospective study using records from seven 
patients admitted to the Christchurch Hospital ICU between 2005 and 2007. 
Unfiltered Windowed FIR Butterworth IIR Yulewalk IIR Chebyshev I IIR Chebyshev II IIR Median LMS
ωc = 0.01, NF = 3 ωc = 0.03, NF = 3 ωc = 0.03, NF = 3 ωc = 0.02, NF = 3 ωc = 0.05, NF = 25
Median APE (%) 13.5 9.7 9.5 8.9 10.1 13.6 9
MAPE (%) 16.8 11.9 11.4 11 11.9 16.4 10.9
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Patients were included if they had one or more severe hypoglycaemic episodes, 
defined as BG < 2.2mmol/L, while on the SPRINT glycaemic control protocol 
(Chase et al. 2008c). Patients were excluded if the hypoglycaemic episode 
appeared to be due to sensor failure or a recording error, based on surrounding 
data and expert clinical opinion. Details of the cohort are shown in Table 3.6. The 
use of these patient records fell under existing ethics approval granted by the 
Upper South Regional Ethics Committee, New Zealand.  
 
Table 3.6: Demographics for the 7 patients who had severe hypoglycaemia  
 
 
Clinically validated metabolic system models were used to produce a continuous 
glucose time series from the clinical BG measurements, insulin treatments and 
parenteral/enteral feed data. Similar to the process used for testing the digital 
filters, randomly selected errors from the Gaussian based error model were 
added to the underlying BG trace, producing in a virtual SG data set. These virtual 
SG data sets consisted of 5-minuted SG measurements. To simulate the real-time 
use of CGM, an algorithm was implemented that stepped through the sequence of 
virtual SG data without knowledge of “future” values. All virtual SG data were 
filtered using the real-time median filter described in Section 3.2.2.3. Thus, the 
combination of real-time data streaming with real-time filtering replicated the 
clinical situation in this study of hypoglycaemia alarming.  
 
3.3.2 Alarm designs 
Two hypoglycaemia alarms were tested in this research, a threshold alarm and 
an integral alarm.  
 
3.3.2.1 Threshold alarm  
In its most simple form, a threshold hypoglycaemia alarm will trigger when a 
single glucose measurement is below a pre-defined threshold. Further 
Patients (N) 7
Age (years) 63 (37 - 81)
Gender (M/F) 4/3
Hypoglyceamia BG level (mg/dL) 2.1 (1.7 - 2.2)
APACHE II 25 (12 - 30)
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conditions, such as multiple measurements below a threshold or an average rate 
of change less than zero can be added to improve the robustness of the alarm. 
This study investigated a threshold alarm with the following alarm conditions: 
 
 3 consecutive virtual SG measurements < threshold 
 Average SG gradient < 0mmol/L.min 
 
Three threshold levels were tested, at 2.8mmol/L, 3.3mmol/L and 3.9mmol/L. 
 
3.3.2.2 Integral alarm  
Integral alarms use the area under the (filtered) SG time series to determine 
when to trigger the alarm. Specifically, in this investigation, the area between the 
virtual SG data and a specified level was calculated within a window of prior 
samples, as shown in Figure 3.1. When this integral became less than a 
preselected threshold value, an alarm was triggered, indicating an impending 
hypoglycaemic episode. In this study, 3 integration window lengths of 5,7 or 13 
SG measurements were tested. Furthermore, for each integration window length, 
the 3 specified threshold values were tested. 
 
Figure 3.1 Integral alarm method. The area below the SG data within the integral 
window is used to trigger the alarm. The integral window can only use data prior to 
the time point of interest, to simulate a realistic clinical scenario. 
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3.3.3 Analysis 
The performance of each alarm variant was quantified by lead time of the alarm 
warning and the number of false alarms. Lead time was defined as the time 
difference between the alarm triggering and the clinical BG measurement that 
diagnosed hypoglycaemia. This value essentially measured the time to intervene 
and prevent severe hypoglycaemia. The number of false alarms was also 
recorded to ensure that the method was accurate. An alarm was considered false 
if both of the following conditions held: 
 
 There was more than one alarm for each actual hypoglycaemic episode per 
patient 
 For two clinical blood glucose measurements either side of the alarm, no 
value was less than or equal to 2.2mmol/L.  
 
To get meaningful results with the random SG error, MC simulations were used. 
Each patient’s model-based, BG profile was passed through the Gaussian CGM 
error generator 100 times, creating 100 different virtual SG sequences per 
patient. Results of these 700 trials with the alarm algorithms were analyzed 
using nonparametric statistics. Negative time values indicate that an alarm was 
triggered before a hypoglycaemic event was measured. 
 
3.3.4 Alarm results 
3.3.4.1 Threshold alarm performance 
A representative example of hypoglycaemia detection using the threshold alarm 
is shown in Figure 2.1. In this figure, multiple virtual SG values cross the alarm 
threshold with a negative gradient, satisfying the conditions for alarming. Thus, 
clinical staff would receive warning of hypoglycaemia, before the clinical BG 
measurement that actually diagnosed hypoglycaemia.  
 
The results of the MC simulations are shown in Table 3.7. These results show an 
important trade-off when determining the threshold to be used with a particular 
threshold alarm design. First, raising the threshold from 2.8mmol/L to 
3.3mmol/L and subsequently to 3.9mmol/L increases both the lead time of 
detection and the BG level at alarm. However, these increases come at the 
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expense of alarm sensitivity and specificity. For example, with a threshold of 
3.9mmol/L the alarm gave a median lead time of 75 minutes, but the median 
number of false alarms was 7. Conversely, with a threshold of 2.8mmol/L, the 
lead time is reduced to a median of 15 minutes, but the number of false alarms is 
also significantly reduced.  
 
 
Figure 3.2 A representative example of a threshold alarm giving warning of 
impending hypoglycaemia. 
 
 
Table 3.7: Threshold alarm results over all 700 MC runs 
 
 
These results highlight the importance of tuning threshold alarms appropriately 
for their intended application. In the critical care setting, where clinical staff are 
extremely busy and time is extremely valuable, the number of false alarms is 
potentially more critical than the lead time. A high rate of false alarms will likely 
waste a significant amount nurse time. However, in terms of lead time, a nurse at 
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Hypoglycaemia warning (mins) -15 [-25 - -5] -40 [-75 - -25] -75 [-110 - -45]
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the bedside should be able to confirm a diagnosis of hypoglycaemia and provide 
treatment within 15 minutes, should the alarm sound. Thus, an alarm for critical 
care might be optimised for sensitivity and specificity at the expense of lead time. 
The opposite could also be true for an otherwise healthy individual using the 
alarm for daily BG control. The results shown here suggest a threshold of 
~3mmol/L would be well suited for critical care applications.  
 
3.3.4.2 Integral alarm performance 
Figure 3.3 shows a representative example of the integral alarm triggering at the 
predicted onset of hypoglycaemia. This example uses the same clinical BG 
measurements as Figure 2.1, but the SG data appears slightly different due to the 
randomly selected CGM error. The integral alarm detects the hypoglycaemia well 
in advance of the clinical BG measurement. 
 
 
Figure 3.3 A representative example of an integral alarm giving warning of impending 
hypoglycaemia. 
 
Table 3.8 shows the results from the MC simulations assessing the different 
integral alarm configurations. Two important trends are evident in the results. 
First, increasing the integral window length increased reliability of the alarm by 
providing a higher degree of filtering, which reduced the number of false alarms. 
For example, increasing the integration window length from 5 to 13, while 
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holding the integral threshold at 0.28 min.mmol/L, reduced the number of false 
alarms from 1 [0 - 2] to 0 [0 - 1]. However, the reduction in false alarms came at 
the expense of lead time, which was likely reduced by the additional filter lag, 
delaying the integral threshold crossing.  
 
Second, increasing the integral threshold increased the lead time, up to a median 
of 145 minutes for the 5 integral filter with a threshold of 1.12. This trend was 
consistent across all integration window lengths and the increase in lead time 
was similar for each variant. The trade-off of increasing the threshold to increase 
lead times was the increase in false alarms. Most notably, for the integral alarm 
of length 7, the number of false alarms increased from 1 [0 - 1] to 2 [1 - 3] when 
the threshold was increased from 0.28 to 1.12 min.mmol/L. 
 
Table 3.8: Integral alarm results for all 700 MC runs 
 
 
Overall, there was a clear improvement in the time of detection of hypoglycaemic 
episodes using SG data compared to standard intermittent BG measurements. 
However, trade-offs were exposed when selecting integration window length 
and integral threshold. Ultimately, the optimal values for window length and 
alarm threshold are likely to depend upon the application of the alarm. In the 
critical care setting lead time is arguably less important than high sensitivity. 
Integration window (n)
Integral threshold (min.mmol/L) 0.28 0.56 1.12
Hypoglycaemia warning (mins) -65 [-110 - -35] -95 [-120 - -55] -145 [-180 - -120]
BG level at alarm (mg/dL) 3.2 [3.1 - 3.3] 3.6 [3.4 - 3.7] 4.3 [4.1 - 4.4]
False alarms 1 [0 - 2] 1 [0 - 2] 2 [1 - 3]
Integration window (n)
Integral threshold (min.mmol/L) 0.28 0.56 1.12
Hypoglycaemia warning (mins) -55 [-95 - -30] -85 [-120 - -50] -130 [-180 - -115]
BG level at alarm (mg/dL) 3.1 [2.9 - 3.2] 3.4 [3.3 - 3.6] 4.2 [3.9 - 4.3]
False alarms 1 [0 - 1] 1 [0 - 2] 2 [1 - 3]
Integration window (n)
Integral threshold (min.mmol/L) 0.28 0.56 1.12
Hypoglycaemia warning (mins) -35 [-73 - -15] -55 [-95 - -25] -120 [-160 - -85]
BG level at alarm (mg/dL) 2.9 [2.7 - 3.0] 3.1 [2.8 - 3.3] 4.0 [3.4 - 4.2]
False alarms 0 [0 - 1] 1 [0 - 1] 1 [1 - 2]
5
7
13
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Thus, a longer integration window might be coupled with a lower integral 
threshold to reduce false alarms at the expense of lead time. 
 
3.3.5 Limitations 
Overall, the low number of data sets available for this investigation may mean 
that the results are not representative of the overall population behaviour. For 
this reason, extensive optimisation of alarm algorithms was not justified. 
However, the results shown here do give a good indication of how different 
alarm parameters affect lead time, sensitivity and the rate of false alarms. 
Repeating the study with a larger cohort would provide a more statistically 
powerful result. However, in the Christchurch ICU, all patients receiving insulin 
are on the SPRINT glycaemic control protocol and only ~4% of patients 
experience hypoglycaemia, making it difficult to recruit a large cohort. Thus, data 
from a different study at a different centre might be needed to obtain a large 
cohort containing clinical hypoglycaemia. 
 
3.4 Summary 
The research presented in this chapter investigated 3 key elements required to 
complete in-silico trials of CGM in critically ill patients. First, CGM error models 
based on available data from the literature were explored. Two models were 
described and can be used for future work: 1) A Gaussian based CGM error 
model, created using ICU specific SG data, and, 2) an autoregressive based CGM 
error model, derived using SG data from people with diabetes. Second, a range of 
digital filters including FIR, IIR and median LMS filters were tested. The median 
filter was the most effective at removing SG error, reducing the overall MAPE 
from 16.8% pre-filtering to 10.9% post-filtering. Third, threshold and integral 
hypoglycaemia alarms were investigated and lead times of 15-145 minutes were 
achieved, depending on alarm parameters. However, the trade-off between alarm 
lead time and sensitivity to detecting hypoglycaemia reinforces the importance 
of tuning alarm parameters for the intended application. Overall, this study 
shows that simple filtering and alarm methods can provide a highly effective 
warning system to alert at the onset of predicted abnormal glycaemia.  
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Chapter 4. In-silico TGC with SG 
This chapter describes an in silico feasibility study conducted to determine 
whether CGM devices could be effectively utilised in the Christchurch Hospital 
ICU, in conjunction with existing TGC protocols. The main goals of this study 
were to show that nurse workload could be significantly reduced, BG control 
could be maintained, and hypoglycaemia could be reduced, with the 
implementation of CGM devices in a successful, effective and existing TGC 
protocol.  
 
4.1 Introduction 
Many different TGC protocols have been trialled in critical care units around the 
world, from sliding scale protocols (Gonzalez-Michaca et al. 2002; Krinsley 2004; 
Zimmerman et al. 2004) to advanced model-based control protocols (Chase et al. 
2007; Evans et al. 2012; Fisk et al. 2012; Plank et al. 2006). The Christchurch 
Hospital ICU has been using the SPecialised Relative Insulin Nutrition Tables 
(SPRINT) protocol since 2005, when the protocol was implemented as a clinical 
practice change (Chase et al. 2008c).  
 
The SPRINT protocol is a nurse driven model-based protocol that was developed 
using simulation methods that utilise clinically validated mathematical models of 
the glucose-insulin regulatory system (Lonergan et al. 2006; Wong et al. 2006). 
Most TGC protocols only adjust insulin in response to BG levels (Meijering et al. 
2006), but SPRINT modulates both insulin and nutrition to obtain maximum 
performance and safety. Thus, SPRINT was introduced as two 'paper wheels' 
shown in Figure 4.1 
 
Start up criteria for SPRINT is 2 BG measurements > 8mmol/L, although 
occasionally a patient will start on SPRINT at the discretion of the attending 
physician. Once on SPRINT, BG is measured at the bedside every 1-2 hours by the 
nurse, depending on the stability of BG. The current BG measurement, previous 
insulin bolus and previous nutrition rates are selected on the corresponding 
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paper-wheel to determine the new treatment. All insulin doses are given as 
boluses to reduce the risk of hypoglycaemia that can occur if an insulin infusion 
is left unattended. 
 
 
Figure 4.1 SPecialised Relative Insulin Nutrition (SPRINT) protocol insulin and 
nutrition wheels.  
 
An analysis of the performance of SPRINT across 371 patients showed excellent 
results. Specifically, more BG measurements were in the desirable glycaemic 
band (4.4-6.1mmol/L) and, although still present on rare occasions, the instances 
of severe hypoglycaemia (BG < 2.2mmol/L) were significantly reduced compared 
to treatment methods prior to SPRINT (Chase et al. 2008c). The only major 
limitation of the new protocol was the number of BG measurements required per 
day, which averaged around 16 per patient per day. At approximately 1.5-4 
minutes per BG measurement, nurses could easily spend a total of 1 hour or 
more measuring BG, which is clinically significant.  
 
CGM devices with their 1-5 minute measurement interval offer far more frequent 
BG measurements than standard intermittent BG monitoring, potentially 
enabling better BG control and further reduction in hypoglycaemia through early 
warning alarms/interventions. Furthermore, most CGM devices only require 3-4 
manual BG measurements per day for device calibration. Thus, nurse workload 
in measuring BG could also potentially be reduced by up to ~75%. However, 
added sensor noise or error is a trade off in some cases of the CGM devices far 
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higher, automated sampling rate and any excess noise must be effectively 
managed. Fortunately, these sensor and algorithm technologies are also 
constantly evolving with every new generation offering improvements. 
 
This study examines how patients might behave when controlled by the SPRINT 
TGC protocol driven by simulated SG measurements, rather than the normal 1-2 
hourly BG measurements taken by the nurse. Hypoglycaemia detection and 
prevention are also tested, as CGM devices offer the ability to potentially detect 
and avert these events much earlier than with current methods. This in-silico 
study thus aims to demonstrate that CGM devices coupled with an effective TGC 
protocol are capable of reducing nursing workload, while maintaining safe and 
effective glycaemic control. 
 
4.2 Subjects and methods 
4.2.1 Subjects 
This study uses patient data from the benchmark cohort, proposed by Chase et 
al. (Chase et al. 2008b). It includes 20 patients who were admitted to the 
Christchurch hospital ICU during the SPRINT protocol clinical practice change 
(Chase et al. 2008c). Each patient spent 5 days or longer on SPRINT, during 
which time some patients experienced breaks in treatment, typically due to 
surgery or other clinical changes. Patients who experienced breaks from SPRINT 
had their BG data segmented into 2 or more uninterrupted treatment sections, 
resulting in 33 individual continuous data sets. Each treatment section was then 
considered an individual ‘patient’ for the purposes of this study. Details of the 
patient cohort are shown in Table 4.1. The use of these patient records falls 
under existing ethics approval granted by the Upper South Regional Ethics 
Committee, New Zealand. 
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Table 4.1 Cohort details, presented as Median [inter-quartile range (IQR)] where 
applicable. 
 
 
4.2.2 Simulated SG data, filtering and hypoglycaemia alarm design 
These methods were implemented using MATLAB. BG profiles were generated 
incrementally for each patient at 5 minute intervals using clinically validated 
metabolic system models (Lonergan et al. 2006; Wong et al. 2006). These BG 
profiles were sampled in-silico and CGM sensor errors were added creating 
virtual SG data.  
 
This study used the Gaussian and Autoregressive based CGM error models 
described in Chapter 3. Two levels of the Gaussian error model were 
investigated. First, the model was implemented as described in Chapter 3, to 
produce equivalent simulated SG errors on a similar cohort to those reported by 
a study of CGM in a medical ICU in 2004 (Goldberg et al. 2004). Second, the 
Gaussian model was implemented at a reduced magnitude, where SG errors 
generated by the model were halved to account for any technological advances in 
these devices since 2004. Overall, SG errors were randomly sampled from the 
appropriate Gaussian distribution and added to underlying BG data, creating 
virtual SG data. The top and middle plots in Figure 4.2 show examples of the SG 
data generated using the Gaussian CGM error model. Figure 4.3 compares the 
probability density functions for the CGM error models. 
 
The autoregressive noise model was based on data from a 2008 study of CGM in 
ambulatory type 1 diabetics monitored using the FreeStyle Navigator CGM 
device (Breton & Kovatchev 2008). This model was implemented as described in 
Chapter 3. Briefly, an overall lag was applied to BG data using a first order 
Number of Patients 33
Age 68 [59.5 - 73]
Gender 60% Male
Length of SPRINT (hours) 167 [81 - 241]
Number of Measurements 102 [57 - 169]
APACHE II 19 [16 - 24]
APACHE II risk of death 33.6 [13.5 - 51.2]
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diffusion model to account for physiological and sensor lags. Next, time-
dependent sensor errors were added to the delayed glucose data, creating virtual 
SG data. The bottom plot in Figure 4.2 shows an example of SG data generated 
using the autoregressive CGM error model. The probability density function 
(PDF) for the autoregressive model in Figure 4.3 is similar to the reduced 
Gaussian model distribution, but the time dependent aspect of the 
autoregressive model is not portrayed. 
 
 
Figure 4.2 Example of simulated SG data overlaying modelled BG data. Top - SG data 
created using the Gaussian model, Middle - SG data created using the Gaussian 
model with reduced magnitude, and, Bottom - SG data created using the 
autoregressive model. 
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Figure 4.3 Model derived probability density functions for the 3 variations of SG error 
over ~250,000 data points 
 
In addition to a random or quasi-random error, CGM sensor error often contains 
a bias or drift aspect (Boyne et al. 2003; Castle & Ward 2010). Drift and bias, 
which can occur due to sensor degradation or bio-fouling over time, were not 
considered in this study. Although mentioned in the literature, these factors have 
not been reported in detail to the author’s knowledge and thus could not be 
implemented in the sensor error models. 
 
Virtual SG data were filtered incrementally, simulating the process that would be 
encountered in a real-time clinical setting. The novel median filter described in 
Chapter 3 was used in this study. Briefly, the filter consists of a composite 3 point 
and 7 point median filter, coupled with a LMS estimator. This filter is effective at 
removing unwanted and potentially un-physiological noise from SG data (Pretty 
et al. 2010). 
 
A simple threshold algorithm was used to trigger an alarm and dextrose 
intervention when a hypoglycaemia appeared imminent. Specifically, if two 
consecutive filtered SG measurements were below 3mmol/L, an intravenous 
dextrose intervention was triggered. Four different sized dextrose interventions 
were tested in this study (3, 6, 12.5, and 25 grams), although these were held 
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constant for any given simulation. The intervention was given over 3 minutes to 
approximate the clinical situation and two interventions could not be given 
within 15 minutes, to allow time for a BG change before the second intervention. 
 
4.2.3 Simulating SPRINT with SG 
A single measurement from the filtered virtual SG data was taken every 1-2 
hours and used to guide the SPRINT protocol, with no other modifications to the 
algorithm. The SPRINT algorithm and its intervention frequency were not 
changed to enable a direct comparison to clinical results and interventions. 
While the SPRINT protocol only used 1-2 hourly values from the filtered virtual 
SG data, the full set of SG data was used for hypoglycaemia alarming and 
intervention. 
 
4.2.4 Analysis 
MC methods were used due to the random nature of SG error, and each of the 33 
patients were simulated over 10 runs. A total of 7 simulations were run to test 
the various CGM error models and hypoglycaemia interventions. First, 3 
simulations were run to test each CGM error model without hypoglycaemia 
intervention, and these were compared to baseline results determined using the 
clinical BG data. Second, 4 simulations were run using the Gaussian CGM error 
model to test the effect of each hypoglycaemia intervention.  
 
Time in a 4.4 - 6.1mmol/L glucose band and number of hypoglycaemic events 
were considered the most important metrics of TGC performance for this 
investigation. Time in band was calculated using only the 1-2 hourly filtered SG 
measurements that were used to drive SPRINT, ensuring an equal comparison to 
the baseline results. Hypoglycaemia was defined as a BG < 2.2mmol/L in the 
baseline case, or a filtered virtual SG measurement < 2.2mmol/L in the 
simulation runs. 
 
Nutrition and insulin interventions prescribed by SPRINT were also examined. 
Differences in these interventions compared to the baseline SPRINT results were 
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analysed to determine the impact of CGM sensor noise on operation of this 
protocol. 
 
4.3 Results 
Table 4.2 shows how glycaemic control was affected when the CGM error models 
were implemented with no hypoglycaemia interventions. The median and IQR 
BG results show no clinically significant difference between the baseline, reduced 
Gaussian error, full Gaussian error, and autoregressive error simulations. The 
time in band is reduced by up to 4.5% with the addition of SG error and 
consequently the <4.4mmol/L, <4mmol/L and <2.2mmol/L bands are slightly 
increased. Insulin and glucose interventions are unchanged, but this may also be 
partially due the discretisation of these interventions in SPRINT (Lonergan et al. 
2006). Per-patient results show similar overall trends. 
 
Table 4.3 shows the results from the 4 simulations of Gaussian error when a 
dextrose bolus intervention was administered at the predicted onset of 
hypoglycaemia. The median and IQR BG results show no clinically significant 
difference between any of the interventions and the baseline. Interventions did 
not increase time in any band when compared to results with no intervention in 
Table 4.2. However, the number of interventions and hypoglycaemic events 
decreases with larger interventions, up to a limit of 12.5g. With an intervention 
of 25g the number of hypoglycaemic events increases. This potentially counter-
intuitive trend continues with 40g interventions (results not shown). Overall, the 
interventions have reduced the number of hypoglycaemic events from 1 in 33 
patient episodes to 0, which is clinically significant. 
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Figures 4.4-4.6 illustrate the affects of using 3, 12.5 or 25 gram dextrose boluses 
to prevent the onset of predicted hypoglycaemia. The shaded band in the upper 
plot represents the target BG band (4.4-6.1mmol/L). Filtered virtual SG 
measurements are shown as red crosses and the underlying modelled BG data is 
show by the solid red line. The interventions are identified by vertical red bars in 
the lower sub-plot of each figure, labelled PN dextrose.  
 
The effect of each intervention size on glycaemia can be very different, which 
highlights the importance of sizing the dextrose bolus appropriately. Figure 4.5 
shows the response to a 12.5 gram dextrose bolus when a patient is approaching 
hypoglycaemia. The intervention successfully lifted BG to a level just above the 
target band, preventing hypoglycaemia. Two additional dextrose boluses were 
deemed necessary by the intervention algorithm, but these occurred within 15 
minutes of a SPRINT BG measurement, so they were not administered. At hour 
19, the SPRINT protocol administered no insulin, which was enough to raise BG 
back into the desired band without the need for the dextrose bolus.  
 
Figure 4.4 shows that the 3 gram bolus had little effect and a second dose was 
given shortly after the first bolus. Later in the monitoring period, there were 
further interventions given and in each case, the 3 gram bolus was not enough to 
lift BG into the desired band. Conversely, Figure 4.6 shows that the 25 gram 
bolus was too large, causing overcorrection of low BG and a loss of control. 
Following a 25 gram treatment, BG rises significantly and the TGC protocol 
overcompensates with insulin at the next 1-2 hourly intervention, causing a 
sudden drop. Hence, an oversized dextrose intervention can increase BG 
variability and increase hypoglycaemia due to the response of the controller. 
 
 
43 
 
 
Figure 4.4 The effect on BG of a 3 grams intervention of glucose at the predicted 
onset of hypoglycaemia.  
 
Figure 4.5 The effect on BG of a 12.5 grams intervention of glucose at the predicted 
onset of hypoglycaemia 
 
Figure 4.6 The effect on BG of a 25 grams intervention of glucose at the predicted 
onset of hypoglycaemia 
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4.4 Discussion 
4.4.1 Performance 
The aims of this in-silico study were to show that nursing workload could be 
reduced, the level of glycaemic control maintained, and early hypoglycaemic 
detection implemented using CGM sensors in the ICU, despite potentially high 
levels of sensor noise in individual measurements. The performance of the CGM 
sensors in this role was evaluated in-silico using MC simulations with stochastic 
CGM error models and ICU patient data. The in-silico model has been extensively 
clinically validated on independent patient data (Chase et al. 2010). 
 
There was no clinically significant reduction in the BG control metrics with the 
addition of SG error, as seen in Table 4.2. The ability to maintain good BG control 
suggest that the additional error introduced by the CGM sensors has little effect, 
at least in the context of the SPRINT protocol. This outcome may be because 
SPRINT is model-derived and the inputs/outputs are discretised, so small sensor 
errors do not generally have a large effect on the insulin and nutrition rates 
selected by the protocol.  
 
The number of patients experiencing hypoglycaemia and the percentage of total 
BG measurements < 2.2mmol/L increased with the addition of SG error. The 
increase in hypoglycaemia shown in Table 4.2 could be due to added SG error 
causing an underlying normoglycaemic level to falsely appear low, or equally, SG 
error adversely affecting the control protocol. Regardless of the cause, the 
increase in hypoglycaemia might be considered clinically unacceptable. However, 
clinically, if CGM devices were to be used in the hospital setting to guide therapy, 
they would need to be trusted and acted upon. Thus, this study investigated also 
using the SG data to trigger intravenous dextrose boluses to prevent 
hypoglycaemia. 
 
The results in Table 4.3 show that intervening with a dextrose bolus at the onset 
of potential hypoglycaemia had little effect on overall BG control. The percent BG 
between 4.4mmol/L and 6.1mmol/L for all four intervention sizes were ~45%. 
However, the number of patients experiencing hypoglycaemia varied 
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substantially depending on the size of the intervention, showing the importance 
of sizing this rescue intervention appropriately.  
 
The 3 gram dextrose intervention had little or no effect on the number of 
patients experiencing hypoglycaemia. Figure 4.4 shows a representative example 
of the effects of a 3 gram dextrose bolus, given at the onset of predicted 
hypoglycaemia. The initial dextrose bolus failed to restore BG adequately, and 
15-20 minutes later a second intervention was given. Furthermore, 
approximately 1 hour later a third intervention was administered, suggesting the 
3 gram intervention is too small. Multiple undersized interventions within a 
short time frame can lead to an unnecessary increase to nurse workload and 
clinical burden.  
 
The number of patients experiencing hypoglycaemia reduced as the intervention 
size increased, to a limit of 12.5 grams. Figure 4.5 shows a representative 
response in BG when a 12.5 g dextrose bolus is given at the predicted onset of 
hypoglycaemia. The intervention causes a rise in BG to ~7.5mmol/L, preventing 
hypoglycaemia and restoring BG to the desired band. Interestingly, in this 
example the following BG at hour 18 has a large positive SG error. When this BG 
is input to the SPRINT controller, an insulin bolus is prescribed and the BG 
continues to fall up until hour 19. This outcome is not a reflection on the size of 
intervention, it simply reinforces the importance of designing the controller 
appropriately if SG measurements are to be used.  
 
Interestingly, when the intervention is increased to 25 grams the results show a 
substantial increase in the number of patients experiencing hypoglycaemia. A 
representative example of a 25 gram intervention is shown in Figure 4.6. The 
intervention at 12.5 hours causes the BG level to rise to over 12mmol/L. At hour 
13, a BG of ~8mmol/L is entered into the SPRINT controller and an insulin bolus 
is administered. This extra insulin, when the patient is likely already quite 
sensitive or still has a lot of insulin on-board, causes BG to drop to below 
2.2mmol/L and a second dextrose intervention is given. This potentially counter-
intuitive trend of rebound hypoglycaemia continues to occur over the following 
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hours as the controller and intervention combination struggle to control BG. This 
indicates that the size of the bolus needs to be carefully selected, maybe on a 
patient-specific or protocol-specific basis, or extra information should be 
provided to the control protocol so it can factor in the effect of the bolus at the 
next intervention.  
 
A final significant result is the potential reduction in clinical burden with the use 
of CGM device. Typically, SPRINT requires 16 measurements per day on average 
at 1.5 - 4 minutes per measurement for all tasks (Lin et al. 2008). Assuming 4 
calibration measurements per day with CGM, the total measurement burden 
could be reduced by 75%. Thus, nurses could potentially gain 18-48 minutes per 
patient per day with the use of CGM, which is clinically significant in a busy ICU 
environment. It is possible that some of this reduction in clinical burden may be 
offset by hypoglycaemia alarms and interventions. However, enhanced alarm 
algorithms and constantly evolving CGM technology may resolve or reduce this 
issue.  
 
4.4.2 Limitations 
Although the virtual patient simulation methods used here are clinically well 
validated (Chase et al. 2007; Chase et al. 2010; Lonergan et al. 2006), results 
from this in-silico study may differ from actual clinical results. In this study, the 
BG sequences used to drive SPRINT were model-based, not real SG output data. 
However, this analysis provides a strong initial proof of concept and the results 
justify a pilot clinical investigation. Equally, the cross validation study using 
independent data for this model in Chase et al. (2010) shows these errors would 
likely be small. 
 
The CGM error models used in this study may not completely describe SG 
behaviour in critically ill patients. The Gaussian error model was based on ICU 
data, however the model was generated using sensor error statistics and the 
time-series information was not available. Thus, SG errors were assumed to be 
independent. The autoregressive CGM error model is more complete in terms of 
modelling the interdependence of errors and the delay in glucose diffusion from 
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blood to the sensor, but the model was generated using data from people with 
type 1 diabetes. Thus, this autoregressive model may not necessarily provide the 
best model of CGM behaviour in ICU patients. It is anticipated that true SG error 
characteristics in critically ill patients fall somewhere between these simulated 
models. However, to date, there is no publically available SG-BG paired data for 
ICU patients to create better models. 
 
Calibration drift due to sensor degradation or bio-fouling over time was not 
considered in this study. Without correction, calibration drift is characterised by 
a glucose bias that increases over time. This drift could potentially reduce control 
and increase the rate of false positives/negatives in hypoglycaemia alarms. 
However, the magnitude of the bias due to drift is often a function of the 
frequency and quality of calibration measurements, which can be controlled 
more readily in a critical care setting. This issue has also not been quantified, to 
date, in the literature for CGM devices in the critical care setting. 
 
4.5 Summary 
This chapter has analysed in-silico the use of CGM sensors with simple filters and 
hypoglycaemia alarms to provide input to the SPRINT TGC protocol. The main 
results and conclusions include: 
 
 CGM devices, even with significant error, had little impact on TGC 
performance and time in a euglycaemic range was between 45-50%, 
compared to 50% in the baseline case. 
 Threshold hypoglycaemia alarms have the potential to reduce the rate of 
hypoglycaemia to zero with minimal false positives. 
 The glucose bolus intervention size is critical. This study found ~12.5g to be 
relatively optimal and that levels of 25-40g can counter-intuitively increase 
hypoglycaemia. Thus, this intervention is also control protocol specific. 
 The use of CGM devices with SPRINT should reduce average nurse burden for 
BG measurements by up to 75%, potentially saving 18-48 minutes per 
patient, per day, which is clinically significant in the very busy ICU. 
 
All of these results justify clinical testing for validation and highlight some of the 
main issues in using CGM devices for TGC in critical care. 
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Chapter 5. Analysing CGM trend accuracy 
The feasibility study in the previous chapter showed that CGM devices have the 
potential to significantly improve safety and BG control when using TGC 
protocols with critically ill patients. Most notably, trend information provided by 
CGM allows algorithms to alarm at the onset of predicted hypoglycaemia, which 
is not practical or useful with intermittent BG monitoring. With trend 
information available from the CGM, new metrics and methods of analyses are 
required to determine the level of trend accuracy. This chapter describes a new 
tool designed to assess trend accuracy of SG data, both for use in control, as well 
as for (primarily) assessing device performance.  
 
5.1 Introduction 
Unlike traditional self monitoring BG devices, which offer a ‘snapshot’ of glucose 
concentration at the time of testing, CGM devices give additional information 
about the rate of change of BG over short periods of time (minutes). This 
information is particularly useful for revealing and predicting abnormal 
glycaemia, such as hypoglycaemia or hyperglycaemia, and deciding on the 
appropriate course of treatment (Beck et al. 2009; Bequette 2010; Hoeks et al. 
2011a; Pretty et al. 2010; Signal et al. 2012a). However, to make good treatment 
decisions it is important to have good trend accuracy, not just good point-to-
point accuracy.  
 
Trend accuracy refers to the ability of a CGM device to accurately capture the 
true 'shape' of glycaemia over time, whereas, point-to-point accuracy assesses 
the discrepancy between a CGM and reference BG measurement at a single point 
in time. One important area where trend information is used is closed loop 
glycaemic control, where CGM devices are coupled with insulin pumps and an 
appropriate control algorithm to provide automatic glycaemic control. Several 
pilot studies have investigated closed loop control in people with diabetes 
(Breton et al. 2012; Clarke et al. 2009; Weinzimer et al. 2008). However, these 
methods are still being developed and it is not used as a standard therapy. 
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Another area where trend accuracy is particularly important is hypoglycaemia 
alarms, which often inherently use trends to predict the onset of hypoglycaemia 
(Bequette 2010; Dassau et al. 2010; Eren-Oruklu et al. 2010; McGarraugh 2010; 
Pretty et al. 2010). In this case, poor trend accuracy can result in a high rate of 
false alarms, or worse, missed hypoglycaemic events.  
 
In these applications, trend accuracy is particularly important because even 
though good trend accuracy doesn't guarantee success, poor trend accuracy is 
likely to cause failure. As trend dependent applications/features, such as closed 
loop control or hypoglycaemic alarms, become more common in CGM devices the 
need for good trend accuracy increases. 
 
Many users of CGM devices are likely to be unaware of the level of trend accuracy 
of their particular device. Furthermore, studies in the literature that use CGM 
devices or investigate CGM performance often report point-to-point accuracy, 
but rarely quantify trend accuracy (Corstjens et al. 2006; Djakoure-Platonoff et 
al. 2003). This lack of clarity could be because there are many methods or 
metrics available for assessing point-to-point accuracy, such as mean absolute 
difference (MAD), mean absolute relative difference (MARD), the Bland-Altman 
plot (Bland & Altman 1999), and Clarke error grid (Clarke 2005). However, there 
are very few metrics to assess trend accuracy (Kovatchev et al. 2004), 
particularly independent of BG level and BG accuracy.  
 
One method that does assess CGM trend accuracy is the continuous glucose error 
grid analysis (CG-EGA) (Kovatchev et al. 2004). CG-EGA evaluates the accuracy of 
continuous glucose monitoring sensors in terms of both point-to-point accuracy 
and trend (rate) accuracy. Results from the CG-EGA are presented in a table, 
showing the proportion of paired BG/SG measurements that fall into clinically 
acceptable, unacceptable and benign zones. While the results produced by CG-
EGA have been reported to be difficult to interpret (Wentholt et al. 2006), the 
method certainly represents a step in the right direction in terms of assessing 
both aspects of sensor accuracy.  
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Hence, there is a major need for independent trend metrics as increasing 
numbers of CGM devices make their way into the market. Both regulatory bodies 
and end users need to be confident that CGM devices have good trend accuracy, 
as well as good point-to-point accuracy, especially if they feature predictive 
hypoglycaemic alarms based on trends. The aim of this study was to develop a 
metric or tool that could quantify trend accuracy and present the results in an 
intuitive plot that is easy to interpret for any user. This tool is intended to be 
used in conjunction with traditional point-to-point accuracy methods to provide 
a fuller assessment of sensor accuracy and clinical utility. This chapter describes 
that tool: the Trend Compass. 
 
5.2 Subjects and Methods 
This chapter introduces a novel trend metric that can be used to assess the trend 
accuracy of SG measurements from a continuous glucose monitoring device, with 
reference to BG reference measurements determined using a gold standard 
measurement device, such as a YSI chemistry analyser. 
 
5.2.1 Quantifying trend 
Trend accuracy can be defined as the level of agreement between the rates-of-
change of two independent devices measuring a single time series, over the same 
time period. An effective and simple way to quantify trend accuracy is derived 
from the geometric interpretation of the dot product. The dot product assesses 
the similarity of 2 vectors A and B: 
 
 
Where            represents two measurements from a BG reference and 
          represent two SG measurements at the same time points. 
Rearranging Equation 5.1 to make   the subject gives a normalized measure of 
similarity between A and B: 
 
               5.1 
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The output of Equation 5.2 provides the angle between the two vectors, A and B, 
where a smaller angle is indicative of better trend accuracy. Thus, Equation 5.2 
can be used with clinical data to quantify the level of trend accuracy between 
paired sets of BG/SG measurements, independent of the point-to-point 
measurement accuracy which is often referred to simply as error.  
 
The value of θ is dependent on the time interval between BG/SG samples, which 
should be held constant when comparing different pairs of vectors. This study 
uses a 1 hour time interval between consecutive samples of BG and SG. More 
frequent sampling, such as 15 minutes, can be analysed with the Trend Compass 
by using a 1 hour window, sliding at 15 minute increments. The sensitivity of the 
Trend Compass to timing errors in the sampling frequency has not been 
investigated as this chapter was written to present the overall method, which can 
be refined by consensus or future studies in due course. 
 
5.2.2 Trend Compass plot 
Overall trend accuracy from Equation 5.2 can be conveyed visually using the 
Trend Compass shown in Figure 5.1. A polar coordinate system is used. The 
angular coordinate depicts the trend accuracy (θ degrees from top or bottom 
vertical) and the radial coordinate shows the reference BG level (See Appendix A 
for a step-by-step guide to using the Trend Compass). Trend accuracy is plotted 
against reference BG level to show how it changes over the range of glucose 
values, because very good trend accuracy is more crucial during hypoglycaemia 
or hyperglycaemia where important treatment choices are potentially affected. 
For example, a mismatch in trend at 8mmol/L would likely lead to less severe 
complications than the same mismatch in trend at 3.2mmol/L. 
 
The top hemisphere of the Trend Compass shows trend accuracy when the 
reference BG rate of change is ≥ 0 (BG is rising - examples F,A,B in Figure 5.2) 
and the bottom hemisphere shows trend accuracy when the reference BG rate of 
        
   
      
  5.2 
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change is < 0 (BG is falling - examples C,D,E in Figure 5.2). Furthermore, the 
hemispheres are divided into two quadrants, which each give information about 
the relative rate-of-change between the reference BG and the SG. For example 'B' 
in Figure 5.2 shows a BG change from 7mmol/L to 8.2mmol/L and an SG change 
from 7mmol/L to 7.5mmol/L, so the top-right quadrant is used. Alternatively, if 
SG is rising more steeply than BG like 'F' in Figure 5.2, then the top-left quadrant 
is used. Note examples 'A' and 'D' in Figure 5.2 have perfect trend accuracy, even 
though there is a significant offset between SG and BG in 'A', so they are plotted 
on the vertical line between quadrants. Importantly, these examples are shown 
to reinforce that this Trend Compass assesses trend accuracy independent of 
point-to-point error. 
 
 
 
Figure 5.1 The Trend Compass, used to assess the trend accuracy of a set of 
measurements relative to a corresponding reference set of measurements. Green 
zones show areas of good trending, and yellow and red zones show areas of 
moderate to severe clinical risk, respectively 
 
 
 
 
BG 
BG 
BG < SG BG > SG
BG < SG BG > SG
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Figure 5.2 Six examples of SG and BG paired measurements with their corresponding 
point on the Trend Compass. Note: comparing 'A' to 'D' shows that the constant bias 
has no effect on how trending is displayed on the Trend Compass (Both examples 
have perfect trend accuracy so θ=0°). 
 
In addition to separating the Trend Compass into four quadrants, two green 
zones around the vertical axis were added to show ‘good’ trend accuracy. To 
present the method, the size of the green zones were set at ±10° on the plot, 
A 
B 
C 
D 
E 
F 
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which captured mismatches in trend of up to 20° (see note at the bottom of 
Appendix A). The size of the green zones was set with conservative acceptability 
in mind to present the method and may be changed by future users as desired, so 
long as it is held constant when comparing the trend accuracy of multiple 
devices. A few survey inputs from physicians suggest these limits are reasonable, 
although this survey was not comprehensively done and a large survey might be 
required for consensus on proper zone settings. 
 
In the radial direction, the Trend Compass has been separated into three zones to 
reflect the clinically significant glycaemic zones: 1) hypoglycaemia; 2) 
euglycaemia; and 3) hyperglycaemia. The boundaries presented in this paper are 
0 to 5mmol/L for hypoglycaemia, 5 to 8.9mmol/L for normoglycaemia, and 
greater than 8.9mmol/L for hyperglycaemia. These zones are similar to what is 
widely accepted and published, but, again, may be changed by the user as 
desired. 
 
Finally, four regions of the Trend Compass are coloured to highlight clinically 
significant zones where trend accuracy is most important. The yellow regions 
show areas where reference BG is above 8.9mmol/L and rising with poor trend 
accuracy. Hence, moderate caution should be applied. The red regions highlight 
areas where the consequences of poor trending could be far more significant, 
such as when reference BG is below 5mmol/L and falling. In both cases, 
treatment decisions based on poor trending in SG data could increase the risk of 
adverse outcomes. 
 
5.2.3 Accompanying numerical trend metrics 
The Trend Compass was intended to be a visual tool that is fast and easy to 
interpret. The use of vector agreement as the basis of the Trend Compass is a 
novel means for assessing trend in this context, and it allows direct, objective 
numerical comparison between devices. For this reason, a simple evaluation 
table can also be created for direct analysis, comparison and/or regulatory 
processes. Table 5.1 represents a simple choice to present the concept and it 
could easily be augmented as desired for analysis or regulatory purposes. 
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Table 5.1 A table of metrics to accompany the Trend Compass plot. 
 
 
Furthermore, analogous to MAD, a numerical metric frequently used to quantify 
point-to-point accuracy (Clarke & Kovatchev 2007; Klonoff 2005a; Kovatchev et 
al. 2008) the user could present trend accuracy using a Trend Index (TI), defined:  
 
 
TI describes the average overall trend accuracy and a lower TI is indicative of 
better global trend accuracy. 
 
5.2.4 Simulated data 
To validate the Trend Compass in-silico, artificial SG and BG data sets were 
created in MATLAB. A glucose trace was created using a random walk model and 
normally distributed error was added to give hourly paired measurements. The 
paired measurement sets are used to illustrate the use of the Trend Compass. 
The data sets simulated four typical (limit case) scenarios that might be 
encountered during real-world use: 
 
 Low glucose variability patient with low sensor error 
 Low glucose variability patient with high sensor error 
 High glucose variability patient with low sensor error 
 High glucose variability patient with high sensor error  
 
Overall trend accuracy
Percent in green
Percent in yellow
Percent in red
When BG is rising BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green
Percent outside green
When BG is falling BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green
Percent outside green
   
 
 
       
 
   
 5.3 
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5.2.5 Clinical data 
Guardian Real-Time (Medtronic; Northridge, CA) Continuous glucose monitoring 
data and YSI 2300 reference BG measurements from 2 patients were used to 
show the Trend Compass in use with clinical data. Each patient was monitored 
for ~3 days, during which time the SG was recorded every 5 minutes and BG was 
determined approximately every 60 minutes. BG measurements were paired 
with the SG measurement that was sampled closest to the time of BG sampling. 
Overall, the median [IQR] sampling interval between BG measurements was 60 
[55 - 62] minutes. Finally, this data was used to show the independence of this 
trend metric to point-to-point error.  
 
5.3 Results 
5.3.1 Simulated data 
The Trend Compass was first tested using simulated paired SG and BG 
measurements, sampled at 1 hour intervals. Figures 5.3-5.6 and Tables 5.2-5.5 
show the trend accuracy results for the four simulated data sets described in 
5.2.4. In all four figures, the blue line represents simulated SG data and the red 
circles represent BG data.  
 
Figure 5.3 shows a low glucose variability patient, with low sensor error and the 
corresponding Trend Compass plot. The Trend Compass plot shows very good 
trend accuracy, with most of the points lying close to the vertical lines at the 
cardinal North (N) and South (S) position (TI = 11.3°). In the radial direction, the 
Trend Compass plot depicts the patient as a low glucose variability patient, as all 
of the points are contained within the normoglycaemic band. Table 5.2 also 
shows good trend accuracy results for this patient with 91.3% of measurements 
falling within the green zones.  
 
Figure 5.4 shows a patient with the same glucose trace characteristics as in 
Figure 5.3, but with a higher level of sensor error. The increase in error has 
resulted in a Trend Compass plot with visibly more points outside the green 
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zones (TI = 28.1°). This result is also reflected in Table 5.3, which reports 39.1% 
of points in the green zones and 8.7% of points in the red zone.  
 
Figure 5.5 shows an example of a patient with high glucose variability, coupled 
with low sensor error. The Trend Compass plot for this patient appears similar to 
Figure 5.3 with majority of points near the N and S positions, and a similar TI of 
11.1°. However, in the radial direction the points are far more spread out due to 
the large range of glucose values in the data set. Table 5.4 shows trend accuracy 
to be good, with 82.6% of data points in the green zones and 0% in the yellow or 
red zones. 
 
Finally, Figure 5.6 shows an example patient with high glucose variability and 
high sensor error. The resulting Trend Compass shows a reduction in trend 
accuracy when compared to Figure 5.5, with a much wider angular spread of 
results (TI = 27.0°). Table 5.5 shows that this data set has 52% in the green 
zones, 8.7% in the yellow zones and 4.2% in the red zone. 
 
5.3.2 Clinical data 
Using clinical SG data with paired BG measurements, the Trend Compass can 
quantify the level of trend accuracy allowing sensor performance to be evaluated 
and compared. The solid blue line in Figure 5.7 shows CGM sensor data and the 
red circles represent BG data from the same patient. Overall, the trend accuracy 
is very good and ~70% of the points lie in the green areas. Furthermore, only 
11.6% of points are in the yellow zone and only 1.4% in the red zone. The TI for 
this data set is 18.2° and this value for TI is potentially slightly skewed by a few 
outlier BG data points seen in the trace. Figure 5.8 uses the same data set as 
Figure 5.7, but with a 4mmol/L constant bias applied to CGM sensor data. The 
Trend Compass plot, performance metric table and TI are remain unchanged 
with the offset SG data, further illustrating the independence of this method from 
point-to-point accuracy, which is unique to this approach. 
 
Figure 5.9 shows the SG data from Figures 5.7 and 5.8, coupled with BG 
measurements from a different data set. The trend accuracy is expected to be 
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marginal because the SG/BG are sampled from different individuals and are 
independent. The Trend Compass shows a wide spread of points indicating poor 
trend accuracy and this is reinforced by the TI of 37. 2°. Sections A and C in 
Figure 5.9 show periods of good trending and Section B shows a period of poor 
trend accuracy. The trend metrics shown in Table 5.8 report 34% of points are in 
the green zones, 13.6% in yellow and 3% in the red zones.  
 
5.4 Discussion 
The aim of this study was to develop a novel tool that could quantify trend 
accuracy, independent of point-to-point accuracy. The results present an 
intuitive plot that gives a quick visual assessment of relative CGM trend accuracy, 
and allows detailed quantified results for in-depth comparison. The Trend 
Compass is described in this manuscript with reference to SG data from a 
continuous glucose monitoring system that is compared to paired BG 
measurements from a reference method. 
 
With the introduction of CGM devices, trend accuracy has become very important 
due to increased investigation of closed loop glycaemic control and the increased 
use of hypo/hyperglycaemia alarm algorithms, which all inherently use trend 
patterns. The Trend Compass was not designed to replace conventional accuracy 
metrics, such as MARD or the Bland Altman plot. In fact, it is intended to be used 
in conjunction with traditional measures of point-to-point sensor accuracy. 
 
Using error metrics alongside the Trend Compass gives the user much more 
useful information about the overall performance of a sensor. Equally, as an 
objective measurement of trend accuracy, the Trend Compass could potentially 
be useful for regulatory bodies when assessing sensor performance prior to 
approval. Thus, it is an added metric not an overlapping one, which is a result of 
its design that it is independent of point-to-point accuracy. 
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SG measurements
BG measurements
BG 
BG 
BG < SG BG > SG
BG < SG BG > SG
Overall trend accuracy
Percent in green 91.3
Percent in yellow 0
Percent in red 0
When BG is rising BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green 0 47.8 0 47.8
Percent outside green 0 4.3 0 4.3
When BG is falling BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green 0 43.5 0 43.5
Percent outside green 0 4.3 0 4.3
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SG measurements
BG measurements
BG 
BG 
BG < SG BG > SG
BG < SG BG > SG
Overall trend accuracy
Percent in green 39.1
Percent in yellow 0
Percent in red 8.7
When BG is rising BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green 0 26.1 0 26.1
Percent outside green 0 26.1 0 26.1
When BG is falling BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green 0 13 0 13
Percent outside green 8.7 26.1 0 34.8
Figure 5.3 (left) BG and SG 
measurements for a stable patient with 
low sensor error. (right) Trend Compass 
plot for this data set with TI metric. 
Table 5.2 Performance table showing 
trend accuracy for this data set 
Figure 5.4 (left) BG and SG 
measurements for a stable patient with 
high sensor error. (right) Trend 
Compass plot for this data set with TI 
metric. 
Table 5.3 Performance table showing 
trend accuracy for this data set 
TI = 11.3° 
TI = 28.1° 
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SG measurements
BG measurements
BG 
BG 
BG < SG BG > SG
BG < SG BG > SG
Overall trend accuracy
Percent in green 82.6
Percent in yellow 0
Percent in red 0
When BG is rising BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green 0 13 30.4 43.5
Percent outside green 0 13 0 13
When BG is falling BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green 0 13 26.1 39.1
Percent outside green 0 4.3 0 4.3
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SG measurements
BG measurements
BG 
BG 
BG < SG BG > SG
BG < SG BG > SG
Overall trend accuracy
Percent in green 52.2
Percent in yellow 8.7
Percent in red 4.3
When BG is rising BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green 0 4.3 26.1 30.4
Percent outside green 0 17.4 8.7 26.1
When BG is falling BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green 4.3 8.7 8.7 21.7
Percent outside green 4.3 4.3 13 21.7
Figure 5.5 (left) BG and SG 
measurements for a variable patient 
with low sensor error. (right) Trend 
Compass plot for this data set with TI 
metric. 
Table 5.4 Performance table showing 
trend accuracy for this data set 
 
Figure 5.6 (left) BG and SG 
measurements for a variable patient 
with high sensor error. (right) Trend 
Compass plot for this data set with TI 
metric. 
Table 5.5 Performance table showing 
trend accuracy for this data set 
 
TI = 27.0° 
TI = 11.1° 
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CGM measurements
BG measurements
BG 
BG 
BG < SG BG > SG
BG < SG BG > SG
Overall trend accuracy
Percent in green 69.6
Percent in yellow 11.6
Percent in red 1.4
When BG is rising BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green 0 24.6 14.5 39.1
Percent outside green 0 7.2 11.6 18.8
When BG is falling BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green 0 26.1 4.3 30.4
Percent outside green 1.4 4.3 5.8 11.6
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CGM measurements
BG measurements
BG 
BG 
BG < SG BG > SG
BG < SG BG > SG
Overall trend accuracy
Percent in green 69.6
Percent in yellow 11.6
Percent in red 1.4
When BG is rising BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green 0 24.6 14.5 39.1
Percent outside green 0 7.2 11.6 18.8
When BG is falling BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green 0 26.1 4.3 30.4
Percent outside green 1.4 4.3 5.8 11.6
Figure 5.7 (left) Clinical CGM data and 
BG measurements from the same 
subject. (right) Trend Compass plot for 
this data set with TI metric. 
Table 5.6 Performance table showing 
trend accuracy for this data set 
 
 
Figure 5.8 (left) Clinical CGM data with 
a 4mmol/L bias and BG measurements 
from the same subject. (right) Trend 
Compass plot for this data set with TI 
metric. 
Table 5.7 Performance table showing 
trend accuracy for this data set 
 
TI = 18.2° 
TI = 18.2° 
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The results for the simulated data show how the Trend Compass can effectively 
differentiate between good trend accuracy and poor trend accuracy. Figures 5.3 
and 5.4 assess the trend accuracy for a stable, with low glucose variability 
patient with different levels of sensor noise. Comparing the plot of SG-BG data for 
each patient it is difficult to determine which data has better trend accuracy, 
although it is obvious that the data in Figure 5.3 has a lower sensor error. It is 
important that the Trend Compass is able to differentiate between the trend 
accuracy of the two devices in a robust way. In this case with a simulated stable 
patient the Trend Compass clearly shows that the data in Figure 5.3 has better 
trend accuracy. This outcome extends to Figures 5.5 and 5.6, which show 
different sensor error levels for the same high glucose variability simulated 
patient. Again, the Trend compass is clearly able to show which sensor has better 
trend accuracy, in this case the data plotted in Figure 5.5. 
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CGM measurements
BG measurements
A
B
C
BG 
BG 
BG < SG BG > SG
BG < SG BG > SG
Overall trend accuracy
Percent in green 34.8
Percent in yellow 13.6
Percent in red 3
When BG is rising BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green 1.5 12.1 3 16.7
Percent outside green 1.5 18.2 13.6 33.3
When BG is falling BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green 0 13.6 4.5 18.2
Percent outside green 3 10.6 18.2 31.8
TI = 37.2° 
Figure 5.9 (left) Clinical CGM data and 
BG measurements from two different 
subjects. (right) Trend Compass plot for 
this data set with TI metric. 
Table 5.8 Performance table showing 
trend accuracy for this data set 
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Another aspect that needed to be robust is the impact of patient variability. 
Comparing Figure 5.3 to Figure 5.5, and Figure 5.4 to Figure 5.6, it is clear that 
the patient variability doesn’t impair the ability of the Trend Compass to reliably 
assess trend accuracy. This aspect is very important as different patients or 
cohorts can have very different glycaemic dynamics, so the assessment of trend 
accuracy must be robust to these differences. Figures 5.3 and 5.5 show two 
different patient dynamics, but with similar levels of sensor error. The Trend 
Compass effectively conveys that in both cases the trend accuracy is very good. 
This is further reinforced with the accompanying performance table and TI 
metric. Figures 5.4 and 5.6 also show two different patient dynamics, but this 
time for a higher level of sensor error. Again, the Trend Compass is consistent in 
showing both data sets with moderate to poor trend accuracy. 
 
When using the Trend Compass with clinical data the usefulness of the method is 
immediately clear, as shown by comparing Figures 5.7, 5.8 and 5.9. Figure 5.7, 
which contains well correlated data collected from one patient, shows good 
trending compared to Figure 5.9, which contains uncorrelated data collected 
from two different individuals. The discrepancies between the trend accuracy of 
the two data sets can be easily interpreted from visual inspection of the Trend 
Compass plots alone. Interestingly, the Trend Compass for the uncorrelated data 
set still has ~35% of points in the green zones. This result is likely due to the 
sections marked ‘A’ and ‘C’ in Figure 5.9, which both show relatively good 
trending between SG and BG by chance.  
 
Figures 5.7 and 5.8 show how the Trend Compass can classify trend accuracy 
independent of point-to-point measurement error. The blue SG trace in Figure 
5.8 is the same data as shown in Figure 5.7, but with a positive 4mmol/L offset. 
This offset significantly increases the point-to-point error, but the Trend 
Compass remains unchanged. This lack of change occurs because the relative 
slope between SG and BG has not changed with the offset, and that relative slope 
is the fundamental mechanism used to quantify trend with this method. This 
example further reinforces the intended use of the Trend Compass to assess 
solely trend accuracy in conjunction with traditional point-to-point 
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measurement error metrics, creating a more complete assessment of sensor 
performance. 
 
The importance of assessing trend accuracy as a function of BG level is made 
clear by the paired BG-SG measurements in section ‘B’ in Figure 5.9. The trend 
accuracy in section B falls within the red zone of the Trend Compass, because the 
BG is falling while the SG is reporting a rise in glucose at a substantially different 
rate. The implications of a drop in glucose being reported as a rise by a CGM 
device could be very dangerous, potentially leading to missed treatment of 
hypoglycaemia. Furthermore, alarm algorithms that use trend information may 
not alert the user at the onset of these events. 
 
5.5 Summary 
The Trend Compass is a tool that can quantify trend accuracy between two 
devices measuring a single time series, such as a CGM device and a reference BG. 
It is robust when used with different patient cohorts (different dynamics), as 
well as different levels of sensor error. The resulting trend accuracy is easily 
interpreted on the Trend Compass plot, and if required, accompanying 
performance table and TI metric. Importantly, it assesses trend accuracy 
independent of BG level and point-to-point accuracy. It is possible for a device to 
have very poor point-to-point accuracy, but excellent trend accuracy. Thus, 
assessing trend accuracy is as important as assessing point-to-point 
measurement error as CGM devices become more widely used. A tool such as the 
Trend Compass provides an easy to interpret, reliable method to do so. 
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Chapter 6. Pilot clinical trial with CGM devices 
This Chapter presents the results and findings of an observational pilot study 
using standard off-the-shelf CGM devices in the Christchurch Hospital ICU. The 
goal of the trial was to assess the reliability of CGM in critically ill patients and to 
determine whether sensor site or CGM device type could have a significant effect 
on SG data. Overall performance reliability results are presented and discussed 
along with several interesting observations, which are presented as case studies. 
 
6.1 Introduction 
The in-silico feasibility study in Chapter 4 showed that CGM devices offered 
several potential benefits over conventional intermittent BG monitoring in the 
ICU. The study showed that CGM devices coupled with a well designed TGC 
protocol and hypoglycaemia intervention protocol, have the potential to improve 
BG control, reduce/eliminate hypoglycaemia and reduce nurse burden. However, 
these findings were based on simulation results using modelled CGM behaviour, 
not real clinical SG data.  
 
Prior to implementing any new device as a clinical practice change, a pilot study 
should be completed to assess the device's true behaviour in its intended clinical 
environment. This necessity is particularly important for CGM devices in the ICU, 
where in the limited literature available, there is some debate as to whether CGM 
devices perform well enough to guide clinical therapy (Brunner et al. 2011; 
Rabiee et al. 2009; Vlkova et al. 2009). Furthermore, the types of patients 
admitted, severity of illnesses encountered, and, treatments and therapies used 
can all vary between critical care centres, reinforcing the importance of testing 
these devices in the particular ICU that intends to use them. 
 
This chapter presents results from an observational pilot study using CGM 
devices in Christchurch Hospital ICU. Specifically, the reliability of CGM devices 
in critically ill patients, and the impact of both sensor calibration and sensor 
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location were tested. The overall goal was to better understand the variability 
induced by these factors, and their potential clinical impact in use for TGC. 
 
6.2 Subjects and Methods 
6.2.1 Subjects 
This study uses data from an observational pilot study of CGM in patients 
admitted to the Christchurch Hospital ICU. This analysis uses CGM and BG data 
from 10 patients who were recruited into the study. All patients were recruited 
by a physician in the ICU and informed written consent was obtained from the 
next of kin if the patient was unable to consent. Inclusion criteria were two 
consecutive BG measurements greater than 8mmol/L, indicating the need for 
insulin therapy using the STAR protocol (Evans et al. 2012). Exclusion criteria 
were an anticipated ICU admission period of less than 3 days. This study and use 
of data was approved by the Upper South A Regional Ethics Committee, New 
Zealand. Table 6.1 shows the patient demographics. 
 
Table 6.1 Patient demographics 
 
 
6.2.2 Continuous Glucose Monitoring 
Each participant in the study was monitored concurrently using 3 independent 
CGM devices for a period of up to 6 days. All CGM devices and sensors used in 
this study were un-modified, off the shelf devices, designed for people with 
diabetes outside of the hospital. Thus, these CGM devices and sensors were being 
assessed off label. Two different CGM devices were tested in this study. However, 
both devices used the same sensor hardware technology. Figure 6.1 shows the 
Patients 10
Age (years) 51 [39 - 64]
Sex (M/F) 5/5
APACHE II 24 [17 - 27]
APACHE III 85 [52 - 99]
SAPS II 52 [30 - 59]
ICU admission (days) 20 [10 - 33]
Outcome (L/D) 6/4
Diabetes (None/T1/T2) 10/0/0
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devices, the Medtronic Guardian Real-Time CGM device and the Medtronic iPro2 
CGM device (Medtronic Diabetes, Northridge, CA).  
 
  
 
Figure 6.1 (Left) Medtronic Guardian Real-Time CGM device. (Right) Medtronic iPro2 
CGM device.  
 
The components that make up each model of CGM are slightly different. The 
Guardian device uses a wireless transmitter to transfer data to the monitor, 
where it can be viewed in real time, and, the iPro2 simply stores data internally 
for download at a later date. The Medtronic Enlite sensor (Medtronic Diabetes, 
Northridge, CA) used with each device is shown in Figure 6.2. 
 
 
Figure 6.2 Side and top view of the Medtronic Enlite subcutaneous glucose sensor, 
which is compatible with both the Guardian Real-Time and the iPro2 CGM devices.  
 
For each patient, two sensors were located on the abdomen, one of which was 
connected to a Guardian Real-Time CGM device and the other connected to an 
iPro2 CGM device (both devices: Medtronic Diabetes, Northridge, CA). A third 
sensor was located on the patient’s thigh and was connected to a second iPro2 
iPro2 
recorder 
iPro2 dock 
Guardian Real-Time monitor 
Wireless 
transmitter 
Subcutaneous sensor  
Connector (Guardian 
transmitter or iPro2 recorder) 
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recorder. This configuration allowed comparison of results across different 
devices and sensor locations within each subject. Thus, enabling inter-site and 
inter-device variability to be quantified 
 
One significant difference between the two CGM devices is the calibration 
algorithm. Calibration algorithms use independent calibration BG measurements 
to convert the raw sensor current (ISIG) into a series of SG values for the user. 
Here, all else equal, different calibration and processing can yield different 
results. 
 
The iPro2 devices store the sensor signal information internally and these 
measurements are retrospectively calibrated after the device is removed. 
Retrospective calibration allows the calibration algorithm to use information 
both before and after the time point of interest to obtain an optimal calibration 
to each reference point. In contrast, the Guardian CGM device displays a glucose 
value in real time and the calibration algorithm can only use prior data for 
calibration, but it thus enables real-time glycaemic management. Thus, both 
devices see the data differently when they process it. However, for real time 
control only a real time device is feasible. 
 
Calibration BG measurements were obtained by specifically trained ICU nurses at 
least 3 times per day as recommended by the device manufacturer (Minimed 
2006). A blood sample was drawn from the patient’s arterial line and a BGA 
(ABL90 FLEX, Radiometer, Copenhagen) was used to determine the glucose 
concentration. The value from the BGA was immediately entered into the 
Guardian Real-Time device and then recorded for retrospective calibration of the 
iPro2 devices. 
 
6.2.3 Intermittent BG monitoring 
In addition to BG measurements used for calibration of SG data, each patient had 
intermittent BG monitoring every few hours. The STAR protocol requires, on 
average, 12-14 BG measurements per day to guide insulin/nutrition therapy 
(Fisk et al. 2012). In this study, BG measurements were determined using Super 
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Glucocard II (Arkray, Japan) glucose meters, by the ICU nurse working at the 
bedside. Several patients had additional BG measurements determined using 
Nova Statstrip (Nova Biomedical, Waltham, MA, USA) and/or Roche Accu-chek 
Inform II (F. Hoffmann-La Roche Ltd, Basle, Switzerland) hospital grade glucose 
meters, which both actively measured and adjusted for haematocrit level. 
Occasionally, a single blood sample was distributed across multiple BG meters to 
assess measurement precision and in those cases the median value was used as 
the 'true' BG. All meter BG measurements collected were distinctly separate from 
BG measurements used for CGM device calibration, providing an independent 
comparator for SG data. 
 
6.2.4 Analysis 
CGM data were stratified into 3 subsets by CGM device type and sensor location 
to allow comparison between the three combinations: abdomen Guardian, 
abdomen iPro2 and thigh iPro2. Overall accuracy of SG data in each subset was 
quantified using MARD and Bland Altman plots were produced to show how SG 
errors were associated with glucose level. Cumulative distribution functions 
(CDFs) were used to show the overall inter-site and inter-device discrepancies in 
SG data.  
 
Trend agreement between SG data sets was assessed using TI, which is described 
in detail in Chapter 5. The TI was calculated for the two abdomen SG data sets to 
assess inter-device trending, and the two iPro2 SG data sets to assess inter-site 
trending. However, in this study the true trend accuracy of each sensor relative 
to a reference set of independent BG measurements could not be assessed due to 
clinical constraints on the frequency of manual BG measurements. Thus, the 
trend agreement between two concurrent SG data sets is presented in its place. 
 
Finally, 3 sets of BG, SG and trend data are presented as case studies, showing 
some of the interesting aspects of CGM behaviour in critically ill patients. These 
case studies highlight unanticipated aspects of CGM behaviour that potentially 
need further investigation before CGM devices are permanently implemented in 
the ICU clinical environment. 
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6.3 Results 
6.3.1 Overall cohort 
The overall results from the analysis of BG and SG data are shown in Table 6.2. 
The BG results show that intermittent BG measurements were taken frequently 
in this study and the median time between consecutive measurements was 1.5 
hours. The median [IQR] BG levels were 6.9 [6.2 - 7.6] mmol/L. Overall, these 
results show that STAR protocol successfully controlled BG to a normal level. 
 
Table 6.2 Blood glucose and SG data results 
 
*See Chapter 5 for a thorough description of Trend Index 
 
The lower section of Table 6.2 show results for each combination of CGM device 
and sensor location assessed in this study. All of these subsets have good CGM 
duration, with most data sets containing more than 3 days of data. For a majority 
of patients, SG data was calibrated at least every 8 hours and between calibration 
BG measurements, reference BG measurements were taken every ~1.8 hours. 
Overall, the median [IQR] results reported by SG data are very similar to those 
results reported by BG data. Assessing the overall accuracy SG data, the MARD 
for the Guardian device in the abdomen was 24%, compared to ~12% for the 
two iPro2 data sets. The trend results show that trending between the two iPro2 
devices located in different sites was better than trending between the iPro2 and 
Guardian Real-Time devices, both located in the abdomen. The median TI for 
Blood glucose results
Number of patients 10
Time between BG (hours) 1.5 [0.9 - 2.3]
Median [IQR] BG (mmol/L) 6.9 [6.2 - 7.6]
CGM results Guardian - Abdomen iPro2 - Abdomen iPro2 - Thigh
Number SG Data sets 10 10 10
Duration of CGM (days) 4.8 [3.0 - 6.0] 4.8 [2.8 - 6.0] 5.3 [3.0 - 6.0]
Time between calibration (hours) 7.5 [5.1 - 8.2] 7.5 [3.6 - 9.0] 6.3 [3.0 - 8.1]
Time between reference BG (hours) 1.8 [1.0 - 2.8] 1.7 [1.0 - 2.7] 1.8 [1.0 - 2.8]
Median [IQR] SG (mmol/L) 6.9 [5.9 - 8.1] 6.7 [6.0 - 7.4] 6.7 [6.1 - 7.3]
MARD (%) 24.0 11.8 12.4
CGM Trend results
Inter-device Trend Index (degrees)*
Inter-site Trend Index (degrees)*
29.0 [20.1 - 34.4]
19.4 [17.8 - 23.4]
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inter-site agreement of SG data was 19.4 degrees and the median TI for inter-
device agreement was 29 degrees.  
 
 
Figure 6.3 Bland Altman plot for the three different CGM device and sensor location 
combinations 
 
The Bland Altman plots in Figure 6.3 show how SG error changes with glucose 
level. The top plot shows data from the abdomen Guardian CGM device. The 
overall mean error is only 0.2mmol/L, but the 95% confidence bounds are at -4.2 
and 4.4mmol/L, suggesting error can be relatively large for this device when 
monitoring critically ill patients. At lower BG levels, the Guardian CGM had a 
tendency to read low and at high BG levels it had a tendency to read high, as 
shown by the positive slope in the scattered data. The middle and bottom Bland 
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Altman plots show data from the abdomen iPro2 and thigh iPro2 CGM devices, 
respectively. Both of these SG data sets have an overall mean error close to zero 
and the 95% confidence intervals are much tighter than that of the abdomen 
Guardian, where the difference is thus between real time and retrospective 
calibration. There appears to be little or no association between SG error and 
glycaemic level in either iPro2 data set. 
 
Figure 6.4 shows two cumulative distribution functions (CDFs), one for inter-site 
discrepancies in SG data and one for inter-device discrepancies in SG data. At the 
time of every 5-minute SG measurement, inter-site discrepancy was calculated as 
thigh iPro2 SG - abdomen iPro2 SG and inter-device discrepancy was calculated 
as abdomen Guardian SG - abdomen iPro2 SG. The inter-site CDF is steep and 
narrow suggesting good agreement between the two CGM devices, irrespective 
of sensor location. Conversely, the inter-device CDF is flatter and wider, 
suggesting the type of CGM device, or calibration method, has a larger impact on 
SG data. The 5th to 95th percentile interval for inter-site is 3.2mmol/L, 
compared to nearly double that value at 6.1mmol/L for inter-device comparison, 
reinforcing that CGM device and/or calibration type has a substantially larger 
impact.  
 
 
Figure 6.4 Inter-site and inter-device discrepancies between SG data. Inter-site 
discrepancies were calculated as thigh iPro2 SG - abdomen iPro2 SG and inter-device 
discrepancies were calculated as abdomen Guardian SG - abdomen iPro2 SG 
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6.3.2 Case studies 
Due to the combinations of CGM devices and sensor locations, this study had the 
unique opportunity to observe several interesting characteristics of CGM 
behaviour in critically ill patients. This section presents 3 of those observations 
as individual case studies. First, Figure 6.5 shows an example of 3 CGM devices 
working very well in the critical care setting. During the first ~24 hours of 
monitoring there was some mismatch between each devices SG data, but for the 
remainder of monitoring the SG traces were almost overlapped. This particular 
patient was an otherwise healthy spinal injury patient with little or no oedema 
and no signs of sepsis. The CGM devices tracked glycaemic trends well and the 
Guardian Real-Time device would have provided useful data at the bedside if 
nurses were able to use the data.  
 
Figure 6.6 shows a Trend Compass plot, assessing the trend agreement between 
the two iPro2 devices monitoring this patient. Overall the trend agreement 
between the devices is good, with the majority of points in the green wedges. 
This result is reinforced by the numerical results in Table 6.3, which show that 
63.1% of points fell in the green zones, and only 4.5% fell in the red zone. 
Furthermore, no points were in the yellow zone.  
 
 
Figure 6.5 Three CGM devices monitoring a patient with good inter-device/site 
agreement 
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Figure 6.6 Trend Compass plot showing inter-site agreement between abdominal 
iPro2 SG data and Thigh iPro2 SG data 
 
 
Table 6.3 Performance Table corresponding to the Trend Compass in Figure 6.6 
 
 
Figure 6.7 shows SG and BG data collected from a patient with severe oedema. 
This patient had an estimated 18 litres of additional fluid onboard during the 
first few days of monitoring, with most of it in the abdominal region. Due to the 
additional fluid, the simple process of inserting each sensor was made difficult 
and the first sensor inserted in the abdomen failed to adhere to the skin, due to 
fluid constantly seeping from the insertion site. This sensor was replaced and the 
Abdomen iPro2 
Abdomen iPro2 
Abdomen iPro2 < Thigh iPro2 Abdomen iPro2 > Thigh iPro2
Abdomen iPro2 < Thigh iPro2 Abdomen iPro2 > Thigh iPro2
Overall trend accuracy
Percent in green 63.1
Percent in yellow 0
Percent in red 4.5
When BG is rising BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green 1.8 25.2 0.9 27.9
Percent outside green 3.6 17.1 0 20.7
When BG is falling BG < 5mmol/L 5mmol/L < BG < 8.9mmol/L BG > 8.9mmol/L overall
Percent in green 9 26.1 0 35.1
Percent outside green 4.5 11.7 0 16.2
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other two sensors, one in the abdomen and one in the thigh, were inserted 
successfully. However, after 2-3 hours, one of the abdominal sensors failed and 
had to be removed early. Thus, Figure 6.7 contains only two complete SG data 
sets. It should be noted that this patient was the only patient in the study to have 
a sensor adhesion failure. 
 
 
Figure 6.7 SG and ISIG data from two CGM devices monitoring a patient with severe 
oedema 
 
The top plot of Figure 6.7 shows SG and BG data collected throughout the 
monitoring period. Abdominal Guardian SG data is much more variable than the 
Thigh iPro2 SG data during days 1-4. After day 5, both SG traces reported similar 
trends in glycaemia. The bottom plot shows the raw sensor signal, or ISIG, for each 
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CGM device over the monitoring period. The ISIG data shows a clear separation in 
sensor sensitivity over the first 4 days of monitoring. The abdominal sensor 
current was typically in the region of 10-20nA, compared to the thigh sensor 
which was between 30-50nA. However, during day 5, the abdomen ISIG rose to 
the level of the thigh ISIG and for the remainder of the monitoring period both 
sensors reported similar dynamics in the region of 30-40nA.  
 
  
Figure 6.8 Example of un-physiological 'step' increases in ISIG and their appearance in 
SG 
 
Figure 6.8 shows two examples of large step increases in sensor current and how 
they appear in the SG data after calibration. Similar to Figure 6.7, the top plot 
shows BG and SG data, while the bottom plot shows ISIG data. The box labelled 'A' 
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in Figure 6.8 illustrates a step increase in the abdominal Guardian ISIG data from 
~20nA to ~40nA. In this instance, the real-time calibration algorithm amplified 
the step causing the SG data to rise from 4.7mmol/L to above 12.2mmol/L. At 
around 1.9 days when the Guardian device was next calibrated, the algorithm 
detected the SG was too high and adjusted it to the correct level. The box labelled 
'B' shows a similar rise in the thigh iPro2 ISIG from ~20nA to ~35nA. However, 
the retrospectively calibrated thigh iPro2 SG only increased from 4.5mmol/L to 
7mmol/L and no further adjustments were made at the next calibration at ~3.4 
days. 
 
6.4 Discussion 
This chapter presents the results of a pilot study investigating the reliability of 
CGM, used off label, in critically ill patients. The results from study give 
significant insight into the performance of CGM devices in this cohort and 
highlight some important aspects that require further investigation, prior to 
clinical implementation 
 
6.4.1 Overall cohort 
The results in Table 6.2 show that glycaemia was monitored closely during the 
study, by intermittent BG measurements and CGM, with both methods producing 
similar overall glycaemic results. In terms of CGM accuracy, the MARD for the 
Guardian SG data was approximately twice the MARD of iPro2 SG data, 
irrespective of whether the iPro2's sensor was located in the abdomen or thigh. 
This result strongly suggests that the accuracy of the device, in terms of MARD, is 
dependent on device type, or, more likely, the resulting calibration algorithm.  
 
The Guardian uses a real-time calibration algorithm that must adjust the 
'calibration factor' using only prior data. Thus, any disturbances that might 
induce error at the time of calibration could result in substantial inaccuracies in 
SG data until the time of next calibration. Conversely, the iPro2 is calibrated 
retrospectively, so one would expect the same disturbances to have less impact 
on the overall accuracy, as future calibration BG values are known and used to 
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obtain the final SG trace. Overall, the MARD values presented are all in the region 
of reported MARD for CGM in outpatients, where the devices were designed to be 
used (Keenan et al. 2012; Kovatchev et al. 2008; Larson & Pinsker 2013), 
indicating that they otherwise performed as might be expected despite the 
different cohort. 
 
Despite the relatively high MARD of the Guardian SG data, the clinical impact of 
those errors was determined to be minor. A Clarke Error Grid analysis of paired 
SG and reference BG data (results not shown) showed that 99.1% of the points 
fell in zones A and B, which would not lead to inappropriate treatment in cohorts 
for which this error grid was designed (Clarke 2005). Furthermore, no points fell 
in the clinically dangerous regions D and E. The same analysis of iPro2 SG data 
showed similar clinical results, with 100% of points in zones A and B. However, 
compared to the Guardian analysis, there were a higher proportion of points in 
zone A for both iPro2 data sets.  
 
The Bland Altman plots in Figure 6.3 highlight another interesting difference in 
the error characteristics of each CGM device type. The Guardian SG error appears 
to be associated with BG level, but the iPro2 error appears independent of BG 
level. At low BG levels the Guardian tended to report under the true value and at 
high BG levels it tended to over report glycaemia. Interestingly, there have been 
reports of associations between CGM error and BG level, but they typically show 
the CGM to report high at lower BG levels and low at higher BG levels (Beardsall 
et al. 2013; Voskanyan et al. 2007). A larger data set is required from patients 
that cover a wider range of glycaemia before the association observed in this 
study can be confirmed. Furthermore, patients on the STAR protocol are 
generally very well controlled (89% of BG measurements in 4.4-8.0mmol/L and 
0.9% < 4.0mmol/L) so it is thus difficult to obtain enough data to conclusively 
assess error characteristics during hypoglycaemia or hyperglycaemia.  
 
To determine the impact of inter-site and inter-device variations on the data 
produced by CGM devices, SG data from one device were compared directly to SG 
data from another, over the entire monitoring period. Figure 6.4 shows that the 
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discrepancy in SG data between two different devices is generally much more 
significant than the discrepancy in SG data due to sensor location. Again, this 
outcome is likely due to the calibration scheme used, as, in this study, the sensor 
technology for all three CGM devices was the same. Furthermore, without an 
accurate reference BG measurement every 5 minutes, it is impossible to 
determine the true underlying BG concentration. However, the true BG is likely 
some combination of the SG data produced by all three CGM devices.  
 
6.4.2 Individual patient case studies 
Three case studies are presented, to show some of the interesting observations 
in data collected from the 10 patients in this study. First, as shown in Figure 6.5, 
CGM devices are capable of working very well in critically ill patients. However, 
there are still several questions that need to be answered before they are 
implemented as normal clinical practice, such as:  
 
 Which patients stand to benefit from CGM?  
 What conditions/drugs/therapies (if any) have a negative effect on sensor 
performance?  
 What are the performance characteristics of CGM in the ICU and how can data 
be utilized? 
 
Fortunately, several researchers have already started asking these questions, 
among others, in an effort to improve healthcare for critically ill patients 
(Adolfsson et al. 2012; Bridges et al. 2010; Kovatchev et al. 2008; Roberts et al. 
2012).  
 
Second, as shown in Figure 6.7, it is possible that conditions, such as severe 
oedema, could have an effect on sensor performance. While the data in Figure 6.7 
represents anecdotal evidence from a single patient in this study, it still 
presented an interesting case study on a topic that has not been thoroughly 
investigated. The main focus for this specific discussion is thus the ISIG produced 
by each sensor.  
 
In particular, the ISIG produced by the abdominal sensor is much lower than the 
ISIG produced by the sensor in the thigh, where there is much less excess fluid. 
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Interestingly, after a few days of monitoring, as the patient's condition improved 
and excess fluid was removed, the ISIG from the abdominal sensor rose to the 
level of the iPro2 ISIG. In addition, for the remainder of monitoring the ISIG from 
both sensors tracked each other well. However, these observations could have 
been due to other factors such as the sensor itself, drugs/therapies, and these 
other factors cannot be ruled out by this study. Further investigation with a 
larger cohort containing patients with severe oedema is required to determine 
whether or not it has an effect on sensor performance. 
 
Third, as shown in Figure 6.8, it is possible for spurious, non-physiological 
changes in the ISIG data to occur without warning. The way that these 'step 
changes' appear in SG data is dependent on the calibration algorithm used. In box 
'A' of Figure 6.8, the 20nA increase in ISIG caused a ~7.8mmol/L increase in SG 
data, whereas in box 'B', a 15nA increase in ISIG only caused a ~2.5mmol/L 
increase in SG data. In box 'A', the rise occurred in the sensor that was monitored 
by the Guardian real-time CGM. As previously mentioned, the Guardian algorithm 
could only prior data to estimate the calibration factor, which converted ISIG data 
into SG data. Consequently, the calibration factor remained fairly constant at 
approximately 5.5, both before and after the rise in ISIG. It was not until 6 hours 
after the rise ISIG, when the next calibration BG was entered, that the calibration 
factor was reduced to 3.  
 
Conversely, the rise in ISIG shown in box 'B' of Figure 6.8 occurred in a sensor 
connected to an iPro2 with a retrospective calibration scheme. Therefore, at the 
time of the rise in ISIG, the calibration algorithm used future data to determine 
that the calibration factor should be reduced from 4.3 to 3.3. This adjustment 
prevented the SG data from rising significantly above reference BG 
measurements. These two examples clearly illustrate one of the major tradeoffs 
between real-time and retrospective calibration of SG data, and thus between 
these types of devices. 
 
Finally, in Figure 6.8, there are several drop outs of ISIG to ~0nA in the sensor 
connected to the Guardian CGM device. These drop outs are frequently observed 
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at the start of monitoring when a voltage is first applied to the sensor. It is 
possible that a loose connection between the sensor and transmitter could have 
caused the dropouts in ISIG later in the monitoring period. Fortunately, the 
calibration algorithms recognize that these dropouts are unusual and simply 
leave gaps in the SG data. 
 
6.4.3 Limitations 
There are three main limitations to this study that need to be addressed. First, 
this study uses BG and SG data from a relatively small proof-of-concept pilot trial 
cohort of 10 critically ill patients. These patients are broadly representative of 
the patients admitted to Christchurch ICU, but a larger study is required to 
provide conclusive evidence regarding the results presented here. Second, 
patients on the STAR TGC protocol tend to remain in the 4.4-8mmol/L glycaemic 
band, and, consequently, a wide range of BG levels are not included in this 
cohort. Again, a larger study with a broader population, potentially from multiple 
centres, would likely provide the data required to assess CGM characteristics in 
hypoglycaemia and hyperglycaemia. Third, it was not possible in this study to 
have a high accuracy reference BG measurement taken every 5-15 minutes, as 
this study was a pilot study done in the unit as observed. Thus, we cannot 
conclude whether all large rises/falls in SG were due to glycaemia or sensor 
artefacts. However, most major rises/falls in SG could likely be identified and 
classified using a stochastic detection method, similar to the work presented in 
Chapter 12. 
 
6.5 Summary 
This study used CGM and BG data from 10 patients to assess the reliability of 
CGM in critically ill patients. Overall cohort results and three case studies were 
used to show several important findings from this study to date. First, CGM 
devices can monitor certain patients with a high degree of accuracy, but some 
illnesses, drugs and therapies might affect sensor performance. Second, severe 
oedema could potentially affect sensor performance, but further investigation is 
required to confirm this. Third, CGM device type can have a significant effect on 
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the accuracy of SG data, but sensor location tends to have less impact. These 
findings will help direct further studies of CGM devices in critically ill patients in 
an effort to get them implemented as a clinical practice change. 
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Chapter 7. Additional uses for CGM in ICU 
The use of CGM devices in critical care units is not limited to improving TGC 
methods. The high density data provided by CGM devices also allows new 
investigations of glycaemia that were not possible with intermittent BG 
monitoring. This chapter investigates the association between glucose 
complexity and mortality in critically ill patients. Specifically, the effects of 
sensor location and device type on complexity analysis is determined and 
discussed. 
 
7.1 Introduction 
The 2001 landmark study by Van den Berghe et al. was the first data showing 
lower BG levels in critically ill patients were associated with improved outcomes 
(Van den Berghe et al. 2006). Since then, it has been determined that that 
glycaemic variability also plays a very important role (Egi et al. 2006; 
Hermanides et al. 2010b; Krinsley 2008). More recently, CGM devices have 
allowed researchers to test the latest hypothesis, that glucose complexity could 
also be associated with mortality in critically ill patients (Brunner et al. 2012; 
Lundelin et al. 2010). Glucose complexity, in a very simplistic view, is a measure 
of the 'fuzziness' of a glucose trace.  
 
The current hypothesis is that a healthy glucose regulatory system will be highly 
reactive to disturbances by making many small adjustments to keep glucose 
concentration within a normal range (Lundelin et al. 2010). Conversely, a failing 
glucose regulatory system will be ‘sluggish’ and the glucose profile should appear 
smooth with very few high frequency adjustments. To date, there have been two 
studies that have investigated glucose complexity in critically ill patients 
(Brunner et al. 2012; Lundelin et al. 2010). Both studies used Detrended 
Fluctuation Analysis (DFA) to quantify glucose complexity, reporting an 
association between the results of DFA and overall patient outcome mortality.  
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Outside of glucose complexity, DFA has already been widely used to quantify the 
scaling and correlation properties of other non-stationary, physiological time 
series. For example, DFA has been applied to inter-breath-interval of human 
respiration, inter-beat-interval of human heartbeat and inter-stride-interval of 
human stride to differentiate between healthy and pathological conditions (Eke 
et al. 2002; Goldberger et al. 2002; Hausdorff et al. 1996; Lee et al. 2004; Peng et 
al. 1995; Peng et al. 2002; Penzel et al. 2003). The aim of this study was to extend 
the knowledge of glucose complexity in critically ill adults by investigating the 
effects of CGM device type/calibration and CGM sensor location on DFA results. 
Furthermore, this study introduces multifractal DFA, an extension to the widely 
used monofractal DFA, to determine, based on the requirements of the 
underlying mathematics, whether it is a more appropriate method for analysing 
glucose complexity in SG data. 
 
7.2 Subjects and methods 
7.2.1 Patients 
This study uses data from 10 patients recruited into a pilot study of CGM devices 
in the Christchurch Hospital ICU, as also presented in Chapter 6. Inclusion 
criteria for the study were an expected duration of ICU admission longer than 5 
days and the need for glycaemic control using STAR protocol (Evans et al. 2012). 
Consent was obtained from the patient or next of kin if the patient was unable to 
consent. This study and use of data was approved by the Upper South A Regional 
Ethics Committee, New Zealand. Table 7.1 shows the cohort demographics. 
 
Table 7.1 Cohort demographics. Displayed as Median [IQR] where applicable 
 
Patients 10
Age (years) 51 [39 - 64]
Sex (M/F) 5/5
APACHE II 24 [17 - 27]
APACHE III 85 [52 - 99]
SAPS II 52 [30 - 59]
LOS (days) 20 [10 - 33]
Outcome (L/D) 6/4
Diabetes (None/T1/T2) 10/0/0
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7.2.2 Continuous glucose monitoring 
As noted in Chapter 6, each participant in the study was monitored using 3 CGM 
devices for a period of up to 6 days. Two sensors were located on the patient’s 
abdomen, one of which was connected to a Medtronic Guardian Real-Time 
monitor and the other connected to a Medtronic iPro2 recorder. The third sensor 
was located on the patient’s thigh and was connected to a second Medtronic 
iPro2 recorder. This configuration allowed inter-site and inter-device variations 
to be assessed.  
 
One significant difference between the two CGM devices is the calibration 
algorithm. Calibration algorithms use independent calibration BG measurements 
to convert the ISIG into a series of SG values for the user. The iPro2 device stores 
the sensor signal information internally and is retrospectively calibrated after 
the device has been removed from the patient. Retrospective calibration allows 
the calibration algorithm to use information both before and after the time point 
of interest to obtain an optimal calibration to each reference point. However, the 
Guardian CGM device displays a glucose value in real time and the calibration 
algorithm can only use prior data for calibration. Otherwise, all sensor 
technology was identical. 
 
Calibration BG measurements were obtained by specifically trained ICU nurses at 
least 3 times per day per manufacturer guidelines. A blood sample was drawn 
from the patient’s arterial line and a BGA was used to determine the glucose 
concentration. The value from the BGA was immediately entered into the 
Guardian Real-Time device and then recorded for retrospective calibration of the 
iPro2 devices. 
 
7.2.3 Glucose complexity 
Glucose complexity was quantified in this study using DFA, which has been 
widely used to quantify the scaling and correlation properties of non-stationary, 
physiological time series. For a self-similar time series (X), the scale invariant 
structure can be described by             , where the power law exponent 
(H) describes the scaling. In some cases, the scaling properties of a time series 
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are associated with changes in physiology and may be useful to help better 
understand certain illnesses or medical conditions (Goldberger et al. 2002; Peng 
et al. 2002). In terms of glucose complexity, the current hypothesis is that a 
healthy glucose regulatory system will make many small adjustments to keep 
glucose concentration within a healthy range and the high complexity is 
characterised by a low value of H. In contrast, a failing glucose regulatory system 
will be ‘sluggish’ and appear smooth with low complexity, characterised by high 
values of H.  
 
Two sub-categories of DFA are available depending on the properties of the 
signal or time series. Monofractal DFA is used when the scaling properties of the 
time series can be quantified by a single power law exponent, which is 
independent of time and space. However, the limitation of monofractal DFA is 
that real world physiological signals often do not exhibit simple monofractal 
scaling behaviour over the entire time period (Goldberger et al. 2002; Ihlen 
2012). In these cases, multiple scaling exponents are required to fully 
characterise the correlation properties of the signal and multifractal DFA should 
be employed.  
 
The results of a multifractal DFA are typically displayed in a multifractal 
spectrum. The width, shape and location of the multifractal spectrum can all be 
used to give important information about the relationship between the time 
series and the physiological phenomenon being studied. This approach has been 
illustrated in previous studies that have used multifractal DFA to help 
differentiate between healthy and pathological conditions, such as heart disease 
(Goldberger et al. 2002).  
 
An example of two spectrums produced using multifractal DFA are shown in 
Figure 7.1. The spectrum plotted with red dots was produced from a signal with 
monofractal scaling properties and the spectrum plotted with blue crosses was 
produced from a signal with multifractal scaling properties, data for both of 
which were provided by Ihlen (Ihlen 2012). Note the spectrum for the 
monofractal signal is very narrow, indicating the scaling exponents are almost 
87 
 
independent of time and space. Thus, a single H from monofractal DFA is 
sufficient to characterise the scaling and correlation properties of the signal. 
 
 
Figure 7.1 Example of multifractal spectrum that is produced from multifractal DFA. 
Note the monofractal signal produces a very narrow spectrum, indicating 
monofractal scaling is present and monofractal DFA is sufficient to characterise the 
scaling and correlation properties of the signal. 
 
This study uses both monofractal DFA and multifractal DFA implemented in 
MATLAB, based on the descriptions provided in (Ihlen 2012; Kantelhardt et al. 
2002). A thorough discussion of both methods can be found elsewhere for both 
monofractal DFA (Eke et al. 2002) and multifractal DFA (Kantelhardt et al. 2002). 
 
7.2.4 Implementation of DFA 
The implementation of DFA on a time series  , can be summarised as follows. 
First, the time series is summed and mean subtracted: 
 
                             
 
   
  7.1 
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Second, the profile      is divided into   non-overlapping segments of equal 
length   and the trend for each segment is approximated using a least-square fit, 
as shown in Figure 7.2 for segment sizes of 32, 64 and 128 SG measurements.  
 
 
Figure 7.2 Three examples showing segmented SG data with linear regression lines. 
The segment size increases from top to bottom. The variance between each 
regression line and the corresponding SG data in that segment is calculated using 
Equation 2. 
 
The variance between the time series and the least-square fit for each segment   
is calculated: 
 
 
Third, the qth order fluctuation function is calculated using Equation 7.3, where a 
monofractal DFA is obtained by holding q=2. Essentially, Equation 7.3 gives a qth 
order RMS of the variances calculated using Equation 7.2. For positive q, large 
deviations from the fitted trend will have more influence on the fluctuation 
function than small deviations, and, for negative values of q small deviations will 
        
 
 
                    
 
 
   
 7.2 
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have a larger influence on the fluctuation function. The degree to which the 
fluctuation function is influenced by q is determined by the magnitude of q.  
 
 
The scaling behaviour of the fluctuation functions is illustrated by analysing a 
plot of log(     ) versus log(s) for each q. For a scale invariant series, the 
relationship is linear and the slope represents the power law exponent, H, as in 
Figure 7.3 (left). For a multifractal time series, the scaling exponent will change 
for different values of q, as shown in Figure 7.3 (right). 
 
  
Figure 7.3 (left) Example plot of log(F) versus log(s) for a single value of q, where the 
slope of the linear regression line is the scaling exponent, H. (right) Example of how 
H changes for different values of q, for a multifractal time series 
 
For the case of q=0, Equation 7.3 cannot be employed so a logarithmic averaging 
procedure is used instead: 
 
 
       
 
  
          
 
  
  
   
 
 
  
 7.3 
          
 
   
             
  
   
  7.4 
Slope = H 
H for q = -5 
H for q = 5 
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Multifractal DFA performs best when the signal being analysed is noise-like, 
rather than a random walk. To determine the type of signal, a monofractal DFA 
can be run prior to multifractal DFA. If the power law exponent, H, is between 0.2 
– 0.8 then the time series is noise-like and multifractal DFA can be run without 
modification. However, if H is between 1.2 – 1.8 then the time series is more like 
a random walk. For random walk signals, the integrating process shown in 
Equation 7.1 can be skipped, and +1 is added to the power law exponents 
determined in the multifractal analysis (Ihlen 2012). 
 
To aid the interpretation of the multifractal scaling properties of a time series, 
the mass exponent (    ), q-order singularity exponent (    ) and q-order 
singularity dimension (    ) are calculated: 
 
 
 
 
A plot of      vs.   (Figure 7.4 - left) or      vs.   (Figure 7.4 - right) can be used 
to determine the degree of multifractal scaling in a time series. A plot of      vs. 
     displays the mulitfractal spectrum. The width, shape and location of the 
multifractal spectrum can all be used to give important information about the 
relationship between the time series and the physiological phenomenon being 
studied.  
              7.5 
           7.6 
                  7.7 
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Figure 7.4 (left) plot of      vs.   and (right)      vs.  , either of which can be used 
to interpret the scaling properties of a multifractal time series. 
 
7.2.5 Analysis 
This study uses DFA to investigate the glucose complexity of 10 critically ill 
patients who were monitored by 3 simultaneous CGM devices during their ICU 
stay. Specifically, it investigates: 
 
1. Whether CGM device type/calibration or CGM sensor location affects DFA 
results. 
2.  Whether monofractal or multifractal DFA is more appropriate for CGM 
signals, given the use of monofractal DFA as a discriminator in (Brunner et al. 
2012; Lundelin et al. 2010). 
3.  Whether DFA results are associated with mortality. 
 
Each patient enrolled in the study had 3 CGM devices monitoring glucose levels 
for up to 6 days. The warm-up period for these devices is 1-2 hours (Minimed 
2006,2010), but due to off label use here the first 12 hours of SG data were 
excluded to ensure the devices were performing properly during the period of 
interest.  
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Data sets with less than 500 SG measurements were excluded and SG data sets 
with less than 1000 SG measurements were analysed with increased care to 
ensure robust results, as this value is a recommended minimum (Ihlen 2012). 
Finally, the SG data were analysed using both monofractal DFA and multifractal 
DFA to determine whether the analysis method has an impact on results.  
 
In particular: 
 Data from the two iPro2 CGM devices, one on the thigh and one on the 
abdomen, were compared to assess sensor location effects independent of 
technology.  
 Data from the iPro2 on the abdomen was compared to data from the 
Guardian Real-Time, located on the opposite side of the patient’s abdomen to 
assess the impact of CGM device type/calibration on DFA results.  
 Analyses were repeated using the ISIG, which removed any effects induced by 
device calibration. 
 
Monofractal DFA results are presented in a table, as the result from each analysis 
is a single scaling exponent, H. Results from the multifractal DFA are presented in 
figures containing a plot of the multifractal spectrum. When comparing results, 
similar values of H from the monofractal analysis and spectrums of similar 
shape/position from the multifractal analysis indicate little or no difference in 
the scaling properties of the time series. In the two case study examples shown, 
plots of the CGM glucose trace and a plot of the scaling exponent as a function of 
q-order statistical moments are also shown. Numerical results are presented as 
median [IQR] where applicable. 
 
7.3 Results 
Of the 30 CGM sensors inserted into the 10 participants during the study, 26 
sensors from 9 patients produced data suitable for analysis. The 4 excluded data 
sets contained less than 500 measurements and were considered too short for 
analysis. Three of the excluded data sets were from a short stay patient 
eliminating all their CGM data, and the other data set was from a sensor with 
adhesion issues that was dislodged early in the monitoring period.  
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7.3.1 Monofractal DFA 
The results from the monofractal DFA are shown in Table 7.2. The top half shows 
the results of DFA when analysing SG data from the CGM devices. It is important 
to reiterate that the Guardian and iPro2 devices use different calibration 
algorithms with the same sensor technology. Thus, these results include any 
effects of calibration on DFA results.  
 
The CGM device type section shows the results when comparing CGM device type. 
Across the cohort, the retrospectively calibrated iPro2 reported significantly 
higher scaling exponents of 1.56 [1.46 – 1.60] compared to 1.43 [1.37 - 1.48] for 
the Guardian Real-Time device (p = 0.03). Furthermore, when comparing the two 
different abdominal devices monitoring the same individual, the H values for 
iPro2 data were 0.10 [0.03 – 0.11] higher than the H values for Guardian data (p 
= 0.08).  
 
The Sensor location section shows the results comparing a sensor inserted in the 
abdomen to a sensor inserted in the thigh of the same CGM device type (iPro2). 
There is no significant difference in the H values for different sensor locations (p 
> 0.1).  
 
The Outcome mortality compares scaling exponents based on ICU mortality. 
Results show no significant difference in the scaling exponent for patients who 
lived compared to patients who died. 
 
The bottom half of Table 7.2 shows results from the same analysis of the ISIG, 
which removes the effects of CGM device calibration. The data sets are stratified 
into the same groups as the top half of Table 7.2 based on CGM type, sensor 
location and mortality. When the effects of calibration are removed, the results 
show no significant differences between the groups, in any of the sub analyses. 
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Table 7.2 Results from monofractal DFA of SG and ISIG data over cohort 
 
* Wilcoxon Rank-Sum test, ** Wilcoxon signed Rank test 
 
 
7.3.2 Multifractal DFA 
Figure 7.5 shows the multifractal spectrums for all SG and ISIG data sets used in 
the analyses. The three subplots on the left side were created using SG data, 
comparing CGM device type (top), sensor location (middle), and outcome 
mortality (bottom). Three equivalent plots on the right side of Figure 7.5 were 
created using ISIG data. There is no significant association between any of the 
CGM parameters tested and the shape, width or location of the multifractal 
spectrums. 
 
Guardian iPro2 P value
Number of data sets 9 8
Scaling exponent (H) 1.43 [1.37 - 1.48] 1.56 [1.46 - 1.60] 0.03*
Difference in H (iPro2 - Guardian) 0.08**
Abdomen Thigh P value
Number of data sets 8 9
Scaling exponent (H) 1.56 [1.46 - 1.60] 1.52 [1.50 - 1.61] 0.90*
Difference in H (Thigh - Abdomen) 0.64**
Lived Died P value
Number of data sets 17 9
Scaling exponent (H) 1.51 [1.46 - 1.57] 1.47 [1.39 - 1.59] 0.50*
Guardian iPro2 P value
Number of data sets 9 8
Scaling exponent (H) 1.42 [1.34 - 1.52] 1.54 [1.37 - 1.60] 0.33*
Difference in H (iPro2 - Guardian) 0.53**
Abdomen Thigh P value
Number of data sets 8 9
Scaling exponent (H) 1.54 [1.37 - 1.60] 1.51 [1.47 - 1.60] 0.73*
Difference in H (Thigh - Abdomen) 0.38**
Lived Died P value
Number of data sets 17 9
Scaling exponent (H) 1.50 [1.35 - 1.55] 1.51 [1.42 - 1.60] 0.36*
Outcome mortality
Analysing pre-calibration ISIG data
Analysing calibrated SG data
CGM device type (both in abdomen)
Sensor location (both iPro2)
0.06 [-0.04 - 0.10]
0.04 [-0.03 - 0.09]
CGM device type (both in abdomen)
Sensor location (both iPro2)
Outcome mortality
0.10 [0.03 - 0.20]
0.04 [-0.06 - 0.11]
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Figure 7.6 shows four examples of how monofractal and multifractal DFA can 
give contradicting results and why the results must be interpreted with care. In 
all four cases, monofractal DFA of the two SG data sets resulted in the same 
scaling exponent. However, the multifractal DFA resulted in significantly 
different spectrums for each of the paired data sets. Furthermore, the width of 
the spectrums suggests the scaling properties of the time series are multifractal 
and that multifractal DFA is a more appropriate analysis technique (Goldberger 
et al. 2002; Ihlen 2012).  
 
Figure 7.8 shows SG data and multifractal DFA results for two example patient 
cases. Example ‘A’ shows SG data from three sensors that report very similar 
glucose traces, with little discrepancy between them. However, the multifractal 
DFA of each of these SG data sets results in three quite different multifractal 
spectrums, indicating that the scaling properties of each signal are unique. In 
contrast, example ‘B’ shows SG data from two sensors that do not track each 
other very well. Despite the large difference in variability, the multifractal DFA 
resulted in two spectrums that are almost identical. These two examples clearly 
highlight the difference between typical variability metrics and complexity 
analyses that assess very different aspects of the signal. 
 
7.4 Discussion 
The aim of this study was to investigate the effects of CGM device 
type/calibration and CGM sensor location on DFA results, as well as whether 
DFA results are associated with mortality, in critically ill patients. Due to the 
configuration of CGM devices and sensor locations in this study, there was a 
unique opportunity to study the effects of these parameters on DFA results. 
 
  
96 
 
 
Fi
gu
re
 7
.5
 M
u
lt
if
ra
ct
al
 s
p
ec
tr
u
m
s 
co
m
p
ar
in
g 
C
G
M
 d
ev
ic
e 
ty
p
es
, 
se
n
so
r 
lo
ca
ti
o
n
s 
an
d
 o
u
tc
o
m
e 
m
o
rt
a
lit
y.
 T
h
e 
p
lo
ts
 o
n
 
th
e 
le
ft
 w
er
e 
cr
ea
te
d
 u
si
n
g 
SG
 d
at
a 
an
d
 t
h
e 
p
lo
ts
 o
n
 t
h
e 
ri
gh
t 
w
er
e 
cr
ea
te
d
 u
si
n
g 
I S
IG
 d
at
a.
 
 
97 
 
 
Fi
gu
re
 7
.6
 M
u
lt
if
ra
ct
al
 S
p
ec
tr
u
m
 c
o
m
p
ar
is
o
n
 f
o
r 
d
at
a 
se
ts
 t
h
at
 h
ad
 t
h
e 
sa
m
e 
sc
al
in
g 
ex
p
o
n
en
t 
fr
o
m
 m
o
n
o
fr
ac
ta
l D
FA
. 
 
98 
 
 
Fi
gu
re
 7
.7
 T
h
is
 e
xa
m
p
le
 s
h
o
w
s 
go
o
d
 a
gr
ee
m
en
t 
b
et
w
ee
n
 S
G
 d
at
a 
fo
r 
ea
ch
 o
f 
th
e 
th
re
e
 C
G
M
 d
ev
ic
es
, 
b
u
t 
th
e 
m
u
lt
if
ra
ct
al
 s
p
ec
tr
u
m
s 
fo
r 
ea
ch
 d
at
a 
se
t 
ar
e 
q
u
it
e 
d
if
fe
re
n
t.
 
99 
 
 
Fi
gu
re
 7
.8
 T
h
is
 e
xa
m
p
le
 s
h
o
w
s 
av
er
ag
e 
ag
re
e
m
en
t 
b
et
w
ee
n
 S
G
 d
at
a 
fo
r 
tw
o
 C
G
M
 d
ev
ic
e
s,
 b
u
t 
th
e 
m
u
lt
if
ra
ct
al
 
sp
ec
tr
u
m
s 
fo
r 
ea
ch
 d
at
a 
se
t 
o
ve
rl
ap
. 
 
100 
 
7.4.1 Monofractal DFA 
The effects of CGM device type on monofractal DFA results revealed an important 
trend. The two sensors located in the patient’s abdomen were identical, but the H 
values from the iPro2 data were significantly higher than H values from the 
Guardian device. This outcome is most likely due to the calibration algorithms 
used to process the raw sensor data. The retrospective calibration utilised by the 
iPro2 device potentially has a higher degree of smoothing/filtering that leads to 
lower complexity of the output SG trace.  
 
Due to privacy restrictions placed on the calibration algorithms, this difference 
could not be fully confirmed by comparing the algorithms directly. However, an 
analysis of the raw pre-calibration ISIG data from the sensors showed no 
significant difference between the H values from each device. Thus, the 
significant difference in H observed when assessing SG data can be attributed to 
the calibration algorithm and/or potentially the CGM hardware used to store and 
transmit data, rather than to the specific sensing mechanism. 
 
Sensor location (thigh iPro2 data vs. abdomen iPro2 data) had little effect on the 
scaling exponent determined through monofractal DFA and the range of H values 
for each sensor location were similar. Furthermore, comparing the results from 
two sensors monitoring the same individual showed no consistent trend of one 
sensor having a higher H value than the other. Repeating the analysis using the 
raw sensor ISIG to eliminate any calibration effects gave similar results and the 
scaling exponent was not dependent on location. These results suggest that CGM 
sensor location, at least thigh vs. abdomen, should not have a significant effect on 
the results of a study using monofractal DFA. 
 
Monofractal DFA of SG data revealed important findings, but there were no 
detectable associations between DFA results and mortality. This result was 
unexpected because two previous studies by Lundelin et al. and Brunner et al. 
both reported a strong association and relatively clear discrimination between 
glucose complexity (H from DFA) and mortality. The authors acknowledge that 
due to low sample size it was unlikely a statistically significant association would 
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be detected. However, the results in Table 7.2 clearly show heavily overlapped 
values that appear unlikely to separate, often with different results for the same 
patient. Similar results are seen in the ISIG data, which eliminates any effects of 
calibration.  
 
7.4.2 Multifractal DFA 
Analyses of SG data using multifractal DFA were unable to associate the shape, 
width or position of the multifractal spectrum with CGM device type, sensor 
location or mortality for this data set. Furthermore, overlaying all of the 
multifractal spectrums from all sensors in a single figure, similar to Figure 7.5, 
showed no clear trends to differentiate between CGM device types, sensor 
locations or mortality outcomes. The ISIG results showed essentially the same 
results. Again, the mortality outcome could be attributed to the relatively small 
sample size and associations could potentially show up in a similar study of a 
larger cohort, although there were no initial results in Figure 7.5 suggesting they 
might arise.  
 
However, one very important finding from the multifractal DFA was the width of 
the multifractal spectrums. Each spectrum was spread across a wide range of 
scaling exponents, which suggests the scaling of SG data is multifractal in all 
cases here, and not monofractal, by nature. Thus, future studies that investigate 
glucose complexity using SG data should test for multifractal scaling and 
consider multifractal DFA in their analyses. 
 
Another interesting finding from the multifractal analysis is depicted in the 
subplots of Figure 7.6. In these four cases, monofractal DFA of both data sets 
produced the same H value, but their multifractal spectrums were clearly and 
significantly different. These differences between monofractal and multifractal 
results are important as they could skew the interpretation of results and lead to 
incorrect conclusions from studies of this nature. These results reiterate the 
need for a thorough analysis and highlight why care must be taken when 
interpreting results. 
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Figures 7.7 and 7.8 clearly illustrate the independence of glucose complexity and 
glucose variability. Figure 7.7 has three SG traces that track each other well and 
have similar variability, but their multifractal spectrums are very different, 
indicating the SG traces have different complexities. Conversely, Figure 7.8 has 
two SG traces that don’t track each other very well and the blue Guardian SG data 
has higher variability than the iPro2 SG data. However, the multifractal 
spectrums for each sensor show very similar multifractal scaling properties for 
each time series, indicating the signal complexities are similar. Therefore, 
complexity analyses should be included in addition to variability analyses to 
determine associations in future studies of glucose dynamics. 
 
7.4.3 Limitations 
There are several limitations of this study that need to be addressed. First, the 
data set used here contains 26 sets of CGM data from a relatively small cohort of 
critically ill patients. Thus, a statistically significant and testable association 
between DFA and mortality was unlikely to be detected. Despite this limitation, 
the analysis did highlight several important aspects that should be considered in 
future studies including the effects of sensor location and CGM 
device/calibration on DFA results. Equally, the total number of sensors available 
for assessing the impact of calibration and location ensure novel results that are 
robust. 
 
Second, the sensors and devices used in this study were different to those used 
by Lundelin et al. and Brunner et al. (Brunner et al. 2012; Lundelin et al. 2010). 
Therefore, a direct comparison between all three studies is not appropriate. The 
devices in those studies were no longer available when this study data was 
collected and a newer generation of technology was used. Thus, the study 
conditions that would allow an exact comparison could not be replicated. 
However, any potential differences due to advancing technology would, again, 
indicate the impact of technology on DFA assessment of physiology. 
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7.5 Summary 
The results of this study revealed or reiterated 5 important aspects that should 
be considered when analysing glucose complexity in critically ill adults: 
 
1. Monofractal DFA results were sensitive to the type of CGM device used to 
collect the glucose data, and the calibration in particular. Data from the 
iPro2 CGM device gave consistently higher DFA results compared to data 
from the Guardian Real-Time CGM device.  
2. Sensor location (abdomen vs. thigh) had no significant effect on DFA 
results.  
3. Multifractal DFA results were not always consistent with monofractal DFA 
results. Furthermore, the width of the multifractal spectrums suggests 
that multifractal DFA is more appropriate for this type of data and should 
be considered in future glucose complexity studies. 
4. Glucose complexity is not the same as glucose variability, and DFA could 
be used in addition to glucose variability analyses to better characterise a 
glucose time series. 
5. An association between DFA results and mortality could not be detected 
in this limited data set.  
 
Further investigations of glucose complexity are required before solid 
conclusions can be drawn. However, this study clearly highlights where care 
should be taken in the design of those studies and the analysis of the results. 
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Chapter 8. Summary of ICU 
The first half of this thesis has investigated CGM in critically ill patients. The 
overall goal of this work was to assess whether these devices, which were 
designed for use outside of the hospital, could perform reliability in the critical 
care environment. Specifically, to determine whether CGM devices could be 
integrated with existing TGC protocols to improve control and safety while 
reducing nurse workload.  
 
Prior to testing CGM devices clinically, a literature search revealed the details of 
several elements that would allow an in-silico study of TGC using CGM devices to 
be completed. Two mathematical models of CGM error characteristics were 
created based on data published in two independent studies. The first model was 
created using accuracy data from a test of CGM devices in critically ill patients 
(Goldberg et al. 2004). This model was comprised of a series of Gaussian 
distributions that captured the point-to-point error characteristics of SG data, 
but assumed consecutive errors were independent. The second model 
incorporated a time-dependent aspect into the model and was based on an 
autoregressive model (Breton & Kovatchev 2008). While more complete in terms 
of a CGM error model, it was created using data from otherwise healthy diabetics, 
not critically ill patients, so there is no assurance it is applicable in critical care.  
 
In addition to modelling CGM error characteristics, several filtering methods and 
hypoglycaemia alarms were tested to determine which algorithms perform well. 
Finite impulse response filters, infinite impulse response filters and a novel 
median LMS filter were tested. The median LMS filter performed particularly 
well and was selected to be used in the in-silico study. In addition to filtering 
methods, several alarm algorithms were also tested. A major risk with TGC 
protocols is hypoglycaemia, which can negatively affect outcomes in critically ill 
patients. Thus, two alarming algorithms were tested to assess their reliability in 
detecting hypoglycaemia, and the amount of lead time that could be given before 
an episode. Both the integral based and threshold based alarms performed well. 
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The CGM error models, median LMS filtering algorithm and a variant of the 
threshold alarm algorithm were coupled with existing patient simulation 
methods, to enable an in-silico clinical trial to be completed. Briefly, the clinically 
validated patient simulation methods use a set of clinically validated 
mathematical models to determine a patient’s response to insulin and nutrition, 
which are prescribed by a TGC protocol. The in-silico study replaced the BG 
measurements required by the TCG protocol, with filtered measurements 
created using the CGM error models. The results showed that the SPRINT TGC 
protocol performed well with filtered SG measurements and nurse workload 
could potentially be reduced by up to 75%. Furthermore, dextrose interventions 
at the predicted onset of hypoglycaemia could effectively eliminate the risk of 
hypoglycaemia with TGC if the proper dose is used. Overall, the results justified a 
clinical trial of CGM devices in the ICU. 
 
An important difference between intermittent BG measurements and the data 
provided by CGM devices is the availability of trend information. For example, 
intermittent BG measurements offer a snapshot of the BG concentration at a 
single point in time, whereas CGM devices give additional information about 
glucose trends. Although there are a wide number of metrics and methods 
available for assessing point-to-point accuracy, there are very few available for 
assessing trend accuracy. Even more importantly, none of those few existing 
trend assessments is independent of point-to-point sensor accuracy. A new 
method of quantifying trend accuracy was developed and presented in an easy to 
interpret graphical interface called the Trend Compass. A performance table and 
TI metric can accompany the table to give further information if required.  
 
The Trend Compass was tested in-silico, where it successfully differentiated 
between good and poor trending in a robust manner, irrespective of underlying 
glycaemia. Real clinical data was also used to show the effectiveness of the Trend 
Compass at quantifying trend accuracy. Furthermore, the clinical data was used 
to highlight the difference between trend accuracy and point-to-point accuracy. 
Overall, the Trend Compass, and accompanying metric table (if required), 
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provide an easy to interpret method of assessing trend accuracy in SG data 
independent to point accuracy.  
 
With positive in-silico study results, a pilot clinical trial of CGM devices in the ICU 
was undertaken. The main goal of the trial was to assess the reliability of off-the-
shelf CGM devices in monitoring critically ill patients, with a specific interest in 
the effects of CGM device type and sensor site on SG data. Thus, each of the 10 
participants in the study was monitored using three CGM devices, a Medtronic 
Guardian Real-Time and a Medtronic iPro2 placed on their abdomen, and a 
second Medtronic iPro2 placed on their thigh. All CGM devices used the latest 
Medtronic Enlite sensing technology, allowing a fair assessment of inter-site and 
inter-device variability in SG data. In addition to CGM, each patient had 12-14 BG 
measurements per day for TGC, which provided a further range of comparator 
data to SG data.  
 
Overall, the accuracy of the abdomen Guardian SG data relative to reference BG 
measurements was lower than both the abdomen and thigh iPro2 SG data. 
Furthermore, an analysis of inter-site and inter-device discrepancies in SG data 
suggested that the CGM device type has a larger impact on observed 
performance than sensor site. Several unanticipated findings were also 
investigated and presented as case studies, as they highlighted important factors 
that require further investigation or may help direct future studies of CGM 
devices in the ICU.  
 
The pilot study showed that CGM devices are capable of monitoring patients with 
a high degree of accuracy. However, certain illnesses, drugs and therapies can 
potentially affect sensor performance. One case study showed that severe 
oedema may have affected sensor performance, but further investigation is 
required to confirm this initial result. The effects of different calibration 
algorithms were also investigated and, in particular, the way they respond to 
artefacts in the sensor data. Overall, the limited data set and preliminary analysis 
indicated that CGM devices have the potential to improve TGC in critically ill 
patients. Such improvements include using SG measurements to drive insulin 
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therapy, and/or, using SG data for hypoglycaemia detection and alarming as 
guardrails. However, further understanding of the clinical factors that affect CGM 
performance is needed, based on larger trials, before improvements to TGC can 
be realized. 
 
The CGM data collected in the pilot study was also used to investigate a new 
hypothesis, that glucose complexity is associated with mortality in critically ill 
patients. More specifically, the unique configuration of devices used in the pilot 
study allowed inter-site and inter-device effects on complexity analysis to be 
assessed. Briefly, it has been suggested that a healthy regulatory system will 
respond quickly to changes in glycaemia, resulting in a complex glucose trace 
that is characterised by frequent, small fluctuations. Conversely, a failing 
regulatory system should appear sluggish, with a smoother texture and longer, 
slower dynamics. The level of complexity in SG data can be quantified using a 
signal processing technique called DFA. 
 
There have been two prior studies that have investigated glucose complexity and 
reported statistically significant associations with mortality. Both studies used 
older, and in one of the studies mixed, CGM technology and a mono-fractal 
version of DFA. The results from our data set suggest that glucose complexity is 
far more strongly and statistically significantly associated with the type of CGM 
device used, rather than mortality. Our data failed to show any significant 
association between glucose complexity and mortality. Furthermore, a multi-
fractal DFA analysis suggested that the SG data in our study, and potentially all 
SG data, is multi-fractal by nature, contradicting the assumptions of the previous 
studies. Thus, future studies of glucose complexity should consider a multi-
fractal approach, at least in addition to mono-fractal analyses, and care should be 
taken when interpreting the results.  
 
Overall, the work presented in Chapters 2-7 contributes valuable information 
and insight into the use of CGM devices in critically ill patients. This work not 
only considers the engineering aspects, but also the clinical perspective, which is 
paramount if CGM devices are going to be implemented permanently. Finally, the 
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positive results discussed here provide a significant step toward achieving the 
ultimate goal of using CGM devices in hospital environments. 
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PART II - CGM IN NEONATAL ICU  
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Chapter 9. Background - Neonatal ICU 
Similar to the adult ICU, patients in the NICU could also benefit from CGM if it 
proves to be reliable and is used effectively. Neonatal hypoglycaemia is a 
common metabolic problem in newborn babies that may cause seizures and 
permanent brain injury in newborns (Stanley & Baker 1999). However, there 
remains significant controversy regarding the definition of hypoglycaemia, and 
consequently, the effect it can have on the child’s later development (Cornblath 
et al. 2000; Koh et al. 1988). Diagnosis is by BG measurements, typically taken 
several hours apart, and episodes of hypoglycaemia that occur between BG 
measurements can go undetected (Harris et al. 2010). Thus, CGM devices with 
their nearly continuous estimate of BG concentration have the potential to 
improve the detection and diagnosis of hypoglycaemia in newborn infants. 
 
9.1 Blood glucose physiology 
Glucose is the principle substrate for cerebral metabolism and maintaining 
glucose homeostasis is critical for an infant's healthy development. Prior to birth, 
neonates receive glucose from their mother through the placenta, via a relatively 
complex set of mechanisms that tend to keep its metabolism relatively constant 
(Hay 2006). At birth, the umbilical cord is severed, removing the maternal supply 
of glucose and forcing the infant to self-regulate its BG concentration (Halamek 
et al. 1997).  
 
Self regulation of BG concentration occurs via a negative feedback system, where 
the endocrine cells of the pancreas act as the primary controller. The endocrine 
cells, or Islets of Langerhans, make up around 1-2% of the pancreas and include 
four types of hormone-secreting cells:  
 
1. Alpha cells: Account for about 18-20% of islet cells and secrete the 
hormone glucagon.  
2. Beta cells: Constitute about 73-75% of islet cells and secrete the hormone 
insulin. 
3. Delta cells: Make up only about 4-6% of islet cells and secrete the 
hormone somatostatin. 
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4. F cells: Only around 1% of islet cells are F cells, which secrete the 
hormone pancreatic polypeptide. 
 
The interactions of these hormones are complex and not completely understood, 
but, in terms of BG regulation, the hormones of primary interest are glucagon 
and insulin. Figure 9.1 is a schematic showing the fundamental aspects of 
endogenous BG self regulation, specifically, the action of the hormones glucagon 
and insulin. 
 
 
Figure 9.1 Schematic showing how BG concentration is controlled via a negative 
feedback system (Marieb & Hoehn 2005)  
 
Low BG levels stimulate the alpha cells in the pancreas to release glucagon, 
which leads to an increase in BG concentration. This occurs predominantly in the 
liver where glucagon stimulates hepatic glucose output by accelerating 
glycogenolysis, and halting glycolysis to allow the reverse process 
gluconeogenesis. Briefly, glycogenolysis is the breakdown of glycogen, into 
glucose, and, gluconeogenesis is the formation of glucose from lactic acid and 
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certain amino acids. Importantly, both of these metabolic pathways result in an 
increase in plasma glucose concentration.  
 
Conversely, high BG levels stimulate the beta cells in the pancreas to secrete 
insulin, which leads to a decrease in BG concentration. Unlike glucagon, which 
acts primarily in the liver, the great majority (80-90%) of insulin mediated 
glucose disposal occurs in muscle cells and adipose tissue. Insulin in the plasma 
binds to receptors on the plasma membrane of the cells, and through a series of 
protein activation cascades, the glucose transporter GLUT-4 is translocated to 
the plasma membrane. The presence of GLUT-4 on the plasma membrane 
facilitates the active transport of glucose from the plasma into muscle cells and 
adipose tissue, thus reducing BG concentration.  
 
In addition to glucose disposal in muscle cells and adipose tissue, insulin also 
alters several other processes, which effect BG concentration. Insulin increases 
the rate at which the liver synthesizes glucose into glycogen for storage 
(glycogenesis), as well as slowing glycogenolysis and gluconeogenesis. 
Furthermore, insulin stimulates lipogenesis, a storage pathway where glucose is 
synthesised into fatty acids, which are eventually stored in adipose tissue. 
 
Any abnormalities or deficiencies in these glucose regulatory processes at birth 
can cause newborns to suffer from metabolic problems, such as hypoglycaemia.  
 
9.2 Neonatal hypoglycaemia 
Neonatal hypoglycaemia is defined as low glucose levels in a newborn baby. 
Causes of neonatal hypoglycaemia include, but are not limited to: low glycogen 
stores, increased glucose use, decreased glycogenolysis or gluconeogenesis, or, 
depleted glycogen stores (Stanley & Baker 1999). Clinically, infants considered to 
be at risk of hypoglycaemia are those born preterm, small for gestational age 
(SGA), large for gestational age (LGA), infant of a diabetic mother (IDM), or sick 
(e.g. Sepsis, asphyxia) (Harris et al. 2010). In at risk babies it is recommended 
that BG concentration be monitored closely, as hypoglycaemia can present both 
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symptomatically (symptoms include jitteriness, irritability, lethargy, seizures, 
apnoea, grunting and sweating (Halamek et al. 1997)) and asymptomatically. 
Currently, a widely used definition of neonatal hypoglycaemia is a BG 
measurement less than 2.6mmol/L, which was deduced from two studies, 
published in 1988 (Koh et al. 1988; Lucas et al. 1988).  
 
The first of these studies measured neurophysiological function via evoked 
potentials during periods of low BG concentration (Koh et al. 1988). The 
researchers sought to determine whether there was a measurable difference in 
evoked potentials between children who are 'symptomatic' and 'asymptomatic'. 
They recruited 17 subjects between 1 day and 16 years of age, but only 5 were 
younger than 4 months old. Each patient experienced either spontaneous 
hypoglycaemia, or, provoked hypoglycaemia by fasting or insulin administration. 
In each subject, either brainstem auditory or somatosensory evoked potentials 
were recorded immediately after every BG measurement. 
 
The results showed 10 out of the 17 subjects had abnormal changes in evoked 
potentials, recorded at BG concentrations ranging 0.7-2.5mmol/L. However, in 
these same subjects, normal evoked potentials were recorded for BG 
concentrations ranging 1.9-5.6mmol/L. Furthermore, in the remaining 7 patients 
no changes in the evoked potentials were observed, despite 1 patient dropping to 
1.9mmol/L. A conclusion of this study was that although it cannot be known 
whether transient abnormalities in the evoked potentials are associated with 
permanent brain injury, BG should be maintained above 2.6mmol/L to prevent 
these abnormalities. Other studies have not been able to demonstrate the same 
findings with evoked potentials and hypoglycaemia (Greisen & Pryds 1989). 
 
The second study investigated the occurrence and persistence of hypoglycaemia 
and how it related to the neurodevelopmental outcome at 18 months of age 
(Lucas et al. 1988). This study recruited 661 newborn infants with a mean birth 
weight of 1337g and a mean gestational age of 30.5 weeks. These infants had 
weekly plasma BG measurements and more frequent plasma measurements 
when finger-stick BG measurements (done 6-hourly for the first 48-72 hours) 
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showed hypoglycaemia (1 fingerstick BG measurement below 1.5mmol/L, or, 2+ 
below 2.5mmol/L). A total of 543 infants were followed up at 18 months, at 
which time Bayley motor and mental development scores (Bayley 1965) were 
determined to quantify neurodevelopment.  
 
The authors reported a strong association between the frequency of low blood 
glucose concentrations and poor Bayley scores at 18 months. In particular, 
babies who had five or more BG measurements below 2.6mmol/L on separate 
days during the first few months of life had lower Bayley scores. Thus, this study 
concluded that BG concentrations below 2.6mmol/L were associated with 
negative outcomes in these infants. However, when this cohort of children was 
assessed at ages 7.5 to 8 years the strong association between low blood glucose 
concentrations and neurological outcome was not apparent, casting doubt on 
earlier findings. Nevertheless, the hypoglycaemic threshold of 2.6mmol/L is still 
widely used for these infants (Burns et al. 2008; Duvanel et al. 1999). 
 
The idea of using a 'one size fits all' threshold for hypoglycaemia is a highly 
contentious subject. The definition of hypoglycaemia almost certainly cannot be 
defined by a single number (Cornblath et al. 2000). It is highly likely that a safe 
glucose concentration at one point in time for a particular patient will be unsafe 
at a different point in time or for a different patient (Halamek et al. 1997). 
Furthermore, the wide range of inter-patient variability suggests that the 
definition should be patient-specific, depending on factors, such as the infants 
physiological maturity and the influence of pathology (Cornblath et al. 2000). 
However, due to the methodological limitations of measuring BG, no data 
currently exists that define the concentration of plasma glucose or its duration 
that causes damage. Thus, a BG measurement below 2.6mmol/L remains a 
widely used definition of hypoglycaemia in infants. 
 
A major limitation of traditional BG monitoring is the frequency of BG 
measurements, which is often restricted due to blood draw constraints or the 
pain and discomfort it causes the infant. Typically, BG is measured every 1-4 
hours in at risk patients and more frequently only if hypoglycaemia has 
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previously been diagnosed. In addition, each BG measurement represents a 
discrete value in time and little can be inferred about the BG concentration 
between measurements, as depicted schematically by Figure 9.2. Thus, it is 
possible for hypoglycaemia to occur between BG measurements and remain 
undetected. 
 
 
 
Figure 9.2 Individual BG measurements represent a discrete value in time and give 
little information about the BG concentration between measurements (3 possibilities 
shown), especially measurements taken several hours apart.  
 
This limitation on the frequency of BG measurements has been especially 
problematic for clinical studies that have attempted to find a causal relationship 
between neonatal hypoglycaemia and a child's later development. However, the 
advancement of continuous glucose monitoring technology in the 1990's offered 
a potential alternative to traditional BG monitoring. In particular, the ability to 
define the BG trajectory between measurements in situations like that shown in 
Figure 9.2. 
 
9.3 The role of CGM 
The first commercially available CGM device was the MiniMed CGMS, which was 
FDA (Food and Drug Administration) approved in 1999 (Mastrototaro 2000). A 
later version, the CGMS System Gold (Medtronic Minimed, Northridge, CA) is 
shown in Figure 9.3 and was used throughout this neonatal application. Briefly, 
the CGMS System Gold consists of a small pager-like monitor that receives 
information from a sensor inserted into the subcutaneous layer, just beneath the 
skin (Klonoff 2005b). The SOF sensors used in this research utilise a glucose 
 
 
Severe hypoglycaemia 
BG1 
BG2 
Potential glucose path 1 
Potential glucose path 2 
Potential glucose path 3 
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oxidase reaction to produce a small electrical current that is proportional to the 
glucose concentration. The monitor provides a value every 5 minutes, but must 
be manually calibrated at least 3 times per day using independent BG 
measurements (Minimed 2003). Importantly, the CGM described here is a 
retrospective device and users remain blinded to glucose levels until after the 
monitoring period.  
 
 
Figure 9.3: Medtronic Minimed CGMS System Gold used in this study 
 
The first reported use of CGM in newborn babies during the neonatal period was 
published in 2005 (Beardsall et al. 2005). The aim of the study was to assess the 
validity of using CGM devices in very low birth weight (VLBW) infants and to 
obtain more data on the prevalence of abnormalities in glycaemia. Sixteen babies 
were recruited into this study with a median gestational age of 26.5 weeks and a 
median birth weight of 706 grams. Monitoring with CGMS began in the first 24 
hours after birth and lasted for up to 7 days which resulted in a total of 1302 
hours of SG data. Across the cohort, the reported median (range) percent 
duration of hypoglycaemia was 0.4% (0-11%) and all episodes were 
asymptomatic. Three babies (19%) had hypoglycaemia that was not detected 
clinically and one baby (6%) had a hypoglycaemic episode that lasted 2 hours 45 
minutes before it was detected by BG measurement. Accuracy of CGM during 
periods of hypoglycaemia could not be assessed due to a low number of BG 
measurements at that level, but the study concluded CGMS is practical for 
 CGMS System Gold monitor 
 SOF Sensor 
 Cable 
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glucose monitoring in VLBW infants and hypoglycaemia is prevalent in this 
population. 
 
In 2009, a second study using CGM in VLBW infants was published (Iglesias 
Platas et al. 2009). Thirty-eight VLBW infants were recruited in the first 24 hours 
after birth and monitoring continued for up to 14 days. The cohort had a median 
gestational age of 27.6 weeks and a median birth weight of 958 grams. Results of 
this study showed that 14 patients (37%) experienced hypoglycaemia and the 
average percentage of time in the register with hypoglycaemia was 0.55%. 
Furthermore, an analysis of each day showed that episodes of hypoglycaemia 
appeared evenly throughout the study period with 2.6-13.2% of patients affected 
per day, after the first day of life. Similar to the study in 2005, this study 
concluded that CGMS is a feasible way of studying glucose levels in VLBW infants 
and, when applied, it reveals “abnormal glycaemia” at a much higher rate than 
standard intermittent BG measurements. 
 
These two studies of VLBW infants were followed by an investigation of CGM in 
102 larger babies considered at risk of hypoglycaemia (Harris et al. 2010). The 
cohort had a median birth weight of 2327 grams and the median gestational age 
of 35 weeks. From the 102 babies recruited, hypoglycaemia was detected in 45 
babies using CGM and in 32 babies using intermittent BG measurements. CGM 
detected 265 episodes of hypoglycaemia lasting between five and 475 minutes, 
with 107 episodes lasting 30 minutes or more. Astonishingly, only 19% of 
hypoglycaemic episodes were detected by standard, clinically specified BG 
measurements, further highlighting the potential benefits of CGM in neonates. 
Recurrent hypoglycaemia presented in 21 babies who had repeated episodes 
lasting longer than 30 minutes. Similar to previous studies, CGM was well 
tolerated and remained in use for up to 7 days. 
 
All three studies reported that CGM was well tolerated by the infants and didn't 
interfere with nursing care. Abnormalities were detected at a much higher rate 
compared to intermittent BG monitoring and SG values provided additional 
information about the duration and severity of hypoglycaemic episodes. 
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However, there were concerns about the accuracy of SG values and whether they 
could be relied on at low concentrations of blood glucose (Beardsall et al. 2005). 
Overall, the agreement between CGMS and glucometer BG readings is acceptable, 
but CGM tends to provide a higher BG value at low BG levels and accuracy is 
lowest on day 1 of monitoring (Beardsall et al. 2013).  
 
To draw sound conclusions from studies utilising CGM, it is not only important to 
have a thorough understanding of the physiology, but also the CGM technology 
used to collect data. Furthermore, signal processing and mathematical 
techniques can be used to enhance the quality of data or aid in the interpretation 
of results. The following chapters investigate CGM in critically ill newborn 
babies, with a focus on hypoglycaemia detection and quantification.  
 
This research is part of a wider study, The CHYLD Study (Children with 
HYpoglycaemia and their Later Development), which is a large multi-disciplinary 
prospective study investigating the development of young children who were at 
risk of developing hypoglycaemia in the early neonatal period. The children are 
followed up at 2 and 4.5 years of age at which point their growth, cognitive and 
neurodevelopment are assessed in relation to the duration, severity, and 
frequency of hypoglycaemia in the first days of life. Ultimately, this research aims 
to improve the definition, diagnosis and management of neonatal hypoglycaemia, 
including the use of CGM. 
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Chapter 10. CGM device calibration 
If CGM devices are to be used effectively in the clinical environment, it is 
important to understand how the sensors/monitors work and any limitations 
associated with their use. Certain aspects of CGM, such as the algorithm used to 
calibrate SG data, can be adjusted or modified to better suit a specific application. 
This chapter focuses on how SG outputs are determined, and specifically, the 
effect calibration algorithms can have on these output measurements. The 
emphasis here is on neonatal hypoglycaemia, so this study investigated how 
device calibration affected metrics used to quantify hypoglycaemia in neonates. 
 
10.1 Introduction 
The CGM system used in this research consisted of a Medtronic Minimed CGMS 
System Gold monitor coupled with a Medtronic Minimed SOF sensor. The SOF 
sensors are inserted using a specifically designed device that ensures the process 
takes only a few seconds and is nearly pain free. Once in place, SOF sensors 
indirectly measure glucose in the interstitial fluid using amperometric enzyme 
electrodes based on glucose oxidase.  
 
This particular sensor uses a 3-electrode configuration, consisting of a platinum 
working electrode where oxidation occurs, a counter electrode where reduction 
occurs, and a reference electrode (Rossetti et al. 2010). Glucose oxidase (GOx) is 
immobilised at the working electrode and catalyses the oxidation of interstitial 
glucose into gluconolactone, per the reaction defined: 
 
 
The cofactor Flavin Adenine Dinucleotide (FAD) acts as electron acceptor, 
reducing to FADH2. The FADH2 is re-oxidised in the presence of oxygen to 
produce hydrogen peroxide (H2O2), in a reaction defined: 
 
                                                10.1 
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The physical makeup of these sensors also includes several permeable polymer 
membranes surrounding the electrodes. These membranes were designed to 
address two significant issues common with subcutaneous glucose sensors 
(McGarraugh 2009): 
 
1. Oxygen deficit: The transport of glucose is restricted to maintain a proper 
glucose-oxygen ratio, as oxygen concentrations are typically 1 order of 
magnitude lower than glucose concentrations. 
2. Interference from other molecules: Molecules such as uric acid and 
absorbic acid may interfere with the process, so their access is restricted. 
 
The H2O2 permeates through the membranes to the platinum working electrode, 
which is poised at 0.535 V relative to the reference electrode (Gross et al. 2000). 
Oxidation of H2O2 at the working electrode produces an electrical current (ISIG), 
which is in the order of nano amps, defined by the 2e- term in the reaction:  
 
 
The CGMS System Gold monitor samples the ISIG every 10 seconds. Over a period 
of 1 minute, the highest and lowest values are discarded and the remaining 4 
measurements are averaged to create interval values (Mastrototaro et al. 2002). 
Over a period of 5 minutes, the highest and lowest interval values are excluded, 
and the remaining 3 interval values are averaged and stored internally by the 
monitor (Mastrototaro et al. 2002). An empirically derived 10 minute time delay 
is added to stored values to account for delays between capillary BG 
concentration and interstitial fluid glucose concentration. Several possible 
sources of delay have been reported including a physiological lag of ~3-12 
minutes, electrochemical sensor lag of 1-2 minutes, and additional lags due to 
filtering (Keenan et al. 2009). The time-shifted ISIG values are considered Valid ISIG 
and form the basis of the SG output. The CGMS System Gold is a retrospective 
device and no glucose data is displayed in real time. 
 
                                 10.2 
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To obtain meaningful glucose levels from the 5-minute Valid ISIG values, 
independent reference measurements of BG are required for calibration. 
Calibration BG measurements are typically obtained using a finger-stick glucose 
meter, similar to those used by patients with diabetes. Finger-stick BG devices 
are reported to have errors in the range of 2-10% (Abbott 2010; Roche 
2007,2008; Solnica et al. 2003), and often have reduced performance in critically 
ill patients due to varying levels of haematocrit, medication and other effects 
(Hoedemaekers et al. 2008; Kanji et al. 2005; Karon et al. 2007). Further 
complicating the matter, it is not uncommon for term newborn babies to have 
elevated haematocrit levels during the first few days of life, reaching 65%+ in 
some cases (Jopling et al. 2009).  
 
The manufacturer specified a calibration procedure that involves an initial 
calibration approximately 1 hour after sensor insertion and then at least 4 times 
per day (Minimed 2003). Calibration BG measurements are manually entered 
into the device by the user and the value is stored until the end of the monitoring 
period. At the completion of monitoring, data from the CGMS System Gold is 
downloaded to a personal computer (PC) using CGMS system solutions software 
V3.0C. The retrospective calibration algorithm uses the manually entered 
calibration measurements to determine calibration parameters, which convert 
the Valid ISIG data into glucose data.  
 
Exact details of the calibration algorithms are not disclosed in the literature due 
to their commercial sensitivity, but several sources suggest the retrospective 
calibration algorithm used by the CGMS Systems Solutions Software employs 
linear regression over a series of calibration measurements (Klonoff 2000; 
Mastrototaro et al. 2002). Linear regression calibration methods may contribute 
to the CGMS System Gold reporting higher values during hypoglycaemia and 
reporting lower values during hyperglycaemia (Beardsall et al. 2013; Voskanyan 
et al. 2007). However, it may also balance the impact of errors in finger stick 
glucose meters by not over-relying on any single calibration measurement. Thus, 
important clinical observations, such as excursions from normal BG levels will be 
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directly affected by the calibration algorithm used and the quality of calibration 
BG measurements.  
 
Several previous studies have investigated CGM calibration schemes, both 
retrospective and real-time, in adults and children (Bequette 2010; Buckingham 
et al. 2006; King et al. 2007). However, in this study, blood gas determinations of 
BG concentrations were available for the dataset and are assumed to be a “gold-
standard” assessment due to their very low error. Alternative calibration 
algorithms can be applied to the CGM readings, utilising the high accuracy BG 
measurements, and compared to the data calibrated using the manufacturer 
algorithm. This chapter explores and quantifies the impact of calibration 
measurement quality, calibration method, and non-linear filtering on metrics of 
hypoglycaemia in neonates using CGM devices.  
 
10.2 Subjects and Methods 
10.2.1 Subjects 
This study used CGM data from 50 babies ≥ 32 weeks gestation that were at risk 
of hypoglycaemia and admitted to the Waikato Hospital NICU. Exclusion criteria 
included serious congenital abnormities or a skin condition preventing 
continuous glucose monitoring. Informed consent was obtained from parents of 
all babies in the study. The study was approved by the Northern Y Regional 
Ethics Committee (New Zealand). Table 10.1 shows the demographics for 
patients enrolled into the study. 
 
Table 10.1 Cohort demographics 
 
Cohort Demographics
Number of CGM traces 50
Sex (M/F) 26/24
Gestational Age (weeks) 34 [33 - 37]
Birthweight (g) 2172 [1880 - 2990]
Primary Risk (# infants):
Diabetes 15
Premature 19
Small or Large for gestational age 14
Other 2
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10.2.2 Continuous Glucose Monitoring 
All patients had interstitial glucose monitoring using CGMS System Gold devices 
and SOF sensors. Sensors were located on the infant’s lateral thigh and were 
connected to the monitor via the supplied cable. Monitoring began on admission 
to the NICU and finished after 7 days or when the baby was no longer considered 
at risk of hypoglycaemia. During the monitoring period nurses recorded all BG 
concentrations, feeding and medication for the management of hypoglycaemia. 
Nurses remained blinded to SG measurements and all calibration BG 
measurements were entered per the manufacturer’s recommendations. Data 
were downloaded to a PC using CGMS system solutions software version 3.0C, 
which calibrated the SG data retrospectively. 
 
10.2.3 Calibration Measurements 
Blood samples were taken by nursing staff via heel-pricking at one hour of age, 
then two to four hourly (before feeds) for 12 hours. In babies receiving 
intravenous dextrose, BG was measured 4 hourly for 12 hours, and then less 
frequently as clinically indicated. The median [IQR] interval between calibration 
BG measurements was 4.8 [3.5 – 6.4] hours. 
 
All BG calibration measurements were made using a BGA (Radiometer, 
ABL800Flex, Copenhagen). This device has a reading range of 0.0 to 60.0mmol/L 
and a C.V. of 1.4-2.2% (Cembrowski et al. 2010; Watkinson et al. 2012). 
Furthermore, a study of a device using the same glucose electrode reported a 
coefficient of variation of 2.1% in ICU patients with little or no decrease in 
performance due to haematocrit, pH or PaO2 (Watkinson et al. 2012). Due to the 
location of the BGA in this study, a short time delay (estimated < 15mins 
maximum) was possible between taking the blood sample and obtaining the 
glucose concentration. 
 
10.2.4 Calibration Algorithms 
The factory calibration algorithm used by the CGMS is based on linear regression 
(Chee et al. 2002; Mastrototaro et al. 2002). The underlying processes used in the 
factory calibration are described in Figure 10.1 (Mastrototaro et al. 2002). 
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Specifically, when only 1 calibration BG is available the algorithm will perform a 
single point calibration (Figure 10.1a). When multiple calibration BG are 
available the algorithm will perform a linear regression calibration (Figure 
10.1b). 
 
 
Figure 10.1 a (left) - Underlying manufacturer calibration process used when a single 
calibration BG is available. b (right) - Underlying manufacturer calibration process 
used when multiple calibration BG values are available. (Mastrototaro et al. 2002) 
 
With multiple calibration BG measurements available, the algorithm uses linear 
regression to calculate a sensitivity ratio. The sensitivity ratio quantifies the 
expected electrical current from the sensor in response to an external glucose 
stimulus. The magnitude of the sensitivity ratio is used to determine the Offset, 
which accounts for any non-linear behaviour in the sensor. It is important to note 
that the Offset values in the dataset used in this study contain other values in 
addition to the 0 or 3 stated in Figure 10.1, suggesting the algorithm has evolved 
since the filing of the patent (Mastrototaro et al. 2002), but that a similar overall 
approach is used. 
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A modified linear regression sensitivity ratio is calculated using the adjusted 
Valid ISIG and calibration BG pairs. This sensitivity, or Slope, is then used as the 
gain/multiplier to give a BG estimate from the Valid ISIG values that are not paired 
with calibration BG measurements. The algorithm described in (Mastrototaro et 
al. 2002) suggests the calibration parameters were held constant for 24 hours, 
starting and finishing at midnight. However, the dataset used in this study has a 
Slope function that gradually changes over time, as shown in Figure 10.2, 
suggesting the version of algorithm used in this study incorporates additional 
smoothing and/or an adjustable calibration window. However, the manufacturer 
calibration method used with the CGMS System Gold is still based on linear 
regression, which is the aspect of interest for this work.  
 
 
Figure 10.2 Representative Slope function from a patient monitored in this study 
 
The linear regression algorithm is aimed primarily at ambulatory individuals 
with type 1 diabetes who use the CGM device to help manage BG levels. One 
reason to utilise linear regression is that this population typically uses a finger 
stick glucometer for calibration, which analyses capillary BG and typically has up 
to 10% error (Abbott 2010; Roche 2007,2008; Solnica et al. 2003). The use of 
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linear regression implicitly balances errors in calibration BG measurements and 
Valid ISIG data. Hence, SG outputs do not necessarily exactly correspond to BG 
measurements, as shown in Figure 10.3. 
 
 
Figure 10.3 Representative section of manufacturer calibrated SG data showing 
discrepancies between SG data and calibration BG measurements. 
 
The calibration BG measurements in this study were determined using a BGA 
with a reported level of error between 1.4-2.2% (Cembrowski et al. 2010; 
Watkinson et al. 2012), which is significantly more accurate than typical 
glucometers. Thus, data were recalibrated to make better use of the accurate 
calibration measurements by forcing the SG output through all calibration BG 
measurements. It should be noted there are many ways that the data could be 
recalibrated and the algorithm used in this study represents just one example 
based as directly as possible upon the details available for the current method 
(Bequette 2010; Mastrototaro et al. 2002; Minimed 2003). 
 
The CGM blood glucose estimation is determined using: 
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Where: 
 BGCGM  – Blood glucose estimate by the CGM (mmol.L-1) 
 Slope – Calibration parameter found using linear regression (mmol.L-1.nA-1). 
Note the parameter Slope is referred to as MLRSR in Figure 10.1. 
 Valid ISIG  – Electrical current detected by the monitor from the sensor (nA)  
 Offset – Calibration parameter to compensate for non-linear sensor 
behaviour, typically observed at high glucose levels. 
 
To recalibrate, Equation 10.4 is rearranged to:  
 
 
Where: 
 BGCal –  Blood glucose level for calibration (BGA measurement) (mmol.L-1)  
 Reqd Slope – Slope that forces BGCGM through calibration measurements 
(mmol.L-1/nA) 
 
The recalibration algorithm adjusts the Slope parameter and forces the output SG 
trace to pass through all calibration BG measurements, while preserving the raw 
sensor current, Valid ISIG, and Offset parameter. At each calibration measurement 
a value of Reqd Slope is calculated using Equation 10.5. Linear interpolation of 
Reqd Slope gives the new, continuous Slope function. Figure 10.4 shows a 
manufacturer calibration Slope function compared to the recalibrated Slope 
function.  
 
The recalibrated Slope function is inserted back into Equation 10.4 with the 
unmodified Valid ISIG and Offset parameters, to give recalibrated SG values. 
Recalibrated SG data provides a comparator to assess the impact of calibration 
on outcome SG trace. A representative example of the effect of calibration on SG 
data is shown in Figure 10.5. 
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Figure 10.4 Comparison of a Slope function generated by the manufacturer’s 
calibration algorithm (black dashed line) and the re-calibrated Slope parameter (red 
line). 
 
 
Figure 10.5 Recalibrated SG data (blue solid line) passes through all calibration BG 
measurements, compared to the same sensor data calibrated using the 
manufacturer’s algorithm.  
0 1 2
0
1
2
3
4
5
6
7
8
Time (days)
S
lo
p
e
 (
m
m
o
l.
L
-1
/n
A
)
 
 
Original slope
Modified slope
1.5 2 2.5 3
0
2
4
6
8
10
12
Time (Days)
B
lo
o
d
 G
lu
c
o
s
e
 (
m
m
o
l/
L
)
 
 
Original CGM Trace
Recalibrated CGM Trace
Calibration BG
129 
 
10.2.5 Non-linear Filtering 
Non-linear filters can be used to remove unwanted and potentially un-
physiological high-frequency noise from the CGM signal. In particular, median 
filters have proven to be a simple and effective method of removing this noise 
and smoothing SG traces (Bequette 2010; Pretty et al. 2010). Several median 
filters of different lengths were tested, including composite median filters. Figure 
10.6 shows a recalibrated SG trace and the effects of 3 different median filters. 
 
A retrospective composite median filter was used in this study because it allows 
faster and slower glucose dynamics to be captured more effectively. The filter 
averages a 3 point median and a 7 point median both centred about the time 
point of interest (Pretty et al. 2010). The filter was implemented both prior to 
recalibration (on the Valid ISIG) and post calibration on the SG output to assess 
any differences due to where in the process filtering occurs. 
 
 
Figure 10.6 Representative SG data with non-linear median filtering from 3 different 
median filters. Sections 'A' and 'B' highlight the effects of each individual filter on 
CGM dynamics that were often observed in this data set. 
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Figure 10.7 Enlarged area 'A' in Figure 10.6 showing a sudden, potentially un-
physiological, drop in the SG data that has been removed by the filter. All three 
filters have effectively removed the artefact. 
 
 
Figure 10.8 Enlarged area 'B' in Figure 10.6 showing the effect of filter length on the 
degree of filtering. The composite 3 and 7 length median filter removes high 
frequency changes, while capturing the overall trend of the SG data. 
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10.2.6 Analyses 
10.2.6.1 Overall cohort 
Four analyses of the CGMS data from the 50 babies were performed in this study:  
 
1. Original SG output 
2. Recalibrated SG output 
3. Recalibrated and median filtered SG output 
4. Filtered Valid ISIG then recalibrated SG output.  
 
Each of the recalibrated variations, with and without filtering, is compared to the 
original SG output to see the effect of recalibrating/filtering on clinical measures 
of hypoglycaemia. Hypoglycaemia was defined as one or more consecutive SG 
measurement(s) below 2.6mmol/L, surrounded by SG measurements greater 
than or equal to 2.6mmol/L. The metrics used to quantify hypoglycaemia were: 
 
 Number: Number of independent hypoglycaemic events  
 Duration: Percent of SG record below 2.6mmol/L 
 Severity: Lowest measurement of hypoglycaemic event. 
 Hypoglycaemic index: Similar in concept to Hyperglycaemic index 
(Vogelzang et al. 2004) and defined as the area between the 2.6mmol/L 
threshold and the SG trace (for SG trace < 2.6mmol/L) summed over the 
entire length of stay, normalised by the length of data record. Note: the units 
used in this study are μmol/L, not mmol/L. 
 
10.2.6.2 Per-patient hypoglycaemic index by day 
A subset of 43 infants with at least 3 days of SG data were analysed for 
hypoglycaemic index on a day-by-day basis. This analysis looked at the re-
occurrence rate of hypoglycaemia in each individual. Seven patients were 
excluded from the analysis due to having less than 3 days of SG data. For each 
day, using the original SG output, patients were ranked by hypoglycaemic index. 
The ranks were preserved for the three recalibrated and filtered CGM analyses to 
highlight changes in hypoglycaemic index for individual patients. For example, a 
patient with a high hypoglycaemic index using default manufacturer calibration 
may have a lower hypoglycaemic index when recalibrated. A further integral 
index metric was used to represent the total hypoglycaemic index across the 43 
patients on that day, quantifying this per-patient result to a single value over the 
cohort for easy comparison. 
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10.3 Results 
10.3.1 Overall cohort 
Figure 10.9 shows the distributions of CGM errors, calculated as CGM minus BG, 
at the time of calibrations. Specifically, these discrepancies represent the residual 
difference between SG values and calibration BG values, after calibrating using 
the manufacturer’s algorithm. Thus, the accuracy of the device cannot be 
deduced from these plots, as all BG measurements were used for calibration and 
the data set contained no independent BG values that could be used as 
references. The top plot shows the distribution for all paired measurements 
(1074 pairs). The middle plot shows the distribution of errors when either the 
CGM or BG measurement was less than or equal to 3mmol/L (145 pairs). The 
bottom plot shows the distribution of errors when either the CGM or BG 
measurement was greater than 7mmol/L (62 pairs). In all plots the dashed 
vertical lines represent the median, and the solid vertical lines represent the IQR. 
 
In terms of capturing hypoglycaemia, the calibration BG measurements detected 
53 hypoglycaemic events during the study. Of these, 16 were at a time when the 
CGM was also hypoglycaemic. However, the other 37 hypoglycaemic calibration 
BG measurements occurred at a time when the baseline CGM was above 
2.6mmol/L.  
 
Figure 10.10 shows a section of SG trace comparing original (black dashed line), 
recalibrated (solid blue line), Recalibrated and filtered (green dotted line), and 
Filtered Valid ISIG then recalibrated variations (purple dash-dot line). In this 
example, overall trends in calibration parameters and SG output are preserved. 
However it is clear in Figure 10.10 that metrics of hypoglycaemia will vary 
depending on the method of signal processing used.  
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Figure 10.9 Distribution of errors between CGM and BG measurements with median 
(dashed vertical line) and inter-quartile range (solid vertical lines), for different 
glucose levels. 
 
 
 
Figure 10.10 Comparison of a section of SG trace containing hypoglycaemia for 
Original CGM, Recalibrated CGM, Recalibrated and filtered CGM, and Filtered Valid 
ISIG then recalibrated CGM. Hypoglycaemia is defined as one or more consecutive SG 
measurement(s) below 2.6mmol/L, surrounded by one or more SG measurement(s) 
above 2.6mmol/L. Note: recalibrating increases the number of hypoglycaemic events 
from 1 to 4, then filtering reduces it back to 1 in this example.  
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Figure 10.11 shows the SG trace in this study that had the largest change in 
hypoglycaemia metrics after recalibration. The original SG trace (black dashed 
line) suffered from particularly bad factory calibration for the first 12 hours of 
monitoring, during which time there was a significant period of hypoglycaemia. 
However, all four calibration BG measurements in the first 12 hours were above 
2.6mmol/L, and consequently the recalibrated SG trace (solid blue line) had no 
hypoglycaemia. 
 
 
Figure 10.11 The SG trace that had the largest change in hypoglycaemia metrics after 
recalibration. The original SG trace (black dashed line) contains a long period of 
hypoglycaemia in the first 12 hours of monitoring. However, all four calibration BG 
measurements in this period were above 2.6mmol/L and consequently the 
recalibrated SG trace (blue solid line) had no hypoglycaemia. 
 
The top section of Table 10.2 compares the number, duration and severity of 
hypoglycaemia events, as well as the hypoglycaemic index for each variation of 
the CGM calibration. The results are presented for the overall cohort and per-
patient to show any potential skewed results from individual patients. The 
bottom section of Table 10.2 shows the effect of recalibration and/or filtering on 
the hypoglycaemic state of patients over the monitoring period. For example, the 
top left cell in bottom section of Table 10.2 (“24”) indicates that 24 patients who 
had hypoglycaemia in the original SG data still had hypoglycaemia in the 
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recalibrated SG data. Conversely, the second row in column one (“1”) indicates 
that 1 patient who had hypoglycaemia in the original SG data had no 
hypoglycaemia in the recalibrated SG data. 
 
10.3.2 Per-patient hypoglycaemic index by day 
Figure 10.12 shows the effect of recalibration and filtering on the hypoglycaemic 
index of individual patients on a day-by-day basis. The top row of Figure 10.12 
shows the hypoglycaemic index for each patient over the first 24 hours of 
monitoring. The second row of Figure 10.12 shows the second 24 hour period 
and the third row shows the third 24 hours. From left to right in each row, the 
change in hypoglycaemic index for each patient due to calibration and/or 
filtering can be seen (the patient order is preserved across these plots). For 
example, the infant with most hypoglycaemia by original CGM calibration on day 
1, shown in Figure 10.11, had no hypoglycaemia with any of the recalibration 
methods. Finally, the integral index summarising these results is also indicated 
on each panel of Figure 10.12. 
 
10.4 Discussion 
The aim of this study was to investigate how calibration and nonlinear filtering 
of SG data affect metrics of hypoglycaemia in at risk preterm babies. This 
knowledge is important for accurately relating hypoglycaemia to long term 
outcomes.  
 
10.4.1 Overall cohort 
The top section of Table 10.2 shows all metrics of hypoglycaemia increased after 
recalibration compared to original CGM results, which can potentially be 
explained by skew in the distribution of BG vs. CGM readings at low BG 
concentrations. Figure 10.9 shows the distribution of errors between the CGM-
BG paired measurements. The data set contains 1074 paired BG-SG 
measurements of which 51% have a BG measurement higher than the CGM and 
49% have a BG measurement lower than the CGM, and these data are, overall, 
relatively centred, as expected from the regression aspect of calibration.  
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Figure 10.12 Comparison of ranked Hypoglycaemic Index for 43 patients (3 days) for 
Original CGM, Recalibrated CGM, Recalibrated and Filtered CGM, and Filtered ISIG 
then Recalibrated. The curved solid line repeats the ranked distribution as 
determined by original SG data. The integral index captures the overall area of each 
panel for a single comparator value. 
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More importantly, the second plot in Figure 10.9 shows a definite positive shift in 
the median when only considering low glycaemic levels. Of the 145 pairs 
containing either a CGM or BG measurement below 3mmol/L, 63% have a BG 
measurement lower than the CGM. These lower measurements pull the SG trace 
down to the more accurate BGA value when recalibrating and cause the 
hypoglycaemia metrics to increase. Additionally, the bottom plot in Figure 10.9 
shows the opposite is also true for high BG concentrations. At least for this 
dataset, CGM readings have a greater tendency to be lower than their BG 
counterparts when the concentrations are above 7mmol/L. 
 
Furthermore, of the 53 calibration BG measurements that were hypoglycaemic, 
only 16 occurred at a time when the CGM was below 2.6mmol/L. The remaining 
37 hypoglycaemic BG measurements were at a time when the CGM was reporting 
values greater than 2.6mmol/L. Thus, recalibrating the SG data to capture the 
‘missed’ events is further justified, especially when using the SG data to classify 
hypoglycaemia.  
 
When comparing recalibrated SG data to recalibrated and filtered SG data, the 
large reduction in the number of hypoglycaemic events in Table 10.2 (193 to 
131) with little change in hypoglycaemic duration (2.6% to 2.5%) can be 
explained with reference to Figure 10.10. Two different phenomena occur that 
reduce the number of events from 4 to 1 in this exemplar case. First, at 3.8 days 
the peak in the SG trace is trimmed by the filter (filter after recalibration) 
preventing it from crossing the normoglycaemic threshold and reducing the 
number of hypoglycaemic events. The opposite can also occur, where a 
hypoglycaemic event observed in the recalibrated SG trace is removed by 
filtering, where, in this case, a trough would be trimmed.  
 
The second phenomenon is seen at ~3.88 to 3.9 days, where high frequency 
fluctuations in SG measurements are smoothed by the filter. Smoothing these 
fluctuations around the threshold is likely to be the major influence on the 
reduced number of hypoglycaemic events observed. The variations in the 
number of hypoglycaemic events observed over the 4 analyses suggests that this 
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metric alone (number of events) may not be reliable when classifying 
hypoglycaemia using CGM due to this variability when near the threshold value. 
 
The bottom section of Table 10.2 shows the number of patients that gained, lost 
or stayed with/without hypoglycaemia when recalibrated and filtered, compared 
to original SG data. Of the 25 babies who had hypoglycaemia in the original data 
set 22 to 24 had hypoglycaemia in the modified data sets, and, 17 to 18 out of 25 
of babies who had no hypoglycaemia in the original data set still had no 
hypoglycaemia. These results suggest that over the duration of monitoring, the 
CGM should be consistent ~80% of the time about which patients had 
experienced hypoglycaemia, independent of calibration method.  
 
10.4.2 Per-patient hypoglycaemic index by day 
Figure 10.12 shows three important trends. First, the hypoglycaemic index, a 
measure of duration and severity, for a patient on any given day can change 
significantly after recalibration. For example, the highest ranked patient on day 
one using the original SG output had a hypoglycaemic index of ~105µmol/L, 
which was reduced to 0µmol/L after recalibration. Conversely, several patients 
have no hypoglycaemic events on day 1 (original CGM), but, after recalibration 
all have a non-zero hypoglycaemic index. For days 2 and 3 there is far more 
agreement in which patients had hypoglycaemia, although in some cases the 
index still changes with recalibration. This outcome suggests that after day one, 
regardless of calibration method, patients who experienced hypoglycaemia could 
be identified with a higher level of confidence. 
 
The next trend shown by Figure 10.12 is that hypoglycaemia is most prevalent 
during day 1. Comparing the plots in row 1 and 2 of Figure 10.12 shows the 
decrease in integral index from day 1 to 2 is in the range of 45% - 54%, 
suggesting hypoglycaemia is more prevalent in the overall cohort on day one, by 
any calibration method. Interestingly, further decreases were not observed from 
day two to three in either the original SG data or the recalibrated/filtered SG data 
of Figure 10.12. This result reinforces the importance of capturing the first 24 
hours of SG data and thus of proper placement and initial device calibration. 
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These first two trends suggest the effects of calibration scheme and/or filtering 
on hypoglycaemia detection are most significant on day 1. This could be due to 
two reasons: First, the error between calibration BG measurements and SG 
measurements tends to be larger on day 1, so recalibrating has more affect. 
Second, these infants are at risk by definition and hypoglycaemia can be more 
prevalent on this first day of life (Bhat et al. 2000; Hawdon et al. 1992). Neither 
effect can be ruled out in this analysis. 
 
The third trend is an increase in integral index with recalibration, regardless of 
the day, which can potentially be explained by the previously mentioned 
tendency of the original CGM device to deliver a higher value at low glucose 
levels due to the linear regression based calibration approach. Conversely, there 
is a reduction in integral index with the addition of filtering, which is likely 
explained by the ‘rounding’ or clipping of troughs, in this analysis. 
 
10.4.3 Limitations 
The main limitation of this study is the number of BG measurements available. 
Due to the pain and discomfort of blood sampling in neonates, typically by heel 
prick, it was unethical to measure BG more frequently than ~4 hourly. Ideally, a 
reference measurement would be sampled for nearly every SG measurement, in 
addition to the ~4 calibration measurements per day. The reference 
measurements would allow the impact of calibration on a ‘true’ level of 
hypoglycaemia to be assessed more thoroughly and conclusively.  
   
The limited number of BG measurements also restricts the recalibration and 
filtering strategies. For example, the delays between BG and interstitial glucose 
could not be optimised so the overall delay was left constant at the manufacturer 
set 10 minutes. Studies in the literature report delays typically in the range of 5-
15minutes (Bailey et al. 2009; Boyne et al. 2003; Garg et al. 2010; Kamath et al. 
2009; Kovatchev et al. 2009). However, without sufficient reference BG 
measurements the delay cannot be determined in this study, for this group of 
patients. Finally, the filter implemented in this study is effective, but represents 
one of a wide variety of available filters. Other more advanced filtering options 
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are available, but without several reference BG measurements it is not possible 
to determine the optimal filtering strategy. 
 
10.5 Summary 
The aim of this study was to investigate how recalibrating and filtering SG data 
affects metrics of hypoglycaemia in preterm infants. The results suggest that 
conventional hypoglycaemia metrics are heavily dependent on both the error in 
calibration BG measurements and the calibration algorithm used. All metrics of 
hypoglycaemia for our cohort increased after recalibration, confirming that the 
original, unmodified SG output tended to report high at lower levels. If highly 
accurate calibration measurements are available it may be more appropriate to 
recalibrate the data, especially when trying to accurately classify hypoglycaemia 
or other specific extreme events. 
 
More importantly and generally, calibration BG measurement error and thus 
calibration algorithms play a significant role in quantifying hypoglycaemia using 
SG data. In particular, metrics such as number of hypoglycaemic events are 
particularly sensitive to recalibration effects. While this conclusion may be 
expected, its potential impact is quantified here, in this case for at risk neonates 
for whom hypoglycaemia may carry long-term negative consequences. 
 
  
142 
 
Chapter 11. Effects of calibration measurement errors 
The recalibration procedure described in the previous chapter was specifically 
designed to utilise calibration BG measurements with minimal measurement 
error that are entered into the CGM monitor without delay. In the clinical 
environment, this is not always possible for a number of reasons. Therefore, it is 
important to have an understanding of how these errors can impact SG data, and 
specifically in this study, how hypoglycaemia metrics are affected. This chapter 
investigates the impact of measurement error and calibration time delays on 
metrics used to quantify hypoglycaemia. 
 
11.1 Introduction 
The recalibration algorithm described in the previous chapter was designed 
under the assumption that the calibration measurements used were very 
accurate and entered into the device without delay. However, in the busy 
neonatal care environment it is possible for unexpected time delays to occur 
between measuring BG and entering the value into the CGM device for 
calibration. The magnitude of time delays can depend on a number of factors, 
including the meter or method used to measure the BG concentration and the 
location of the BG sensors relative to the patient (Aragon 2006; Carayon & 
Gurses 2005; Ginsberg 2009).  
 
Calibration algorithms cannot currently detect or correct for these time delays. 
Consequently, any delay could potentially introduce significant error in the 
output SG trace, especially during periods of rapidly changing BG (Castle & Ward 
2010). For example, if the blood glucose level is steadily dropping at 0.08mmolL-
1min-1, a perfectly accurate BG measurement entered just 15 minutes late will be 
1.2mmol/L higher than the true BG level. Thus, when CGM devices are used in 
the neonatal unit where time delays are possible, it is important to understand 
the potential impact of these delays and whether or not they are clinically 
significant. 
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Another source of inaccuracy that could impact SG data is calibration BG 
measurement error. As mentioned in the previous chapter, point-of-care 
glucometers normally have measurement errors in the range 2-10% and can 
exhibit reduced performance in critically ill or neonatal care patients, 
particularly due to medications or fluctuating haematocrit levels (Carayon & 
Gurses 2005; Hoedemaekers et al. 2008; Kanji et al. 2005). In contrast, BGAs can 
measure BG concentrations with less than 2% error for a wide range of patient 
states, with little influence from haematocrit, PH, or PaO2 (Watkinson et al. 
2012). Hence, the choice of calibration measurement sensor could have a 
significant impact on CGM accuracy, independent of calibration timing.  
 
These errors can add uncertainty to the SG data and consequently to any 
glycaemic metrics calculated from it. Therefore, studies utilizing CGM devices to 
quantify glycaemic events, such as hypoglycaemia, should be aware of these 
potential sources of error and the potential impact on results. In particular, any 
uncertainty in SG data would limit the detectable resolution of any true clinical 
changes and should be accounted for in the study design. This chapter quantifies 
the effect of timing delays and calibration BG measurement errors, both together 
and separately, on metrics used to classify hypoglycaemia in newborn infants. 
 
11.2 Subjects and methods 
11.2.1 Patients 
This post-hoc analysis uses CGM device data and BG data from 155 newborn 
infants admitted to Waikato Hospital NICU during the SUGAR-BABIES trial. 
Eligibility for the study included babies greater than 35 weeks gestation, less 
than 48 hours old and at risk of neonatal hypoglycaemia. Primary risk factors for 
neonatal hypoglycaemia included having a mother with diabetes, prematurity 
and/or being small or large for gestational age. All patients were monitored 
using a CGMS System Gold device and SOF sensor, which was inserted in the 
baby’s lateral thigh as soon as was practical after birth.  
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Patients with less than 24 hours of CGM data were excluded from this study and 
SG data sets exceeding 72 hours were trimmed. This data was used to create one 
of two timing error models and for the main analysis. Across all 155 infants, the 
median [25th - 75th percentile] duration of CGM recordings was 1.8 (1.5 – 2.0) 
days with 5.90 (5.1 – 6.9) calibrations per day. This study and use of data was 
approved by the Northern Y Ethics Committee, New Zealand. Table 11.1 
summarises the demographics of this cohort. 
 
Table 11.1 Cohort demographics 
 
 
11.2.2 Timing error models 
Timing error models are used to assess the impact of delays entering BG 
measurements into the CGM for calibration. Two models were created for this 
study, one using data from the Waikato Hospital NICU study and one using data 
from an on-going CGM study in the Christchurch Hospital ICU. The Christchurch 
Hospital ICU study and use of data was approved by the Upper South A Regional 
Ethics Committee, New Zealand.  
 
All calibration BGs in both centres were determined using a BGA (Waikato: 
Radiometer ABL800Flex, Copenhagen; Christchurch: Radiometer ABL90Flex, 
Copenhagen). The BGA recorded the time and glucose concentration 
electronically, but nurses were required to manually enter the BG value into the 
CGM where it was stored internally and used for calibration. The time 
discrepancies between measuring BG and entering it into the CGM for calibration 
form the basis of this model. These delays were calculated as CGM calibration 
Cohort Demographics
Number patients 155
Sex (M/F) 80/75
Gestational Age (weeks) 37 [36 - 38]
Birthweight (g) 2705 [2404 - 3393]
Primary Risk (# infants)
Diabetes 50
Premature 57
SGA or LGA 41
Other 7
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time minus BGA measurement time and restrict the data set to the positive time 
domain as it is not possible to enter a calibration BG prior to measuring BG 
concentration in the BGA. Any additional time delays between obtaining the 
blood sample and determining the glucose concentration were considered 
negligible due to the close proximity of the BGA to the patients.  
 
Data from Waikato Hospital included 1947 time delay values that could be 
included in the model. The vertical blue bars in Figure 11.1A show the 
distribution of time delay data and the red line shows the exponential model (µ = 
12.96) that was used to capture the data. Figure 11.1B shows a similar plot for 
the 155 time delay values from the Christchurch Hospital study, which were also 
modelled by an exponential decay model (µ = 8.84).  
 
 
Figure 11.1 A) Raw timing error data and exponential model fit from the Waikato 
Hospital study. B) Raw timing error data and exponential model fit from the 
Christchurch Hospital study. 
 
11.2.3 Measurement error models 
Measurement error models describe the level of inaccuracy in a calibration BG 
measurement, commonly parameterized by accuracy and precision. A wide 
range of error levels for different devices can be found in the literature (Critchell 
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et al. 2007; Ho et al. 2004; Nuntnarumit et al. 2011; Rao et al. 2005). However, 
this study focused on three glucose meters, shown in Figure 11.2: 
 
1. Abbott Optimum Xceed (Abbott Diabetes Care, Alameda, CA) 
2. Nova Statstrip Glu (Nova Biomedical, Waltham, MA, USA) 
3. Roche Accu-chek Inform II (F. Hoffmann-La Roche Ltd, Basle, Switzerland). 
 
 
 
Figure 11.2 The three glucose meters used in this study. From left to right: Abbott 
Optium Xceed, Nova Statstrip Glu, Roche Accu-chek Inform II. 
 
All three statistical error models were developed using data from the 
Christchurch ICU study. Under this protocol, every blood sample drawn for BG 
analysis was first analysed by the BGA and then the remaining blood distributed 
across up to 15 separate BG meters (up to 5 of each model). Not every type of 
glucometer was available for each patient in the study, so the numbers of paired 
meter-BGA measurements available was different for each model. All BG 
measurements were made by trained staff, minimizing potential user associated 
error (Ginsberg 2009).  
 
All devices used in this study measure glucose concentration in a whole blood 
sample and display a plasma equivalent glucose concentration as recommended 
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by the International Federation of Clinical Chemistry and Laboratory Medicine 
(D'Orazio et al. 2006). Furthermore, BGA’s in the same family as the ones used in 
this study have also been shown to correlate well with lab plasma glucose 
determinations (Scott et al. 2008), allowing direct comparison between all 
devices.  
 
For each glucometer measurement, the error between the glucometer and BGA 
value was calculated as meter – BGA, so that a positive error is indicative of a 
high meter value. Errors were stratified into bins, based on the BGA 
measurement. Mean and standard deviation of each bin was then used to 
describe the error distribution for each bin, which was assumed Gaussian around 
any bias. Positive bias assumes the glucose meter is reading higher than the 
recorded BGA value, and vice-versa. 
 
The Abbott Optium Xceed is an inexpensive and commonly available device that 
measures the glucose concentration of a whole blood sample, and estimates the 
plasma equivalent glucose concentration using a constant adjustment factor of 
1.12 (Abbott 2010). This factor is derived from the difference between plasma 
glucose and whole blood glucose concentration for an individual with a normal 
haematocrit level. The Abbott test strips are validated for a haematocrit range of 
20-70 (Abbott 2010). The top section of Table 11.2 shows the error model 
derived from the experimental Abbott and BGA data. There were a total of 724 
paired meter-BGA measurements available for the model.  
 
The Nova Statstrip GLU was designed for point of care (POC) testing in the 
hospital environment and adjusts for haematocrit level when calculating plasma 
glucose concentration. The Nova test strips used in this study were validated for 
a haematocrit range of 20-65% (Nova 2011). The middle section of Table 11.2 
shows the error model derived from the 229 paired meter-BGA measurements.  
 
The Roche Accu-chek Inform II was also designed for POC testing and monitoring 
in hospitals. This device also adjusts for haematocrit level and test strips were 
validated for a haematocrit range of 10-65% (Roche 2007). The bottom section 
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of Table 11.2 shows the error model derived from 344 paired meter-BGA 
measurements.  
 
Table 11.2 Measurement error data for the Abbott Optium Xceed, Nova Statstrip, 
and Roche Accu-chek Inform II glucose meters. The Nova and Roche models have a 
reduced number of bins to avoid skewing due to low measurement numbers. 
 
 
All three measurement error models were validated against the error 
characteristics described by the manufacturers (Abbott 2010; Nova 2011; Roche 
2007). The Roche and Nova measurement error models compared well to the 
manufacturers data. The Abbott measurement error model has increased bias 
and variation compared to the manufacturer’s data. Finally and equally 
importantly, the models and specific values described here are comparable to 
what has been reported in the literature for these devices (Makaya et al. 2012; 
Nuntnarumit et al. 2011). Thus, the models summarised in Table 11.2 are 
representative of these devices in use. 
 
11.2.4 Analysis  
This analysis used CGM and BG data from 155 babies admitted to the Waikato 
Hospitals NICU. Timing and measurement errors were randomly sampled from 
Reference BG (mmol/L) < 5.9 6.0 - 6.9 7.0 – 7.9 8.0 – 8.9 > 9.0
Number of measurements 141 277 224 42 40
Error mean (mmol/L) 0.5099 0.5433 0.2299 0.1952 0.635
Error std. dev. (mmol/L) 0.4982 0.7519 0.5521 0.8748 0.3965
Reference BG (mmol/L) 7.0 – 7.9
Number of measurements 141
Error mean (mmol/L) -0.0823
Error std. dev. (mmol/L) 0.2471
Reference BG (mmol/L) 7.0 – 7.9
Number of measurements 160
Error mean (mmol/L) -0.4212
Error std. dev. (mmol/L) 0.2645
<6.9 >8.0
Abbott Error Model 
Nova Error Model 
Roche Error Model 
<6.9
67
-0.0134
0.2564
>8.0
21
-0.1905
0.3463
10
-0.27
0.09490.2615
-0.181
174
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the models described in Sections 11.2.2/11.2.3 and added to calibration BG 
measurements, as depicted in Figure 11.3. 
 
Figure 11.3 Example of the error that was added to calibration BG measurements to 
simulate measurement error and delays in entering calibration BG measurements 
into the CGM. 
 
The calibration BG measurements with added error were used to calibrate the SG 
data and hypoglycaemia in this CGM data was quantified by: 
 
 Number: Number of independent hypoglycaemic events  
 Duration: Percentage of SG recordings below 2.6mmol/L 
 Hypoglycaemic index: Total area between the 2.6mmol/L threshold and the 
SG trace (when SG < 2.6mmol/L), divided by the total monitoring duration 
 
MC methods were employed to ensure robust results from the randomly 
sampled errors. Each simulation consisted of 1000 runs and a total of 11 
simulations were completed, one for each individual model (two timing error 
models and three measurement error models) and one for every possible 
combinations of timing/measurement error models (a further 6 simulations). 
The simulation protocol can be summarized as follows: 
 
0 5 10 15 20 25 30 35 40
3
3.1
3.2
3.3
3.4
3.5
3.6
3.7
3.8
3.9
4
Time (mins)
B
lo
o
d
 G
lu
c
o
s
e
 (
m
m
o
l/
L
)
 
 
Calibration BG
Calibration BG with added error
Measurement error 
Timing error 
150 
 
1. For every simulation run on a each patient, the difference in hypoglycaemia 
metrics for the 'random error' SG data and the original 'no error/baseline' SG 
data are determined. These differences are calculated as hypoglycaemia in SG 
data with error - hypoglycaemia in baseline SG data, so a positive result 
suggests an increase in hypoglycaemia with the error(s) added to calibration 
BG measurements. 
2. The median difference in hypoglycaemia across 1000 MC runs for each 
patient was recorded 
3. The results for the overall cohort are presented as a median [25th -75th 
percentile] (5th - 95th percentiles) of the values calculated in step 2 for all 
patients. 
 
Figure 11.4 shows a representative example of the variation in a SG data trace 
across 1000 runs in the simulation for this subject. The baseline SG data 
calibrated with no error in calibration BG measurements is shown by the red line 
in Figure 11.4. 
 
 
Figure 11.4 Example of the variation in SG data across 1000 runs in a simulation, 
shown in blue. The red line shows the SG data when calibrated with no additional 
error. 
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11.3 Results 
11.3.1 Timing error only 
Table 11.3 shows timing error tends to have little effect on the number of 
hypoglycaemic events. The results for either timing error model both have a 
median difference from the original metrics of 0 and the 5th-95th range variation 
is only ±2 events. Percent duration and hypoglycaemic index are increased by 
timing error for both models. The Waikato model caused a median increase of 
0.21% to the duration of hypoglycaemia and 0.27µmol/L to hypoglycaemic 
index. Simulations using the Christchurch model caused a median increase in 
duration of 0.17% and a median increase in hypoglycaemic index of 0.18µmol/L. 
 
Figure 11.5 shows a data set that has a period where timing error in calibration 
BG measurements has a larger impact on the SG data that measurement error. 
Between 500 - 700mins, the timing error results in a wider range of SG values, as 
shown by the thick green band. However, for the remainder of the SG data the 
measurement error appears to be dominant. 
 
11.3.2 Measurement error only 
The results from simulations using only measurement error are also shown in 
Table 11.3. The Abbott results show a negative difference across all metrics 
compared to baseline results. Hence, the Abbott results tended to under-report 
all hypoglycaemic metrics. The number of hypoglycaemic events recorded had a 
difference of -1[-3 0](-8 0) events. The median number of hypoglycaemic events 
reported from simulations using the Nova model were the same as baseline 
results. However, there was a slight tendency for percent duration and 
hypoglycaemic index to be over reported, with results of 0.49[0.1 1.6](-0.1 6.7)% 
and 2.93[0.5 8.2](0 16)µmol/L, respectively. The Roche sensor tended to over-
report hypoglycaemia to the highest degree, with median differences of 4.45% 
and 19.4µmol/L for duration and index, respectively.   
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Figure 11.5 A) Example patient where timing error in calibration BG has a large effect 
on the calibrated SG data. B) The same data set with measurement error added to 
calibration BG. Note between 500 - 700mins timing error has a larger impact than 
measurement error. 
 
The tendency of each measurement error model to cause under or over 
reporting of hypoglycaemia metrics can be seen in Figure 11.6. The top plot of 
Figure 11.6 shows a representative SG data set after a simulation using the 
Abbott measurement error model. The middle plot shows the same dataset after 
simulation using the Nova measurement error model and the lower plot shows 
the data after simulation using the Roche measurement error model. In each plot, 
the coloured band shows the 5th -95th percent range of reported measurements 
at each time point, across 1000 simulation runs. The dark blue line shows the 
recalibrated SG data with no error and the red crosses show calibration BG with 
no error.  
 
This specific SG dataset contains a significant hypoglycaemic event that occurs 
between 430 and 570 minutes. However, when simulating with the Abbott 
measurement error model (A in Figure 11.6) this hypoglycaemic event only 
appears in approximately 50% of the 1000 simulation runs. In the Nova (B in 
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Figure 11.6) and the Roche (C in Figure 11.6) simulations this hypoglycaemic 
event is detected for 100% of the MC runs. As a consequence of the negative bias, 
especially in the Roche model, this event tends to drop below the 2.6mmol/L 
threshold earlier and rise later than the baseline trace, resulting in a concomitant 
increase in the hypoglycaemia duration and index metrics, as well. 
 
Figure 11.7 shows the baseline (no error) duration of hypoglycaemia (x-axis) 
plotted against the duration of hypoglycaemia for each run (y-axis), for a 1000 
run simulation. The spread in the y direction shows the amount of variation in 
the hypoglycaemia metric across the 1000 runs. The black, blue and red lines 
show the 25th, median and 75th percentiles, respectively. The left plot shows 
results when using the Abbott model and the plot shows a clear tendency to 
under-report the duration of hypoglycaemia. The right plot in Figure 11.7 is for 
the Roche model and in this plot the duration metric has been over estimated, 
shown by the majority of results being above 45° line. 
 
11.3.3 Combined timing and measurement error 
The combination of measurement and timing error leads to an increase in both 
the median difference and variation of these across all metrics. However, the 
measurement error has a significantly larger impact than the timing error on 
hypoglycaemia metrics.  
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11.4 Discussion 
11.4.1 Timing error vs. Measurement error 
The results suggest that measurement error has a much larger effect than timing 
error on the metrics used to quantify hypoglycaemia. The Nova measurement 
error model, which had the least impact of the 3 measurement error models, 
increases the median duration of hypoglycaemia by more than double that of the 
either timing error model. Furthermore, the median hypoglycaemic index from 
the simulation using the Nova measurement error model is an order of 
magnitude greater than the result from the simulation using the Waikato timing 
error model. Additionally, when the effects of measurement and timing error are 
combined, there is little change to the results compared to measurement error 
alone. These results clearly illustrate the dominance of measurement error over 
timing error in the overall cohort, and that the observed timing errors have little 
impact on these hypoglycaemic metrics.  
 
On a per-patient level, it is possible for the impact of timing error to be much 
more significant than that of measurement error. For example, in Figure 11.5, the 
calibration BG just after 500 minutes is determined during a period of steep 
glucose ascent. When timing error alone is randomly added to this calibration 
BG, as in panel A, we see a wide range of possible SG values for each time point 
between 500 - 700 minutes. However, in panel B, when simulating measurement 
error alone the rate of change of glucose has little or no effect and the range of 
possible SG values remains fairly constant throughout the entire monitoring 
period.  
 
Clinically, when real-time CGM devices are used to monitor glycaemia, the effects 
of these errors can be reduced by acknowledging the state of the SG trace at the 
time of calibration. If glycaemia appears stable then it is likely that impact of 
timing error is negligible, and the time between measuring BG and entering it in 
to the CGM is not vital. This approach allows time and care to be taken to ensure 
the most accurate measurement of blood glucose levels is obtained and the 
resulting calibration is optimal for the conditions. For example, a BGA might be 
used instead of a POC glucometer if timing errors are less critical. However, for a 
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patient with a rapidly changing glucose concentration at the time of calibration, 
timing error can become more significant than measurement error. This issue is 
particularly important when monitoring newborn babies glucose levels as they 
can fluctuate significantly during the first few hours of life. In these specific cases, 
it is imperative that the calibration measurement is obtained and entered into 
the CGM quickly, perhaps using a glucometer instead of a BGA to reduce timing 
error and delay. 
 
11.4.2 The Impact of Bias  
The tendency of Abbott to under-report the hypoglycaemic metrics, while Nova 
and Roche over-report, is caused by the level of sensor measurement bias, which 
is a property of the device itself. For the Nova and Roche error models, a negative 
bias causes the trace to be pulled down more frequently during calibration in the 
simulations. Hence, the number of hypoglycaemic events tends to increase, as 
well as the time and area below the threshold. In contrast, the positive bias in the 
Abbott meters causes the trace to be pulled up during calibration causing 
hypoglycaemia to be under-reported. These effects are clearly shown in Figure 
11.6. 
 
The Abbott meter, which is not designed specifically for the ICU environment, is 
likely more sensitive to clinical factors including varying haematocrit and certain 
medications. Hence, the relatively large bias and low precision may not reflect 
the underlying device capacities without these influences. The cohort data used 
to create the models came from patients with haematocrit levels of 24-36% and 
while they all remained within the validated range for the test strip, these 
haematocrit values are significantly lower than the normal haematocrit level of 
40-45%. In this study, the low haematocrit levels combined with a constant 
correction factor of 1.12 would have contributed to the large positive bias seen in 
the Abbott model.  
 
For example, using a whole blood to plasma conversion equation from the 
literature (Mahoney & Ellison 2007) and a haematocrit value of 27%, the ‘true’ 
conversion factor is calculated to be 1.07. This value is 5% lower than the 1.12 
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used by the Abbott device. Additionally, newborn babies can have haematocrit 
levels as high as 65% (Jopling et al. 2009) causing the Abbott meter to under-
report the true plasma glucose by ~6%. Thus, this factor can have a substantial 
impact when used in these cohorts. 
 
The clinical impact of these findings is important for future studies using CGM 
devices to classify hypoglycaemia in neonates. Glucometer device characteristics, 
such as bias, and clinical factors, such as haematocrit levels, could have a 
substantial impact on the results of a glycaemia study. Thus, it is imperative they 
are reported in detail, which is not always the case. 
 
For example, if two separate studies were investigating hypoglycaemia using 
CGM devices, the study outcomes could differ simply due to the type of glucose 
meter used to calibrate the CGM. Thus, it is important to select an appropriate 
method of measuring glucose for calibration when undertaking CGM studies. It is 
equally important to understand the range of impact or uncertainty that the 
device may impart to the results. Finally, the use of mixed CGM device types or 
calibration algorithms should be accounted for. 
 
11.4.3 Variation in hypoglycaemia metrics  
The IQR and 5th-95th range in the results table are used to assess the variation in 
the hypoglycaemia metrics across the 1000 MC runs. The results showed a 
counter-intuitive trend. Specifically, the Roche results had a wider 5th-95th range 
(more variation in results), for duration and index, than the results from the 
lower precision Abbott meter.  
 
This counter-intuitive trend can be explained using Figure 11.7, which shows the 
duration of hypoglycaemia from each of the 1000 simulation runs as a function of 
baseline duration, for each SG dataset. In plot A, it is the positive bias in the 
Abbott model that causes a reduction in hypoglycaemia, which ultimately leads 
to truncation of the percent duration at zero. This truncation reduces the 
perceived variation due to the precision of the meter. Conversely, plot B in Figure 
11.7 illustrates how the negative bias in the Roche model increases the 
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prevalence of hypoglycaemia, allowing more variation (due to precision) to be 
observed in the metric. For example, in plot A, a baseline duration of 10% 
hypoglycaemia results in a maximum duration of ~30% and ~25% of simulation 
runs showing no hypoglycaemia. However, in plot B, for baseline duration of 
10% the range of values for durations from the 1000 runs spans from 0 to ~80%, 
making the Roche meter appear worse despite greater precision. Such counter 
intuitive results further reinforce the need to understand, in detail, the 
calibration device and measurement value when assessing clinically significant 
outcomes. 
 
11.4.4 Limitations 
The main limitation of this study is the method used to calibrate the CGM after 
adding timing and measurement error to calibration BGs. As stated previously, 
the calibration algorithm was designed to be used with very accurate calibration 
BG measurements, with little or no timing error. Thus, it inherently assumes the 
calibration BGs are perfect and forces the SG trace to pass through them. This 
approach makes it particularly sensitive to errors in calibration BG 
measurements. Inbuilt calibration algorithms based on linear regression would 
likely reduce the effect of calibration errors on hypoglycaemic metrics, but it is 
likely that the trends discussed in this study will still remain.  
 
11.5 Summary 
Overall, measurement error tends to have a much larger impact on 
hypoglycaemia metrics than timing error. However, if a patient is particularly 
variable, then timing error can have a much more measureable impact. The effect 
of bias in calibration BG measurements was twofold: 1) A negative error bias 
increases the prevalence of hypoglycaemia; and, 2) it also increases the amount 
of variation seen in hypoglycaemic metrics. The opposite was also true for 
positive biases. Finally, if CGM devices are to be used clinically for assessing 
events such as hypoglycaemia it is important that the investigators are aware of 
the potential impact that errors in calibration BG measurements can have on SG 
data.  
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Chapter 12. Detecting Unusual SG measurements 
In addition to the effect of device calibration and errors in calibration BG 
measurements, the detection of artefacts is another important aspect of CGM that 
needs further investigation. Artefacts occasionally appear in the SG data and are 
typically characterised by unusually large step changes in glucose level, often for 
no apparent reason. These step changes are frequently larger than the commonly 
observed limits of physiological behaviour. Detecting unusual SG measurements, 
even without knowing the cause, offers the user valuable feedback on the quality 
of SG data at any point in time, and can thus better inform decision making. This 
chapter presents a novel method for detecting unusual SG measurements, using a 
modified stochastic forecasting method developed for insulin sensitivity 
prediction. 
 
12.1 Introduction 
If CGM devices are going to be used in the clinical setting to monitor, diagnose 
and potentially aid in the treatment of abnormal glycaemia, clinicians need to 
know the data are reliable and accurate. In the context of detecting 
hypoglycaemia in neonatal infants, investigators would benefit from knowing 
whether a significant drop in glucose is likely 'real' or simply an artefact of the 
device. Sensor artefacts are known to occur (Bequette 2010; Keenan et al. 2009), 
but an understanding of the cause of seemingly random jumps or drops in SG 
data are still being investigated. A thorough review of the literature in 2011 
found 10 studies that reported abnormal CGM behaviour due to motion or 
pressure, but still concluded that this area was poorly understood and needed 
further research (Helton et al. 2011). 
 
Even with a limited understanding of what causes artefacts in SG data, it is still 
possible to detect these anomalies in a probabilistic sense. Consider a scenario 
where SG data are retrospectively analysed to classify hypoglycaemia in 
neonates, where frequent BG measurements are not available. Three consecutive 
measurements in a SG trace read 4mmol/L, 2.5mmol/L and 4mmol/L. If 
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hypoglycaemia was classified as a measurement below 2.6mmol/L, then this 
sequence would be recorded as a hypoglycaemic event. However, if the rest of 
the SG trace was very stable with low variability, intuition would suggest this 
'event' is potentially a sensor artefact. Figure 12.1 shows an example of a 
hypoglycaemic drop in glycaemia that could potentially be an artefact of the CGM 
device rather than a true representation of the underlying glucose concentration. 
 
 
Figure 12.1 Plot of SG data showing a sudden drop to 2mmol/L at approximately 1 
day after monitoring began. The drop is followed by a sudden rise, suggesting this 
feature is potentially an artefact of the CGM device rather than a true representation 
of the underlying glucose concentration. 
 
The idea of detecting outlier SG data using automated algorithms is not 
completely new. Previous studies have investigated different methods of 
detecting outlier measurements including a discrete wavelet transform based 
online detector (Quan et al. 2010) and a post-processing support vector machine 
(Leal et al. 2013; Tarin et al. 2010). However, currently, there is no reliable and 
widely used method of determining whether sudden drop-outs or changes in SG 
data are likely to be “true” or simply an artefact. 
 
This chapter develops and presents a tool to aid clinicians in identifying unusual 
CGM behaviour, retrospectively or in real-time, and highlights sections of the 
CGM glucose trace that potentially need to be interpreted with care. Specifically, 
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the focus is to identify unusual CGM sensor behaviour, not unusual glycaemic 
excursions. 
 
12.2 Subjects and methods 
12.2.1 Subjects 
This study used CGM data from 50 babies ≥ 32 weeks gestation that were at risk 
of hypoglycaemia and admitted to the Waikato Hospital NICU during the BABIES 
study. Exclusion criteria included serious congenital abnormities or a skin 
condition preventing continuous glucose monitoring. Informed consent was 
obtained from parents of all babies in the study. The study was approved by the 
Northern Y Regional Ethics Committee, New Zealand. Table 12.1 shows the 
demographics for patients enrolled into the study. 
 
Table 12.1 Cohort demographics 
 
 
 
12.2.2 Continuous glucose monitoring 
All patients had interstitial glucose monitoring using the CGMS System Gold and 
SOF sensors. Sensors were located on the infant’s lateral thigh and were 
connected to the CGMS system monitor via the supplied cable. Monitoring began 
on admission to the NICU and finished after 7 days or when the baby was no 
longer considered to be at risk of hypoglycaemia. During the monitoring period 
nurses were asked to record all BG concentrations, feeding and medication for 
the management of hypoglycaemia. However, they remained blind to the glucose 
concentrations determined by the device by design. 
Cohort Demographics
Number of CGM traces 50
Sex (M/F) 26/24
Gestational Age (weeks) 34 [33 - 37]
Birthweight (g) 2172 [1880 - 2990]
Primary Risk (# infants):
Diabetes 15
Premature 19
Small or Large for gestational age 14
Other 2
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The device was calibrated per the manufacturer’s recommendations and all of 
the data entered into the device were checked against clinical records for 
accuracy. Upon completion of monitoring, data were downloaded to a PC using 
CGMS system solutions software version 3.0C, which calibrated the CGM 
readings retrospectively. A total of 234 days of SG data (67438 measurements) 
were collected and the median [IQR] duration of monitoring per-patient was 4.7 
[4.0 - 5.7] days. 
 
12.2.3 Calibration measurements 
The CGM device required calibration 2-4 times daily to convert the electrical 
current produced by the sensor into a meaningful glucose value. Blood samples 
were taken by nursing staff via heel-pricking and the glucose concentrations 
were used to calibrate the CGM device. The median [IQR] interval between 
samples was 4.8 [3.5 – 6.4] hours.  
 
All BG calibration measurements were made using a BGA (Radiometer, 
ABL800Flex, Copenhagen) that analysed a whole blood sample using the glucose 
oxidase method. This device has a reading range of 0.0 to 60.0mmol/L and a C.V. 
of 1.4-2.2% (Cembrowski et al. 2010; Watkinson et al. 2012). Furthermore, the 
study by Watkinson et al. showed that a device from the same family, using the 
same glucose electrode, had a coefficient of variation of 2.1% in ICU patients and 
performance was not affected by haematocrit, pH or PaO2 (Watkinson et al. 
2012). Due to the location of the analyser, a short time delay (estimated < 
15mins maximum) was possible between taking the blood sample and 
introducing the resulting measurement into the device. 
 
12.2.4 Stochastic model 
A stochastic model based on the kernel density method was implemented to 
classify unusual SG measurements using the previous SG measurement and 
information about the history of CGM behaviour. This lag-1 model is an extension 
to the methods described by Lin (2007) who developed a stochastic model for 
predicting variability over time in insulin sensitivity. 
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 and                
  
 
 
 
 
The model was generated using Equations 12.1 and 12.2, which define the 2-
dimensional kernel density estimation in conditional SG measurement 
variability. Each          
   and          
   is a normal probability density 
function centred at the corresponding xi and yi. To ensure that x and y are 
positive,     and     normalise each          
   and          
   to the positive 
domain. Specifically, for a given SG measurement CGMn-1, Equation 12.1 provides 
a continuous, empirical estimate of the conditional probability density function 
for the next SG measurement, CGMn. These conditional probability density 
functions provide the basis for classifying SG measurements and identifying 
unusual CGM behaviour.  
 
12.2.5 SG measurement classification 
Using the stochastic model, a given SG measurement, CGMn, is classified as 
follows:  
1. The previous measurement, CGMn-1, is used to find the corresponding 
conditional PDF from the model.  
2. CGMn is located in the PDF and its percentile value in the conditional PDF 
is determined.  
3. The percentile is used to classify CGMn, where a very high or very low 
percentile is indicative of an outlier. These outliers are classified as 
unusual SG measurements. 
 
The measurement-to-measurement sections of the SG trace were colour coded 
based on the percentile value, to highlight areas of unusual CGM behaviour 
quickly and effectively. Three ranges were used to specify the colour: within 80% 
range (10th-90th percentile) was blue, within 90% range (5th-95th percentile) 
was cyan, within 99% range (0.5th-99.5th percentile) was yellow, and outside 
99% range was red. These intervals were chosen based on the data used in this 
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study and can be customised for different patient groups and/or different CGM 
sensors. As the scale starts at 80% range, the focus here is on classifying outliers, 
rather than the full range. 
 
12.2.6 5-fold validation of stochastic model 
A 5-fold validation was used to check the fit of the stochastic model. The data set 
(N=50) was randomly divided into 5 sets of 10 patients. For each 10 patient 
group, the remaining 40 patients were used to create a stochastic model which 
was then tested on the group of 10 patients. The model fit was assessed by 
counting the number of clinical SG measurements (from the 10 patients) 
captured by the model’s 80% range, 90% range and 99% range.  
 
MC methods were used to reduce the effect of randomly selected outliers on 
overall results. MC methods provide a robust means of estimating the range of 
possible outcomes for a process involving one or more random variables. In this 
study, the MC simulation involved repeating the 5-fold validation 25 times, and 
reporting the Median [IQR] results.  
 
12.3 Results 
12.3.1 Clinical SG data and stochastic model generation 
Figure 12.2 shows a plot of all the SG data (CGMn-1, CGMn). The contour lines 
represent the 5th, 25th, 50th, 75th, and 95th percentiles of the stochastic model 
surface. Figure 12.3 shows a distribution of the data density by glycaemic level. 
Figure 12.4 shows a surface plot of the stochastic model. Conditional probability 
density functions are slices parallel to the CGMn axis, and each slice has an area 
under the curve of 1.0. Figure 12.5 shows a comparison of the PDFs obtained 
from the model versus the PDFs obtained directly from the SG data. Each PDF 
shows the expected distribution of CGMn given a previous measurement (CGMn-1) 
of 2, 4, 6, 8 or 10mmol/L. It should be noted that the PDFs could be generated for 
any value of CGMn-1 within the bounds of the model, and that Figure 12.5 shows 
just five examples. Table 12.2 shows numerical results from the MC validations 
which confirm a good model fit. 
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Figure 12.2 Plot of SG measurement pairs (CGMn-1, CGMn) with contour lines 
representing the 5th to 95th percentiles, from the bottom of the plot up. 
 
 
 
Figure 12.3 Density of the data set by glycaemic level. Density is shown as a percent 
of the total data set (67,438 measurements). 
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Figure 12.4 Stochastic model surface for this data set. Conditional probability density 
functions are the surface slices along CGMn-1 axis, each slice has an area under the 
curve summing to 1.0. A colour gradient was used to show the height of the surface. 
 
 
 
Figure 12.5 Comparison of conditional probability density functions for different 
levels of CGMn-1. PDFs from the model are solid lines and empirical PDFs from actual 
SG data are dotted 
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Table 12.2 Results from a 5-fold validation of the model 
5-fold Model Validation (25 MC runs) 80% range 90% range 99% range 
Variation across MC runs (Median [IQR]) 0.83 [0.79 - 0.86] 0.91 [0.89 - 0.93] 0.99 [0.98 - 0.99] 
 
 
12.3.2 Classification of representative SG data 
Figures 12.6, 12.7 and 12.8 show examples of SG traces that have been coloured 
using the stochastic classification method. Figure 12.6 shows a stable trace, 
which is almost entirely dark blue, indicating the measurement-to-measurement 
change throughout the trace is not unusual. Figure 12.7 shows a trace with 
several potentially unusual measurements throughout the trace. The 
hypoglycaemic event that occurs at approximately one day after monitoring 
began is coloured red and classified as very unusual (>99% range). Figure 12.8 
shows a trace with a few potentially unusual measurements for the first three 
days of monitoring. After day 3 a high proportion of the SG measurements in this 
figure are classified as very unusual and are coloured red. 
 
 
 
Figure 12.6 Stable SG trace with no yellow or red measurements indicating no SG 
measurements were classified unusual. 
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Figure 12.7 SG trace with several measurements classified as mildly unusual. Note 
the hypoglycaemic event at ~1 day which has been classified as very unusual (red). 
 
 
 
Figure 12.8 SG trace with several measurements classified as mildly unusual. After 
day 3 the trace is classified as very unusual (red) and could be indicative of sensor 
malfunction. 
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12.4 Discussion 
12.4.1 Clinical SG data and stochastic model generation 
The aim of this study was to design a tool that could aid clinicians in identifying 
unusual CGM behaviour that should potentially be interpreted with care. 
Stochastic modelling methods from Lin (2007) and a method of colouring SG 
traces were used to highlight unusual CGM behaviour clearly and efficiently, in 
either real-time or retrospectively. 
 
Figure 12.2 and Figure 12.3 give information about the raw data used to create 
the stochastic model. More than 99% of the data is within 2-10mmol/L range, 
shown in Figure 12.3. There are several outliers in Figure 12.2 that have a very 
large change in glycaemia over the 5 minute CGMS Gold measurement interval. 
The high data density means these outliers have little effect on the model fit, 
shown by the smooth and tight percentile lines in Figure 12.2. However, below 
2mmol/L there are 97 SG measurements and due to the relatively low data 
density the outliers have more impact on the model fit. This effect is clearly seen 
in the 95th percentile line of the model, which strays upward at levels below 
2mmol/L. Similarly, above 10mmol/L, there are only 232 measurements and the 
percentile lines all have a wave-like shape, again showing the effect of outliers 
where data density is low. A greater data density would alleviate these issues 
without changing the approach. 
 
The quality of data used to create a stochastic model will affect how future SG 
measurements are classified. If a model is created using low quality data, 
containing a significant number of outliers, then the model could potentially 
classify future outlier measurements as ‘usual’ or ‘expected’. Data quality is 
particularly important when using small data sets, as single outliers can have 
more effect on the overall model. However, the growing use of databases and 
electronic records means that collecting large amounts of data that are fully 
representative will become easier, even for specific sub-cohorts. Thus, this work 
foreshadows an application with potential for effective and typical clinical use in 
future, as the method of creating such models is general. 
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Figure 12.4 shows the surface of the stochastic model. The colour gradient shows 
how the shape of the model changes in the domain of CGMn-1 and that a single, 
global probability density function is not applicable to this data set. Figure 12.5 
further reinforces this conclusion with 5 probability density functions taken 
from the model at different CGMn-1 values, resulting in 5 different shaped density 
functions. These PDFs are also used to show that the model fits the empirical 
data well. The model PDFs (solid lines) overlay the empirical data (dotted lines) 
with only minor discrepancies.  
 
Additionally, the model fit was checked using a 5-fold validation, with results 
shown in Table 12.2. Across the 25 MC runs, the 80% range typically captured 
83% of the data, the 90% range typically captured 91% of the data and 99% 
range typically captured 99% of the data. These results show the model to 
capture the SG data well over the expected range of SG values, with little 
variation in the percentage of data captured in each range.  
 
12.4.2 Classification of representative SG data 
Figure 12.6, Figure 12.7 and Figure 12.8 show different SG data sets and how the 
stochastic model classified the individual SG measurements within them. Figure 
12.6 shows a very stable, flat SG trace with only small variations over the 3.5 
days of monitoring. The SG trace passes near all calibration measurements and 
there doesn’t appear to be any unusual CGM behaviour. The stochastic model 
classified almost the entire trace as dark blue indicating no unusual CGM 
behaviour. The interpretation of this trace would not likely be influenced with 
the additional information provided by the model. 
 
Figure 12.7 shows a less stable SG trace with a lot more variability. This trace 
contains a few yellow and red sections that potentially need to be interpreted 
with care. The focus of this discussion is the ‘hypoglycaemic event’ that occurs at 
~day 1. In the sequence of 5 measurements that lead up to the 1.8mmol/L 
minimum, there are two drops of ~1mmol/L per 5 minute measurement interval 
(~12mmol/L/hour). The model has determined these drops are extreme 
outliers, as would be expected physiologically, and consequently, they have been 
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coloured red. The trace then rises to above 4mmol/L in 5 measurements, 
similarly with two rises of ~1mmol/L per 5 minute measurement interval. 
Although the physiological limits of glucose rate-of-change are still unknown, the 
level of sensor error that has been reported in previous CGM studies (Breton & 
Kovatchev 2008; Goldberg et al. 2004) suggest that this hypoglycaemic event 
could potentially be either glycaemia or sensor error, with the error being the 
more likely cause. 
 
Interestingly, the bottom of the ‘hypoglycaemic event’ at ~day 1 contains a dark 
blue classification; indicating the measurement-to-measurement change 
immediately after the nadir was not unusual. This outcome was not unexpected, 
because the lag 1 model classified the change between any two consecutive SG 
measurements independent of previous classifications. Additionally, the data in 
Figure 1 is generally centred on the line CGMn-1 = CGMn. Consequently, the model 
surface in Figure 12.4 peaks along or near this line. Thus, for the hypoglycaemic 
event at day 1 when the CGM reported 1.8mmol/L followed by 1.9mmol/L, CGMn-
1 ≈ CGMn, and the change was classified as expected (blue = within 80% range).  
 
It is important to note that the aim of the stochastic model is not to try and 
determine the accuracy of the CGM device or the specific cause of a drop in CGM 
glucose, but rather to highlight the fact it should be interpreted with care. 
Furthermore, if the stochastic model was implemented in a real-time clinical 
setting and the downward SG measurements were observed, it would be 
beneficial for the clinician to know whether or not the sequence of 
measurements is typical of CGM devices and that patient cohort.  
 
It should also be noted that without an accurate BG measurement at ~1 day, no 
exact conclusion can be drawn about the whether the hypoglycaemic event in 
this data was a sensor artefact, or a true glycaemic event. However, this lack of 
confirmation is often the reality with CGM data. Clinical protocols might use 
stochastic information to justify an added BG measurement to clarify a 
potentially significant event. After an event, such traces would yield insight not 
present at the bedside.  
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Figure 12.8 shows an example of SG data that becomes increasingly more 
variable and unstable at approximately day 3 of monitoring. Before day 3, the SG 
trace is predominantly blue and cyan with only small patches of yellow and 
occasionally red. However, after day 3 the SG trace is almost entirely red 
indicating the stochastic model has classified these measurements as very 
unusual. The sudden apparent degradation of reliable SG measurements could be 
due to a sensor failure. This conclusion is not unreasonable, given the sensors 
used in this study were validated for 3 days of continuous monitoring. Again, 
without more frequent, accurate BG measurements during the period after day 3, 
no definitive conclusions can be drawn. However, this example represents 
another potential use of this stochastic model classification method that might be 
useful to users of CGM devices in determining sensor failures. 
 
Finally, the stochastic model and classification methods were used 
retrospectively in this study. For real-time use, a stochastic model would be 
generated using prior SG data, and further SG measurements would be entered 
into the system in real-time. Classification of paired SG measurements (CGMn-1, 
CGMn) takes a fraction of a second, so the corresponding colour coded segment of 
SG trace would be displayed without significant delay, estimated as less than 1 
second. The major limitation in implementing the method in real-time is the 
ability to stream SG data to a computer or onboard processing in real-time. 
Although the technology is available, only a limited number of CGM devices 
currently offer the necessary capabilities. 
 
12.5 Summary 
A stochastic model based method was presented and shown to be capable of 
classifying SG measurements to highlight unusual CGM behaviour. The method 
uses a colour coded SG trace to convey the information quickly and efficiently 
and is computationally light enough to be used retrospectively or in real-time. 
 
There are several potential uses for the stochastic classification, which include, 
but are not limited to, classification of hypoglycaemia and detection of potential 
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sensor failure. Equally, they can augment alarm methods (Pretty et al. 2010) or 
be used to time BG measurements more optimally, such as in neonates where 
blood draws are restricted. Overall, while BG measurements are required to 
draw definitive conclusions about glycaemic events, the stochastic model 
provides another level of information to aid users in interpretation and decision 
making. 
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Chapter 13. Using CGM to detect neonatal hypoglycaemia 
Chapters 9-12 discussed the inner workings of CGM devices and how to utilise 
them in clinical studies of neonatal hypoglycaemia. Research in this chapter 
applies that knowledge and some of those techniques to analyse neonatal 
hypoglycaemia in a large cohort of at risk infants. Furthermore, the 
advantages/disadvantages of CGM and intermittent BG monitoring are discussed. 
Finally, a potentially optimal protocol for monitoring glycaemia in newborn 
babies is presented in the conclusions. 
 
13.1 Introduction 
Only a small number of studies have investigated neonatal hypoglycaemia using 
CGM devices. To the author’s knowledge, since the first report of CGM in VLBW 
infants in 2005 (Beardsall et al. 2005) there have been two other published 
studies of CGM in newborn infants (Harris et al. 2010; Iglesias Platas et al. 2009). 
These studies report the prevalence of hypoglycaemia to be ~2.4% of all SG 
values and the hypoglycaemic time per patient to be between 0-11%. 
Furthermore, CGM is reported to detect hypoglycaemia at a significantly higher 
rate than intermittent BG monitoring, due to hypoglycaemia often occurring 
between consecutive BG measurements. Although there are obvious benefits to 
CGM, there have also been concerns about the devices accuracy at low glucose 
concentrations and its ability to detect hypoglycaemia (Ligtenberg et al. 2011). 
 
Correlation between SG measurements and paired meter BG readings in 
neonates is in the range of 0.87 - 0.96 (Beardsall et al. 2005; Beardsall et al. 2013; 
Iglesias Platas et al. 2009). Mean error of CGMS values in neonates ranges from 
6.9% to 12.7% over 7 days of monitoring, with the highest error occurring on 
day 1 (Beardsall et al. 2013). In addition, a bias exists that causes the CGM to 
over read at low glucose levels and under read at high glucose levels (Beardsall 
et al. 2013). Bias of this nature is likely due to regression in the calibration 
algorithm, which was discussed in detail in Chapter 10. Overall, CGM accuracy in 
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this group of patients is acceptable and SG data can provide valuable information 
about hypoglycaemia that cannot be obtained by intermittent BG monitoring.  
 
This chapter investigates hypoglycaemia in a large cohort of at risk neonates 
whose glucose levels were monitored using CGM devices. Knowledge and some 
of the techniques discussed in previous chapters are utilised to ensure robust 
and reliable results. Ultimately, results from this research will be compared to 
developmental outcomes at 2 and 4.5 years of age, to improve the definition, 
diagnosis and management of neonatal hypoglycaemia. 
 
13.2 Subjects and Methods 
13.2.1 Patients 
This analysis uses CGM device data and BG data from 161 newborn infants born 
in Waikato Hospital, New Zealand. Babies greater than 35 weeks gestation, less 
than 48 hours old and at risk of neonatal hypoglycaemia were eligible for the 
study. Primary risk factors for neonatal hypoglycaemia included having a mother 
with diabetes, prematurity and/or being small or large for gestational age. This 
study and use of data was approved by the Northern Y Ethics Committee, New 
Zealand. Table 13.1 summarises the demographics of this cohort. 
 
Table 13.1 Summary of patient demographics. Data are shown as median [IQR] 
where appropriate 
 
 
Cohort Demographics
Number patients 161
Sex (M/F) 83/78
Gestational Age (weeks) 37 [36 - 38]
Birthweight (g) 2755 [2410 - 3410]
Primary Risk (# infants)
Diabetes 54
Premature 58
SGA or LGA 42
Other 7
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13.2.2 Clinical procedures 
All patients had interstitial glucose monitoring using CGMS System Gold devices 
and SOF sensors. Sensors were located on the infant’s lateral thigh and were 
connected to the monitor via the supplied cable. Monitoring began as soon as 
practical after birth and finished after 7 days or when the baby was no longer 
considered at risk of hypoglycaemia. During the monitoring period nurses 
recorded all BG concentrations, feeding and medication for the management of 
hypoglycaemia. Nurses remained blinded to SG measurements and all calibration 
BG measurements were entered per the manufacturer’s recommendations. Data 
were downloaded to a PC using CGMS system solutions software version 3.0C.  
 
Blood glucose concentrations were measured according to current clinical 
guidelines in Waikato Hospital. Blood samples were obtained by heel lances at 
one hour after birth, then three to four hourly before feeds for the first 24 hours, 
then six to eight hourly for the subsequent 24 hours. All blood glucose 
concentrations were measured using a BGA (Radiometer ABL800Flex, 
Copenhagen). This BGA has a reading range of 0.0 to 60.0mmol/L and a C.V. of 
1.4-2.2% with little or no decrease in performance due to variations in 
haematocrit, pH or PaO2 (Cembrowski et al. 2010; Watkinson et al. 2012). All BG 
measurements collected during the study were used for CGM calibration 
 
Mothers were encouraged to provide skin-to-skin contact and feed the baby 
within the first hour after birth. Prior to birth many mothers expressed and 
stored breast milk, and when possible babies who did not breast feed adequately 
were given expressed breast milk by syringe. Babies who were to be formula fed 
were offered up to 60 ml/kg·day on day one and 90 ml/kg·day on day two. In 
addition, some babies were given 200mg/kg dextrose gel as an experimental 
treatment for hypoglycaemia diagnosed by a BG measurement <2.6mmol/L. 
 
13.2.3 Data processing 
All SG data were recalibrated using the algorithm described in Chapter 10, 
primarily to address 3 main issues with CGMS use in neonates. First, the 
calibration BG measurements from the BGA have little or no measurement error 
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and an accurate record of the time of measurement is electronically stored by the 
BGA. These highly accurate, timely BG measurements address the issues 
discussed in Chapter 11, specifically the effect of calibration errors on measures 
of hypoglycaemia. Thus, the effects of timing error and measurement error are 
eliminated, or at least minimised, in this analysis.  
 
Second, recalibrating removes any bias introduced by linear regression aspects 
of CGM calibration. An over reading bias has been reported at low glucose levels 
causing hypoglycaemia to be under reported (Beardsall et al. 2013). 
Recalibration forces SG data to pass through all calibration BG measurements 
and removes any bias that might otherwise be present. 
 
Third, there have been concerns about the accuracy of the CGMS System Gold in 
neonates. MAPE by day is reported to be 13% on day 1 and between 7-8% on 
days 2 through 7 (Beardsall et al. 2013). Furthermore, on days 2-7 at least 73% 
of measurements are below the American Diabetes Association's (ADA's) 
recommended target of 10% error. However, on day 1 only 56% of 
measurements were below 10% error. Recalibrating with frequent calibration 
BG measurements addresses the issue of reduced accuracy during the first day of 
monitoring, while preserving important glucose dynamics captured by CGM.  
 
The first and last hour of SG data were trimmed from all data sets to remove end 
effects that are often present in this data. After trimming, SG data sets shorter 
than 1 day were excluded from the analysis. Remaining CGM and BG data were 
reference to the time of birth, to allow a fair comparison between patients. 
Finally, median filtering using the composite filter described in Chapter 10 
removed unwanted and potentially un-physiological dynamics from SG data.  
 
13.2.4 Analysis 
Hypoglycaemia was assessed in both the BG data and the recalibrated/filtered SG 
data for each patient. For SG data it was defined as one or more consecutive SG 
measurement(s) below 2.6mmol/L, surrounded by SG measurements greater 
than or equal to 2.6mmol/L. For BG data a single measurement below 
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2.6mmol/L was considered an episode of hypoglycaemia. The metrics used to 
quantify hypoglycaemia were: 
 
 Number: Number of independent hypoglycaemic events  
 Duration: Percent of SG record below 2.6mmol/L 
 Severity: Lowest SG measurement of hypoglycaemic event. 
 Hypoglycaemic index: Similar in concept to Hyperglycaemic index 
(Vogelzang et al. 2004). It is defined as the area between the 2.6mmol/L 
threshold and the SG trace (for SG < 2.6mmol/L) summed over the entire 
length of stay, normalised by the length of data record. Note: the units used in 
this study are μmol/L, not mmol/L.  
 
An additional sub-analysis investigated the evolution of glucose levels over time 
in these at risk babies. Separate CDF plots were generated using SG data from 0-
12, 12-24, 24-36 and 36-48 hours after birth. Each plot contained a CDF per 
patient and the analysis only included patients with more than 2 hours of SG 
data. The number, n, of patients included is shown in the box in each plot. 
 
13.3 Results 
Table 13.2 shows results from the analysis of 161 CGM and BG data sets. 
Throughout the study period 2271 BG measurements were recorded and 399 of 
them diagnosed as hypoglycaemic. Of the 399 hypoglycaemic episodes, 198 
occurred when the CGM was calibrated and producing data. The CGM detected a 
total of 337 hypoglycaemic episodes, which suggests that 139 episodes were 
missed by intermittent BG measurements.  
 
CGM also offered insight into the duration of hypoglycaemia. Across the cohort, 
6.5% of SG measurements were hypoglycaemic and the hypoglycaemic index 
was 18µmol/L. In terms of the severity of hypoglycaemia, 52% of CGM 
hypoglycaemic episodes were between 2.4 - 2.6mmol/L. It should be noted that 
it was possible for hypoglycaemia to occur below the factory CGM cut-off of 
2.2mmol/L because of the calibration method used. Figure 13.1 shows an 
example of BG monitoring compared to CGM. Between 200-400 minutes after 
birth, both methods detect an episode of hypoglycaemia. However, later in the 
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monitoring period at 1400mins, and again at 2200mins, the CGM reports 
hypoglycaemia that occurred between consecutive BG measurements 
 
Table 13.2 Hypoglycaemia results from CGM device and BG data 
 
 
Per-patient results from the analysis are also shown in Table 13.2. The median 
number of BG measurements per patient was 13 and the median number of 
episodes of hypoglycaemia was 2. The results from SG data show a median 
monitoring period of 1.9 days and a median number of hypoglycaemic episodes 
of 1. The median per-patient duration of hypoglycaemia was 4.4%, which is 
slightly less than the 6% reported for the entire cohort, suggesting there were a 
few patients with long durations of hypoglycaemia that have skewed the results 
slightly. A similar trend is seen in per-patient hypoglycaemic index results, but 
the magnitude of skewing is greater. 
 
Overall cohort results
BG results
Number of BG measurements 2271
hypoglycaemic BG measurements 399
Number of BG measurements during CGM 1741
hypoglycaemic BG during CGM 198
CGM results
Duration of CGM monitoring (days) 327.8
Number of hypoglycaemic episodes 337
Percent duration of hypoglycaemia (%) 6.5
Hypoglycaemic index (µmol/L) 18
Hypoglycaemia between 2.4 - 2.6mmol/L 174
Hypoglycaemia between 2.2 - 2.4mmol/L 81
Hypoglycaemia between 2.0 - 2.2mmol/L 35
Hypoglycaemia below 2.0mmol/L 47
Per-patient results
BG results
Number of BG measurements 13 [10 - 16]
hypoglycaemic BG measurements 2 [1 - 3]
CGM results
Duration of CGM monitoring (days) 1.9 [1.6 - 2.3]
Number of hypoglycaemic episodes 1 [1 - 3]
Percent duration of hypoglycaemia (%) 4.4 [0.0 - 10.3]
Hypoglycaemic index (µmol/L) 6.3 [0.0 - 21.1]
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Figure 13.1 SG data and BG data for a representative patient. Note the CGM device 
and BG measurement between 200-400mins both capture hypoglycaemia, but later 
in the monitoring period at 1400mins and 2200mins the CGM captures 
hypoglycaemia missed by the BG measurements. 
 
 
 
Figure 13.2 Time after birth of first SG measurement. 
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Figure 13.2 shows the time after birth that the CGM device started outputting 
data. The median [25th - 75th percentile] time after birth until SG data was 
available was 206 [174 - 270] minutes. Figure 13.3 shows the number of 
hypoglycaemic episodes that occur during the first few days after birth, 
comparing both glucose monitoring techniques. Majority of BG hypoglycaemia 
occurs during first 12 hours after birth during which time the CGM reports a 
lower number of episodes. However, after the first 12 hours after birth, the CGM 
consistently reports more hypoglycaemia than intermittent BG monitoring alone. 
 
 
Figure 13.3 Hypoglycaemia as a function of time after birth. The blue dashed line 
shows hypoglycaemia detected using intermittent BG measurements and the red 
line shows the number of hypoglycaemic episodes detected using SG data. 
 
Each plot in Figure 13.4 shows the CDF of each patient's SG data for the stated 
time period after birth. The heavy black vertical line represents the 
hypoglycaemic threshold to clearly show the level of hypoglycaemia. During the 
period of 0-12 hours after birth 57% of patients experienced hypoglycaemia, 
diagnosed using SG data. This reduced during the period 12-24 hours after birth 
to 39%, and further reduced to 25% and 19% in the subsequent two 12 hour 
time periods, respectively. There were at least 141 sets of SG data in each 
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analysis. These results, in conjunction with those seen in Figure 13.3, clearly 
show that hypoglycaemia is most prevalent in the first day of life in at risk 
infants. 
 
 
Figure 13.4 CDFs of each patient's SG data for the stated time period after birth. The 
black vertical line represents the hypoglycaemic threshold and 'n' is the number of 
patients in each sub-analysis. 
 
 
13.4 Discussion 
The aim of this study was to assess neonatal hypoglycaemia in a large cohort of 
at risk infants who were monitored using CGM devices. Results from the SG data 
are compared to results from intermittent BG monitoring. 
 
In this group of at risk neonates, ~17% of BG measurements diagnosed 
hypoglycaemia. Interestingly, over 50% of hypoglycaemic episodes were 
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diagnosed in the first 6 hours after birth and over 80% in the first day, as shown 
in Figure 13.3. In addition, as a percentage of the number of BG measurements 
per day, hypoglycaemia accounted for 27% of measurements on day 1 and only 
7% on day 2. Thus, it is unlikely the results are skewed due to increased 
sampling on day 1. Nevertheless, these results suggest capturing the first 24 
hours of BG data in babies at risk of hypoglycaemia is critical. 
 
Another interesting aspect of Figure 13.3 is the level of hypoglycaemia detected 
in SG data compared to BG data, throughout the first day of monitoring. The 
recalibration forces the SG trace to pass through all BG measurements, so it is 
expected that the number of hypoglycaemic episodes detected by CGM be at least 
the number detected by BG. However, as Figure 13.2 shows, the median time 
before the CGM device outputs data is approximately 3 hours 25 minutes and in 
some rare cases SG data isn't available for 10-12 hours. During the first 6 hours 
after birth in this study, BG measurements detected 148 hypoglycaemic episodes 
that occurred before SG data was available. Thus, on day 1 it is essential to have 
frequent intermittent BG measurements in at risk infants, even if CGM devices 
are used in parallel. 
 
During days 2 and 3 after birth, when CGM and BG measurements occur 
concurrently, SG data consistently reports a higher number of hypoglycaemic 
episodes. This is clearly shown in Figure 13.3, and also in Table 13.2. Considering 
only BG measurements that were done during CGM monitoring, there were 198 
episodes of hypoglycaemia detected by BG and 337 detected by CGM. For 
example, Figure 13.1 shows episodes of hypoglycaemia at 1400mins and 2200 
minutes after birth that were missed by intermittent BG measurements. If these 
episodes were asymptomatic, it is likely that clinical staff would have never been 
aware of them without CGM. This example further reinforces the benefit of CGM 
in these infants. 
 
The prevalence of hypoglycaemia appears to diminish at the end of day 3 and 
remain almost non-existent during days 4-7. However, SG data sets in this study 
were relatively short, with a median [25th - 75th percentile] length of 1.9 [1.6 - 
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2.3] days. There is a not enough data in this study to draw definitive conclusions 
about the prevalence of hypoglycaemia during the entire first week after birth. 
 
One of the main advantages of CGM in a study of this nature is the ability to 
classify the duration of hypoglycaemia, which is not possible with infrequent 
intermittent BG measurements. Across the cohort, 6.5% of SG measurements 
were below 2.6mmol/L and per patient the median [25th - 75th percentile] were 
4.4% [0-10.3%]. These results are marginally higher than other results in the 
literature, such as the median (range) of 0.4% (0 - 11%) reported by Beardsall 
and colleagues. However, this outcome is likely due to the cohort used in this 
study. All infants enrolled in the study were at risk of hypoglycaemia and had at 
least one diagnosed hypoglycaemic BG measurement. Hence, the results here 
appear reasonable given the cohort selection. 
 
Overall, the number of patients experiencing hypoglycaemia diminishes over the 
first 48 hours. Figure 13.4 shows CDFs for each patient during four 12 hour 
blocks over the first 48 hours. The number of patients with SG values below 
2.6mmol/L drops from 57% during 0-12 hours to 19% during 36-48 hours. In 
addition, each block of 12 hours had at least 141 patients contributing data so 
the decrease observed is robust to insufficient data. This trend of diminishing 
hypoglycaemia over the first 48 hours is also supported by the BG results. 
 
This study has several limitations that need to be addressed. First, although 
feeding protocols are present in all neonatal hospital environments, the use of 
dextrose gel for treatment of hypoglycaemia was experimental in the study that 
supplied this data. Researchers involved with this study are still blind to the 
control/placebo arms so they could not be separated for individual analysis. 
Second, the SG data sets are relatively short in this study as it was only the first 
48 hours that were of interest to the study that supplied this data, so it not 
possible to draw conclusions after this time period. Finally, the time after birth 
that SG data was available varied from 2-12 hours. Typically, the CGMS System 
Gold will start outputting data after 1-2 hours, but it is not always possible to get 
a sensor inserted in the infant straight after birth. 
187 
 
13.5 Summary 
Overall, this study has show that hypoglycaemia in at risk neonates is most 
prevalent on the first day after birth. An optimal measurement protocol for at 
risk infants would likely involve CGM for the first week after birth with frequent 
intermittent BG measurements for the first day. The duration of hypoglycaemia 
in these patients can vary from 0-10+%, but typically lies in the region of 4-6%. 
Results from this research will be valuable when assessing long term outcomes 
of these patients and the effects hypoglycaemia might have had on their 
neurological development. 
 
  
188 
 
Chapter 14. Summary of CGM in NICU 
The second half of this thesis has investigated CGM in critically ill infants in 
neonatal intensive care. The overall goal of this work was to assess whether 
these devices, which were designed for use outside of the hospital, could perform 
reliably in the NICU and give additional information to conventional methods of 
BG monitoring. Specifically, CGM devices were used to monitor newborn infants 
at risk of hypoglycaemia to improve our understanding of the rate and severity 
of this common metabolic problem.  
 
Three previous studies that used CGM devices in neonates reported that the 
devices were well tolerated by infants and SG data revealed trends in glycaemia 
that were missed by the standard approach using intermittent BG 
measurements. Hence, the use of CGM devices appeared to show a well-tolerated 
measurement that provided clinically significant new data. However, there were 
still concerns about the accuracy of CGM devices in infants, particularly on the 
first day of monitoring and at low BG levels where calibration may not be robust. 
With a thorough understanding of the CGM technology, signal processing and 
mathematical techniques could be used to enhance the quality of the data and/or 
aid in the interpretation of results.  
 
Calibration algorithms convert raw sensor signals into useful SG data and the 
effects of CGM device calibration on metrics used to classify hypoglycaemia were 
investigated. The built-in factory algorithm is based around linear regression and 
SG data tended to report high at low BG levels. An alternative calibration scheme 
was tested, that made more optimal use of the high accuracy calibration BG 
measurements available in the NICU from a BGA. Novel non-linear filtering was 
also implemented to reduce the impact of any sudden, outlying drops/rises in SG 
data due to sensor noise or artefacts.  
 
The results showed that all metrics of hypoglycaemia increased after 
recalibration and the CGM device was confirmed to be reporting higher values at 
low BG levels. Filtering had a significant effect on the number of hypoglycaemic 
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episodes, but the duration of hypoglycaemia showed little change. These results 
highlighted two important considerations for future studies of CGM devices in 
neonates. First, if high accuracy calibration measurements are available, from a 
BGA or lab, then it may be more appropriate to recalibrate SG data. Second, when 
assessing hypoglycaemia in SG data, the duration of hypoglycaemia and/or 
hypoglycaemic index are more robust metrics when using CGM devices than the 
standard approach of counting the number of hypoglycaemic episodes. 
 
The sensitivity of these hypoglycaemia metrics to errors in calibration BG 
measurements was also assessed. Specifically, error in BG measurements and 
delays in entering calibration BG measurements into the CGM device were 
investigated in-silico. Three BG error models were created using clinical data 
from an assessment of glucometer accuracy in ICU patients, and two timing error 
models were created using data from two investigations of CGM devices in 
critically ill patients.  
 
Across the cohort, measurement error tends to have a much larger impact on 
hypoglycaemia metrics than any clinically observed or realistic timing error. 
However, if a patient is particularly variable, then timing error can have a much 
more measureable impact due to the high rate-of-change of BG. This specific 
issue is most notable if calibration occurs during a time of high BG rate-of-
change. The effect of bias in calibration BG measurements was twofold: 1) A 
negative error bias increased the prevalence of hypoglycaemia; and, 2) it also 
increased the amount of variation seen in hypoglycaemic metrics between MC 
simulations. The opposite was also true for positive biases. Clinically, if a patient 
is variable, then calibration BG measurements should be entered into the device 
with minimal delay, potentially at the expense of a high accuracy measurement 
from a BGA or similar. However, if the patient’s glycaemia is relatively stable, 
then it is more beneficial to get the most accuracy BG measurement possible 
within clinical constraints. These outcomes highlight a need to use these devices 
in concert with observations about patient-specific dynamics that are readily 
observable in the SG data. 
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Further, if CGM devices are going to be used in the clinical setting to monitor, 
diagnose and potentially aid in the treatment of abnormal glycaemia, clinicians 
need to know the data are reliable and accurate. In the context of detecting 
hypoglycaemia in neonatal infants, investigators would benefit from knowing 
whether a significant drop in glucose is likely 'real' or simply an artefact of the 
device. Stochastic modelling methods, originally developed for insulin sensitivity 
prediction, were utilised and developed to detect outliers in SG data. In this work 
the emphasis was on detecting unusual episodes of hypoglycaemia, but the 
method presented is fully general. 
 
A stochastic classification model, based on kernel density estimation, was used to 
classify unusual SG data. SG data were displayed on a time series plot and colour 
coded based on their likelihood of being 'real', so that outlier data could be 
quickly and easily identified. The stochastic classification successfully identified 
unusual CGM device behaviour, and in particular several questionable episodes 
of hypoglycaemia. Overall, while BG measurements are required to draw 
definitive conclusions about glycaemic events, the stochastic model provides 
another level of information to aid users in interpretation of the relatively very 
rich data provided by CGM devices and thus in decision making. 
 
With a series of tools/methods available and a better understanding of how to 
utilise CGM devices in neonates, hypoglycaemia in a cohort of 161 at risk infants 
was investigated. All patients had monitoring using the Medtronic CGMS System 
Gold, which was calibrated multiple times per day using BG measurements from 
a BGA. Due to having high accuracy calibration measurements, SG data were 
recalibrated and forced to pass through the calibration BG measurements to 
eliminate the impact of any error that could have been introduced by the linear 
regression aspect of factory calibration. Both BG data and SG data were used to 
quantify hypoglycaemia, and the results were compared.  
 
Results from BG measurements showed that ~17% of BG measurements taken 
during the study identified hypoglycaemia and over 80% of the episodes 
occurred in the first day after birth. Hypoglycaemia was detected at a higher rate 
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by BG measurements than SG measurements on the first day after birth, largely 
due to delays in inserting the CGM sensor and a short warm-up period. However, 
with concurrent BG and SG data available, the SG data consistently identified 
hypoglycaemia at a higher rate suggesting the BG measurements were not 
capturing some episodes. The SG results showed that the duration of 
hypoglycaemia in these patients can vary from 0-10+% of the monitoring period, 
but typically lies in the region of 4-6%. Overall, this work showed that 
hypoglycaemia in at risk neonates is most prevalent on the first day after birth 
and an optimal measurement protocol for at risk infants would likely involve 
CGM for the first week after birth with frequent intermittent BG measurements 
for the first day.  
 
In summary, the research presented in Chapters 9-13 shows that CGM devices 
can add value to traditional BG monitoring in the neonatal unit. The findings 
presented in this thesis will be especially valuable when assessing long term 
outcomes of these patients, and in particular, the effects hypoglycaemia might 
have had on their neurological development. 
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Chapter 15. Future work 
The work presented in this thesis shows how CGM devices can be used 
effectively and robustly in both adult and neonatal ICUs to aid clinical care. In 
particular, it shows how to use them to maximise their strengths and minimise 
or manage their weaknesses. Overall, the results are promising and these devices 
have the potential to work reliably in both clinical departments. However, 
further research is needed before the maximum benefits of CGM can be realised. 
This chapter outlines several aspects of future work that could be investigated to 
advance the knowledge of CGM and ultimately improve care for critically ill 
patients.  
 
15.1 Adult ICU Future work 
The research presented in the first half of this thesis showed that CGM devices 
have the ability to improve TGC methods in an adult critical care unit. A pilot trial 
of CGM devices demonstrated that off-the-shelf CGM devices, currently targeted 
towards outpatient diabetes monitoring, are capable monitoring certain ICU 
patients with a high level of accuracy. A larger observational trial of CGM devices 
is required to determine which patient, illness, drug and/or therapy 
combinations negatively impact CGM performance. With a sound understanding 
of how these factors influence device performance, prospective patients who 
would most benefit from using CGM could be identified based on the expected 
level of CGM device performance. A larger trial of CGM devices should also 
include the newly released hospital CGM device, Sentrino, which is reported to 
have excellent reliability and safety in critically ill patients and, importantly, is 
approved for use in those patients (Kosiborod et al. 2013). 
 
Data collected from a larger trial of CGM device in ICU could also be used for a 
variety of different in-silico studies. An ICU specific mathematical model of CGM 
error characteristics could be developed, allowing virtual SG data to be 
generated that mimics the behaviour of the actual CGM device. Virtual SG data 
could be used in conjunction with clinically validated mathematical models of the 
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insulin-nutrition regulatory system to develop TGC protocols. Unlike the in-silico 
research in this thesis, which replaced BG measurements collected by nurses 
with virtual SG data, a complete model of CGM dynamics and errors would allow 
specifically designed TGC protocols to make use of all SG data. Furthermore, 
alarming algorithms could then be optimally designed to be implemented as 
guardrails to protect patients from abnormal and dangerous glycaemic 
excursions, such as hypoglycaemia. 
 
Ultimately, the aim of such future studies should be to develop the technology 
and protocols that would allow a fully automated closed loop system to operate 
in the ICU. These computer driven protocols would likely modulate insulin 
and/or nutrition to ensure excellent control of BG, with minimal user input. With 
technology constantly evolving, closed loop control in the ICU could potentially 
be realised in the not too distant future. 
 
15.2 Neonatal ICU Future work 
The research presented in the second half of this thesis showed that CGM devices 
can be used in conjunction with traditional BG monitoring to improve 
hypoglycaemia detection and classification in neonates. This research was 
carried out as part of a wider study, The CHYLD Study, which is a large multi-
disciplinary prospective study investigating the development of young children 
who were at risk of developing hypoglycaemia in the early neonatal period. 
 
The infants who had CGM are scheduled to be followed up at 2 and 4.5 years of 
age at which point their growth, cognitive and neurodevelopment is assessed in 
relation to the duration, severity, and frequency of hypoglycaemia in the first 
days of life. These results will not only assess the impact of neonatal 
hypoglycaemia as it is currently defined (BG < 2.6mmol/L), they will also 
potentially allow improved definitions of hypoglycaemia to be identified. New 
definitions or diagnostic guidelines for hypoglycaemia could change clinical 
practice methods all over the world, and, more importantly, reduce the number 
of negative complications associated with abnormal glycaemia in the NICU. 
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Another avenue that could be explored with the addition of CGM devices in the 
NICU is prophylactic dextrose gel treatments, as a means of preventing 
dangerous hypoglycaemia. A recent study investigating the effectiveness of 
dextrose gel in treating hypoglycaemia, identified by intermittent BG 
measurements, showed that dextrose gel was effective at restoring low BG 
concentrations to normal levels. Thus, the next logical step is to integrate real-
time CGM devices and alarming algorithms in to the NICU so that a preventative 
gel treatment can be administered at the predicted onset of hypoglycaemia, 
reducing or even eliminating the risk of that episode.  
 
Overall, it is anticipated that CGM devices could be implemented in a similar way 
to the ICU, for closed loop control of BG and safeguarding against the negative 
outcomes associated with abnormal glycaemia. A version of the CG protocol 
STAR has been developed for, and is currently used in, the Christchurch Hospital 
NICU. CGM devices could be integrated with this computerised system to 
improve BG monitoring, and ultimately improve care for infants in the NICU. 
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Appendix A 
 
 
Use top left 
quadrant of Trend 
Compass 
Use bottom right 
quadrant of Trend 
Compass 
Use top right 
quadrant of Trend 
Compass 
Use bottom left 
quadrant of Trend 
Compass 
Is BG2-BG1 ≥ 
SG2-SG1 
Is BG2-BG1 ≥ 
SG2-SG1 
 
Is BG2 ≥ BG1 
Use top hemisphere of 
Trend Compass 
Use bottom 
hemisphere of Trend 
Compass 
    
      
       
                     
                                         
 
 
 
Calculate angle between a and b using Equation 2, then divide by 2*: 
 
 
Plot a point on the Trend 
Compass: 
   – Degrees from the vertical 
r – Value of BG2 
 
Using the Trend Compass. 
For example if BG changes from BG1 at T1 to BG2 at T2 
and SG changes from SG1 at T1 to SG2 at T2. Units for BG 
and SG should be converted to mmol/L and T to hours. 
 
We define a = [T2-T1, BG2-BG1] and b = [T2-T1, SG2-SG1] 
 
Yes 
 
No 
 
No 
 
Yes 
 
No 
 
Yes 
 
*Note: The angle ( ) is divided by 2 to give    so the full range of theoretic angles can be displayed on each quadrant. The theoretical limit is BG rising 
vertically and SG falling vertically (or vice versa), which would result in 180° between the vectors (displayed as   =90° on the Trend Compass). 
